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 Abstract 
Human immunodeficiency virus-1 (HIV-1) and all other viruses are known to interact with 
multiple host cellular proteins during their replication in the target cell. While many of these 
host cellular proteins facilitate viral replication, a number of them are reported to repress viral 
replication. These host cellular proteins are known as restriction factors and they represent the 
host's first line of defense against the viral pathogens. Sterile alpha motif and HD domain 
containing 1 (SAMHD1) has been identified as a HIV-1 restriction factor that blocks early-
stage virus replication in dendritic and other myeloid cells. 
SAMHD1 is the target of the viral protein x (Vpx) from simian lentiviruses and HIV-2. Vpx 
mediates the recruitment of the Cullin4-DDB1-DCAF1 ubiquitin ligase machinery to 
SAMHD1 leading to polyubiquitination and subsequent degradation of SAMHD1. Previous 
studies on monocyte-derived dendritic cells suggested that the Vpx-induced rescue of HIV-1 
infection from early type I IFN-induced blocks was independent of SAMHD1, since Vpx 
mutant Q76A, which is unable to recruit DCAF1 and to degrade SAMHD1, still increased HIV-
1 infection in type I IFN treated cells. The rescue in healthy blood donor cells was not observed 
when Q76A mutant Vpx virus-like particles were used, suggesting that – in conflict with 
previous reports – SAMHD1 degradation is required for efficient Vpx-mediated rescue of HIV-
1 from the type I IFN-induced early antiviral blocks. To investigate the role of SAMHD1 in the 
Vpx-mediated rescue of HIV-1 from the type I IFN-induced block in myeloid cells at more 
detail, we generated CRISPR/Cas9 THP-1 cells, a monocytic acute myeloid leukemia cell line, 
lacking a functional SAMHD1 gene. In line with previous studies, the lack of SAMHD1 protein 
had no impact on the level of the type I IFN-induced early block to HIV-1 infection as compared 
to control or parental THP-1 cells. However, while Vpx was able to rescue HIV-1 infectivity in 
parental THP-1 or CRISPR/Cas9 control cells from the type I IFN effects, no rescue was 
observed when SAMHD1 protein was absent. To investigate whether the enzymatic activity of 
SAMHD1 was required for the Vpx-mediated rescue of HIV-1 infection from the early type I 
IFN-induced blocks, we reconstituted expression of wild type or different catalytically-inactive 
SAMHD1 mutants in SAMHD1-/- cells and found that Vpx increased HIV-1 infectivity in the 
presence of wild type, but not H233A mutant SAMHD1, suggesting that the enzymatic activity 
of SAMHD1 is required for a Vpx-induced rescue of HIV-1 infection from the type I IFN-
induced block. We also generated a CRISPR/Cas9 THP-1 cell clone, which had one disrupted 
SAMHD1 allele and one allele, in which the entire nuclear localization signal (11KRPR14) was 
deleted in frame, generating an internally NLS-disrupted endogenously expressed SAMHD1 
protein. In these cells, SAMHD1 was predominantly localized to the cytoplasm, although a 
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fraction was also observed in the nucleoplasm, suggesting for an alternative nuclear import 
pathway, independent of the classical 11KRPR14 NLS. In these cells, Vpx still rescued HIV-1 
from the type I IFN-induced early block to infection. Of note, SAMHD1 degradation was 
profoundly delayed, suggesting that Vpx-induced polyubiquitination of SAMHD1 is sufficient 
to overcome the early IFN-induced block to HIV-1 in myeloid cells. SAMHD1 not only acts as 
a host restriction factor against lentiviral, endogenous retroviruses, hepatitis B virus, 
herpesviruses (HSV-1) and poxviruses, mutations in the SAMHD1 gene have also been linked 
to the immune disorder Aicardi-Goutières Syndrome (AGS), a genetic disease mimicking 
congenital virus infection. Recurrent mutations and reduced expression levels of SAMHD1 have 
been suggested to play a role for the oncogenesis of several cancers such as colon and Rectum 
Adenocarcinoma (COAD/READ), lung cancer, cutaneous T-cell lymphoma, acute myeloid 
leukemia (AML), and chronic lymphocytic leukemia (CLL). Interestingly, SAMHD1’s 
function as a possible tumor suppressor is complexed by its role as a resistance factor in 
nucleoside analogue-based anti-cancer therapies. Cytarabine (ara-C), a deoxycytidine analog, 
is the single most important drug in the treatment of AML and other hematological 
malignancies, exerting its cytotoxic effects through its activated triphosphate (ara-CTP), 
eventually leading to DNA damage and cell death. We and others demonstrated that SAMHD1 
is able to detoxify cells by hydrolytic activity towards ara-CTP. Accordingly, primary AML 
blasts treated with Vpx to deplete SAMHD1 as well as THP-1 CRISPR/Cas9 SAMHD1 knock-
out cells showed increased sensitivity towards ara-C induced cytotoxicity. Using these knock-
out cells as a back-bone, we expressed a large panel of SAMHD1 mutants harboring non-
synonymous single nucleotide polymorphisms (SNPs) that have been identified in patients with 
AML, READ, STAD or COAD and performed differential analyses of ara-C sensitivity as well 
as restriction activity towards HIV-1 infection to unravel possible mechanistic differences in 
both activities. In this respect neutralization of ara-C induced cytotoxicity was found to be a 
very good surrogate for the enzymatic dNTPase activity of SAMHD1, and using naturally 
occurring SAMHD1 variants ensured that these proteins were not artificially defective, hence 
for the first time a direct comparison of enzymatic activity and anti-HIV-1 activity could be 
investigated in the same cells. We are currently investigating the effects of these SAMHD1 
SNPs on oligomerization and sensitivity for degradation by Vpx. The identification of 
SAMHD1 SNPs altering the sensitivity to certain anti-cancer chemotherapies could also be a 
key for future personalized treatment strategies. Furthermore, the ability of our assays to 
uncouple SAMHD1 enzymatic activity from virus restriction could help to understand the 
contribution of SAMHD1’s dNTPase activity towards HIV-1 restriction and since the Vpx-
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induced rescue of HIV-1 infection from the type I IFN induced block was shown to depend on 
SAMHD1, may help to unravel the IFN-induced early blocks against HIV-1. In Summary, 
SAMHD1 plays a bigger role in the type I IFN-induced block than currently is appreciated and 
further investigation of its cellular function may provide insights into the underlying 
mechanisms and contributing additional factors. 
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 Zusammenfassung 
Das menschlichen Immunschwäche-Virus 1 (HIV-1) und weitere Viren interagieren mit einer 
Reihe von intrazellularen Proteinen während ihrer Replikation in der Wirtszelle. Während 
einige von diesen Proteinen die Replikation vorantreiben gibt es aber auch Proteine, die die 
Replikation behindern. Diese Proteine werden als Restriktionsfaktoren bezeichnet und 
repräsentieren die erste Abwehr der Wirtszelle gegen Viren. Ein Restriktionsfaktor von HIV-1 
ist SAMHD1. SAMHD1’s dNTPase Funktion hindert retrovirale Replikation wahrscheinlich 
durch den Abbau intrazellularer dNTPs. Vpx von HIV-2 und SIV kann SAMHD1 binden und 
markiert es für den proteosomalen Abbau mit Hilfe der Cullin-4-DDB1-DCAF1-Ubiquitin-
Ligase-Maschinerie. Bisherige Studien in Blutmonozyten differenzierte Makrophagen 
(MDD)Zellen haben gezeigt, dass die Vpx-induzierte Erhöhung der HIV-1 Infektion von 
SAMHD1 unabhängig ist, da die Vpx Mutante Q76A, welche nicht in der Lage ist, DCAF1 zu 
rekrutieren und SAMHD1 zu degradieren, die HIV-1 Infektion erhöht in type 1 IFN α /LPS 
vorbehandelten Zellen. Wir zeigen hier, dass in gesunden Blutspendern Vpx Q76A keine 
Erhöhung der HIV-1-Infektion induziert. Daraus schließen wir, dass SAMHD1-Degradation 
wahrscheinlich mit auschlaggebend ist für die Vpx-induzierte Erhöhung der HIV-1 Infektion 
in IFN-1 vorbehandelten Zellen ist. Um die Vpx-induzierte Erhöhung der HIV-1 Infektion in 
IFN-1 vorbehandelten Zellen genauer zu charakterisieren, haben wir THP-1-SAMHD1-knock-
out-Zellen erstellt. Der Verlust des SAMHD1-Gens hatte keinen Einfluss auf den IFN-1 Block, 
jedoch zeigte sich, dass SAMHD1 fundamental ist für die Vpx-induzierte Erhöhung der HIV-1 
Infektion in IFN-1 vorbehandelten Zellen. Desweitern haben wir untersucht ob SAMHD1 
katalytisch aktiv sein muss für die Vpx-induzierte Erhöhung der HIV-1-Infektion. Wir konnten 
zeigen, dass die katalytisch inaktive SAMHD1-Mutante H233A nicht in der Lage war, die HIV-
1-Infektion zu erhöhen in IFN-1 vorbehandelten THP-1-Zellen. Um zu beweisen, dass 
SAMHD1-Degradation fundamental für die Vpx-induzierte Erhöhung der HIV-1-Infektion in 
IFN-1-vorbehandelten Zellen ist, haben wir einen CRISPR/Cas9-THP-1-Zellklon erstellt, 
welcher ein gestörtes SAMHD1-Allel hat und dessen anderes Allel keine 
Zellkernlokalisationssignal (11KRPR14) mehr beinhaltet. Aufgrund dessen befand sich 
SAMHD1 in diesem Zellklon im Zytoplasma. Vpx war in der Lage, in dem NLS-Klon die HIV-
1 Infektion in IFN-1 behandelten Zellen zu erhöhen. Jedoch war die SAMHD1-Degradation 
durch Vpx in diesen Zellen deutlich verlangsamt im Vergleich zu parentalen THP-1-Zellen. 
Darüber hinaus stehen Mutationen in SAMHD1 mit der Autoimmunerkrankung Aicardi-
Goutières-Syndrom (AGS) in Verbindung. Des Weiteren wurde gezeigt, dass Mutationen in 
SAMHD1 und reduzierte SAMHD1-Expression in Verbindung mit der Entstehung von Krebs 
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steht wie zum Beispiel bei akuter myeloische Leukämie (AML), chronische lymphatische 
Leukämie (CLL) und Darmkrebs. SAMHD1 ist auch ein Resistenzfaktor in der 
Nukleosidanalog-basierten Krebstherapie. Cytarabin (ara-C) ist ein Deoxycydidinanalog und 
ist das wichtigste Krebsmedikament in der Bekämpfung von AML. Die aktive Form von ara-C 
ist ara-CTP, welche in die DNA eingebaut wird und zum Zelltod führt. Wir und weitere 
Wissenschaftler haben gezeigt, dass ara-CTP ein Substrat von SAMHD1 ist und SAMHD1 in 
der Lage ist, ara-CTP zu hydrolysieren. THP-1-Zellen behandelt mit Vpx und SAMHD1-knock-
out-Zellen haben eine höhere Sensitivität zu ara-C als Kontrollzellen. Wir haben SAMHD1-
knock-out-Zellen genutzt, um natürlich vorkommende SAMHD1-Einzelnukleotid-
Polymorphismen (SNPs), welche in AML, READ, STAD oder COAD identifiziert wurden, zu 
exprimieren, um deren Effekte auf ara-C-Sensitivität und HIV-1-Restriktion zu untersuchen. 
SAMHD1-SNPs, die die ara-C Sensitivität verändern, können in der personalisierten 
Bekämpfung von Krebs sehr von Bedeutung sein. Des Weiteren hilft die Analyse von 
SAMHD1-SNPs die Bedeutung der dNTPase Aktivität von SAMHD1 für die HIV-1 Restriktion 
besser zu charakterisieren.  
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SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM standard error of the mean 
shRNA short hairpin RNA 
siRNA small interfering RNA 
SIV Simian immunodeficiency viruses 
SNP Single Nucleotide Polymorphism 
ssRNA  single stranded ribonucleic acid 
STAD Stomach adenocarcinoma 
Tat trans-activator of transcription 
TCGA The Cancer Genome Atlas 
TRIM Tripartite motif-containing protein 
U units 
UNAIDS Joint United Nations Programme on HIV/AIDS 
Vif viral infectivity factor 
VLP virus like particle 
Vpr viral protein R 
Vpu viral protein U 
Vpx Viral protein X 
wt wild type 
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 Introduction 
 Human Immunodeficiency Virus Type 1 (HIV-1) 
Human immunodeficiency virus 1 (HIV-1) is the primary cause of the acquired 
immunodeficiency syndrome (AIDS) and was identified in 1983/1984 (Barre-Sinoussi et al., 
2004, Gallo et al., 1983). Worldwide, approximately 37 million people are infected with the 
majority being in developing countries (UNAIDS, 2018), which led to 32.0 million AIDS-
related deaths since the start of the epidemic (UNAIDS, 2018). 1.8 million people got newly 
infected with HIV-1 in 2018 (UNAIDS 2018). Since the first cases of HIV were reported more 
than 35 years ago, 78 million people have become infected with HIV and 35 million have died 
from AIDS-related illnesses (UNAIDS 2018). HIV-1 efficiently infects CD4+ T cells, whereas 
cells of the myeloid lineage are less susceptible for infection with HIV-1 because they exhibit 
multiple post-entry blocks (Ho et al., 1995). Transmission of HIV occurs by the transfer of 
blood, semen, pre-ejaculate, vaginal fluid or breast milk.1 The infection with HIV causes a 
progressive depletion of CD4+ T cells in the host, ultimately compromising cell-mediated and 
adaptive immunity. The infected individual becomes more susceptible to life-threatening 
opportunistic infections, which eventually leads to the patient’s death.  
Three characteristic stages of HIV-1 infections can be defined (Swanstrom and Coffin, 2012): 
(1) acute early infection, in which the virus replicates leading to rapid depletion of T cells. (2) 
Clinical latency, in which HIV viremia is largely controlled, and T cell counts increase again 
as the virus turns silent and evades the immune system, the latent stage, which can last for 
several years. (Ozato et al.) (3) AIDS, a stage occurring with decreasing levels of CD4+ T cells 
and increasing viral load. Among all HIV-infected patients, approximately 17 million are on 
antiretroviral treatment (UNAIDS, 2016). This treatment consists of highly active antiretroviral 
therapy (HAART), a multiagent treatment containing at least three drugs, decreasing the 
patient’s viral load by blocking HIV entry. Interferons (IFNs), a set of cytokines, can reduce 
HIV-1 replication in certain types of natural target cells by inducing the expression of a set of 
antiviral genes that inhibit HIV-1 replication. This was observed in clinical trials in HIV-1 
infected patients (Mildvan et al., 1996, Torriani et al., 2003) as well as in cell culture systems 
(Bitzegeio et al., 2013, Agy et al., 1995, Ho et al., 1985, Baca-Regen et al., 1994). There are 
several limiting factors that stand in the way of achieving a complete cure of HIV/AIDS such 
as the high mutation rates of the virus which leads to the evolution of drug-resistant variants as 
well as drug toxicity over a long treatment and the latency of the virus in the host genome (Ho 
                                                 
1 https://www.cdc.gov/hiv/basics/transmission.html 
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et al., 2013). To date, there is no vaccine available and current treatments and diagnostics are 
rather expensive. A new strategy to combat HIV-1 was taken in consideration after a patient 
known as the “Berlin patient” underwent total remission of HIV-1 after receiving two 
allogeneic hematopoietic stem-cell transplantations (HSCTs) from a homozygous CCR5Δ32 
(CCR5Δ32/Δ32) donor as well as additional total body irradiation (Hutter et al., 2009). CCR5 
expression and infection by HIV variants that interact with the CCR5 coreceptor is prevented 
due to the 32-base-pair deletion leading to HIV-1 resistance in these cells (Simmons et al., 
1996). Another patient referred to as “London patient” received HSCT transplantation from 
homozygous CCR5Δ32 (CCR5Δ32/Δ32) donor in 2012 without chemotherapy and until now 
no viral load was detected (Gupta et al., 2019). Despite these promising results standard-of-care 
therapy won´t be possible due to the rarity of suitable donors. Therefore, a comprehensive 
understanding of the HIV-1 life cycle and defining latent reservoirs is crucial for finding an 
affordable and commercial cure for HIV-1 infection.   
 HIV-Classification, genome organization and virion structure 
HIV is an enveloped lentivirus belonging to the family Retroviridae. It is a single-stranded, 
positive-sense RNA virus. Once HIV has entered the target cell, the virally encoded reverse 
transcriptase (RT) reverse transcribes the viral RNA into double-stranded DNA which is a 
unique feature of Retroviruses. There are multiple strains of HIV-1 which are subdivided in 
four distinct groups: M (major), following alphabetically N (non-M-non-O), O (outlier) and P 
(putative) (Hemelaar, 2012). HIV-1 belonging to group M is responsible for approximately 90 
% of worldwide HIV infections. On the other hand, HIV-2, an HIV type that shares 50 % 
sequence homology with HIV-1, shows lower virulence and infectivity (Nyamweya et al., 
2013). The other groups are locally confined to sub regions of Africa (Hemelaar, 2012), 
Portugal and France (Schim van der Loeff and Aaby, 1999, Soriano et al., 1996, Soriano et al., 
2000, Damond et al., 2001). 
The HIV-1 genome consists of two single stranded RNA molecules 9,7 kb of size that are 
imbedded in the core of the virus particle. The genome is flanked by short repeats at both ends 
(U3 and U5) (Wain-Hobson et al., 1985; Ratner et al., 1985). During reverse transcription, those 
repeats are duplicated, thereby forming the long terminal repeat sequences (LTRs). The 5’ LTR 
region harbors the active promotor which is essential for transcription of the viral genes. The 
HIV genome consists of three major open reading frames: gag which codes for the groupe 
specific antigen (GAG) polyprotein; pol which codes for integrase, reverse transcriptase and 
the Pol precursor of viral enzyme protease; and the envelope (env) gene coding for Vpu, Vif, 
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Tat, Rev, Nef, and Vpr. Cellular or viral proteases process these precursors into mature particle-
associated proteins. The 55-kDa Gag precursor Pr55Gag is cleaved into three independently 
folded proteins: matrix (MA), capsid (CA), nucleocapsid (NC), p6 domains and spacer peptides 
during or after the release of progeny virions (Bell and Lever, 2013). The 160 kd Gag-Pol 
polyprotein consists of the protease (PR), integrase (IN) and reverse transcriptase (RT). 
Proteolytic digestion by cellular enzymes converts the glycosylated Env precursor into gp120 
surface (SU) and gp41 transmembrane (TM). The HIV-Env glycoprotein defines the tropism 
and mediates the entry into target cells. Cell tropism is mainly determined by CCR5 or CXCR4 
expression on target cells (Regoes and Bonhoeffer, 2005). The remaining six open reading 
frames encode the following proteins: accessory proteins Vif (virion infectivity factor), Vpr 
(viral protein R), Rev (regulator of virion), Tat (trans activator of transcription), Vpu (viral 
protein U) and Nef (negative factor) (see Figure 1) (Coffin et al., 1997). 
 
 
Figure 1: HIV-1 genome.  
HIV-1 consits of nine opne reding frames. The coding region is flanked by long terminal repeats (LTRs). Gag 
encodes  MA, CA, SP1, NC, SP2 and p6,  pol encodes PR, RT and IN domain and  the env gene which encodes 
envelope (Henderson et al.). Additional genes encode a set of accessory proteins vif, vpr, vpu, nef and tat. 
(Sandmeyer and Clemens, 2010) 
 
HIV-2 codes for virus protein X (Vpx) instead of Vpu, absence of Vpu is partially responsible 
for the reduced virulence and infectivity of HIV-2 (Vicenzi and Poli 2013). HIV-1 forms 
spherical particles measuring ~140 nm in diameter , which are enveloped by a lipid bilayer 
derived from the host cell plasma membrane (Herold et al.) (Briggs et al., 2003). Particles 
released from infected cells are initially in an immature state and upon protease activation a 
major rearrangement takes place. Gag is cleaved at five distinct cleavage sites leading to 
structural rearrangements resulting in a cone shaped capsid and to the mature, infectious virion 
containing the viral ribonucleoprotein particle, IN and RT (Campbell and Hope, 2015).  
 HIV-1 Replication 
HIV-1 is a lentivirus and as an intracellular obligate parasite it depends on and exploits the host 
cell machinery (life cycle depicted in figure 2). The infection cycle starts with the interaction 
of gp120 which is part of the HIV-1 spike together with gp41 and CD4, the major cell surface 
receptor for primate lentiviruses (Chan and Kim, 1998, Bour et al., 1995). CD4 binding not 
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only serves to virion attachment to the target cell but also induces a major rearrangement in the 
gp41 protein structure, leading to engagement of the co-receptors C-C motif chemokine 
receptor 5 (CCR5) or C-X-C motif chemokine receptor 4 (CXCR4) (Trkola et al., 1996, Wu et 
al., 1996). This induces conformational changes taking place in gp41, the hydrophobic region 
at the N-terminus, the so-called fusion peptide inserts into the host cell membrane (Freed et al., 
1990, Weissenhorn et al., 1997, Chan et al., 1997). After the so-called six-helix bundle is 
formed leading to close proximity of the opposed membranes and the formation of the fusion 
pore, the viral core is released into the cytoplasm (Herold et al., 2014, Doms and Moore, 2000).   
 
Figure 2: Schematic representation of the f HIV-1 life cycle.  
The first step is the attachment of HIV-1 to a target cell followed by fusion of the virus with the host cell plasma 
membrane which results in viral core entry. Uncoating and reverse transcription of the viral RNA (vRNA) into 
viral DNA (vDNA) and the formation of the pre-integration complex takes place in the cytoplasm. The viral genome 
is transported in the nucleus where integration takes place. Transcription products and mRNA are exported into 
the cytoplasm where translation of the viral mRNAs into viral proteins occurs. Some viral proteins (e.g. Tat and 
Rev, both expressed from spliced viral mRNAs) can shuttle back into the nucleus to regulate proviral transcription 
and expression of viral structural and enzymatic proteins from partially spliced or unspliced mRNAs. These are 
exported from the nucleus by interaction of Rev with the Rev-response element in a way dependent on the cellular 
protein Crm1. Gag and GagPol assemble at the plasma membrane and recruit other viral structural proteins to 
the assembly site. The viral bud is pinched off by the cellular ESCRT machinery. Gag and GagPol are 
proteolytically cleaved and structural rearrangement takes place to form a mature, infectious viral particle. From 
(Ganser-Pornillos et al., 2008) 
The diverse expression of cellular co-factors or antiviral resistance factors including post- entry 
restriction factors are often the reason for the differences in HIV-1 infectivity in different cell 
types. Intriguingly, a majority of restriction factors including tripartite motif-containing protein 
5 (TRIM5α), apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G 
(APOBEC3G), sterile-alpha motif and HD domain containing protein 1 (SAMHD1) and 
myxovirus resistance 2 (MX2) target the early phase of HIV-1 infection at or during reverse 
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transcription as well as at the step of nuclear import (Malim and Bieniasz, 2012). During the 
early stages of the infection process the single stranded RNA (ssRNA) is converted into double 
stranded DNA (dsDNA) by the reverse transcription enzyme which also harbors a ribonuclease 
H (RNaseH) activity (Baltimore, 1970, Temin and Mizutani, 1992). Reverse transcription 
presumably takes place in the cytosol were reverse transcription complexes are formed 
containing ribonucleoproteins, IN and RT and cellular host factors. For DNA synthesis the host 
cell’s dNTP pool is crucial. The synthesized DNA, which is flanked by long terminal repeats 
(LTRs) and several viral (e.g. RT, IN, CA, Vpr) and cellular (e.g. Lens epithelium–derived 
growth factor (LEDGF)) proteins form the pre-integration complex (PIC) and are targeted to 
the nucleus (Maillot et al., 2013). In addition to the linear double stranded viral DNA reverse 
transcription and nuclear import also yields two types of circular DNA termed 1-LTR and 2-
LTR circles, which are a marker for nuclear import (Li et al., 2001). A characteristic feature of 
retrovirus replication is the integration of the viral genome into the host cell chromosome, 
preferably in transcriptionally active regions (Schroder et al., 2002). Integration of viral DNA 
is catalyzed by the viral Integrase (IN) (Farnet et al., 1996).The integrated viral genome (so-
called provirus) serves as a template for the synthesis of viral RNA and maintains there for the 
lifespan of the host cell. It can either remain as a latent provirus or transcriptional activation 
can take place (Van Lint et al., 2013, Lusic and Siliciano, 2017). Transcription factors are 
recruited to the promotor in the 5´LTR region, which leads to the expression of viral genes. Tat, 
Rev and Nef are early transcribed viral accessory proteins which are expressed from fully 
spliced mRNA that is recognized as ‘cellular’ mRNA taking the same nuclear export pathway 
as most cellular mRNAs. The indispensable viral protein Tat increases the efficiency of 
transcription by binding to transactivation response RNA structure (Tar) and recruiting cellular 
factor such as RNA polymerase II (Kao et al., 1987, Fisher et al., 1986, Dayton et al., 1986). 
Accumulation of Rev facilitates nuclear export of viral unspliced or partially spliced mRNAs 
which are not exported by the normal cellular mRNA export pathway and encode Gag and Gag-
Pol, Env, Vpr, Vif and Vpu (Jeang et al., 1999, Schwartz et al., 1990). After Gag synthesis, Gag 
is recruited to the membrane by MA where it anchors to the plasma membrane by using its 
myristyl residue as an anchor (Ono et al., 2004) and thereby initiates the recruitment of Env, 
viral GagPol and the accessory proteins Nef, Vpr and Vif and their incorporation into viral 
particles (Dorfman et al., 1994). Thereby, an immature viral bud is formed which is pinched off 
and released from the plasma membrane by the recruitment of the cellular ESCRT components 
(Bieniasz, 2006). In order to initiate infection of a new target cell the virion has to go through 
a maturation process (Peng et al., 1989, Kohl et al., 1988). The maturation process is initiated 
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by the activation of the protease which leads to Gag and GagPol cleavage into their components. 
Furthermore, Env distribution is changed and Gag subunits are rearranged to form the mature 
virion (Chojnacki et al., 2012).  
 Restriction factors 
In response to virus infection, cells have evolved antiviral factors, so called restriction factors. 
The incoming virus is sensed by the host cell proteins and, in response, viral replication and 
propagation is blocked. Many restriction factors are type I interferon (IFN) induced or type I 
IFN supports their activity (Schoggins et al., 2011, Jimenez-Guardeno et al., 2019). Type I 
interferon is a family of innate cytokines, including 13 IFNα subtypes and 2 types of IFNβ and 
during acute virus infection, type I interferons are mainly released by plasmacytoid dendritic 
cells (Fitzgerald-Bocarsly et al., 2008). IFNs can reduce HIV-1 replication in certain types of 
natural target cells by inducing the expression of a set of antiviral cellular genes that inhibit 
HIV-1 replication (Li et al., 2014, Chelbi-Alix and Wietzerbin, 2007). Besides being interferon 
inducible, restriction factors can have the following characteristics: self-sufficient activity, 
constitutive expression in some cell types, cause a significant decrease in viral infectivity, often 
act in a species-specific manner and are often antagonized by viral accessory proteins (Blanco-
Melo et al., 2012). The following proteins are some of the known restriction factors that target 
HIV-1 and other primate lentiviruses (Figure 3). Tripartite-motif-containing 5 (TRIM5) 
proteins (Stremlau et al., 2004), Bone marrow stromal antigen 2 (Tetherin/ BST-2) (Neil et al., 
2008, Van Damme et al., 2008), sterile alpha motif and HD domain containing 1 (SAMHD1) 
(Hrecka et al., 2011, Laguette et al., 2011a) the apolipoprotein B mRNA-editing enzyme 
catalytic polypeptide-like 3G/F (APOBEC3G/F) proteins (Sheehy et al., 2002), myxovirus 
resistance 2 (MX2) (Goujon et al., 2013a), serine incorporator 5/3 (Serinc3/5) (Usami et al., 
2015, Rosa et al., 2015) and interferon-induced transmembrane proteins (IFITMs) (Lu et al., 
2011). 
APOBEC3G/F proteins belong to the AID/APOBEC family (apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide-like) of cytidine deaminase enzymes and they restrict a broad 
range of viruses including hepatitis B virus  as well as endogenous and pathogenic retroviruses 
(Suspene et al., 2005, Mahieux et al., 2005, Delebecque et al., 2006, Browne and Littman, 
2008). In the absence of functional Vif protein and upon HIV-1 infection, APOBEC3G/F are 
incorporated into budding virions. During reverse transcription of the viral RNA, 
APOBEC3G/F catalyze cytosine-to-uracil deamination in the newly transcribed viral DNA 
leading to G-to-A hypermutations. This results in amino acid substitutions and premature STOP 
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codons which will result in the production of defective proteins as well as non-functional viral 
particles, achieving a strong inhibition of HIV-1 replication (Zhang et al., 2003, Mangeat et al., 
2003, Harris et al., 2003). APOBEC3G binds to viral RNA during reverse transcription and 
prevents proper elongation by building a ‘road block’ at certain positions (Pollpeter et al., 
2018). APOBEC3G/F are normally excluded from virions by the interaction with the viral Vif 
protein which recruits a ubiquitin ligase complex that leads to proteasomal degradation of 
APOBEC3G/F and prevents incorporation (Malim, 2006). 
Tetherin/BST-2 is a transmembrane protein with an N-terminal transmembrane domain and a 
C-terminal glycosyl-phosphatidylinositol group. Due to the proteins unique structure, one end 
of the protein stays attached to the plasma membrane and the other to the viral membrane, 
hindering HIV-1 release. The trapped virions are eventually internalized and degraded via the 
endosomal/lysosomal pathway (Neil et al., 2008, Van Damme et al., 2008, Perez-Caballero et 
al., 2009, Miyakawa et al., 2009). 
Tripartite motif (TRIM) proteins are a large family of E3 ubiquitin ligases which are important 
for cellular processes including cell differentiation, autophagy, carcinogenesis, apoptosis, 
antiviral immunity, and innate signaling (Ozato et al., 2008, Hatakeyama, 2017, Rajsbaum et 
al., 2014, Nisole et al., 2005). TRIM proteins consist of an N-terminal RBCC structure, which 
consists of an N-terminal RING E3 ligase domain (R), one or two B-box domains (B), and a 
coiled-coil domain (CC). The C-terminal domain(s) divides the TRIM proteins into subgroups. 
The most frequent domain is the PRYSPRY domain among TRIM family members. The 
PRYSPRY domain of TRIM5alpha is crucial for the binding to the retroviral capsid and 
determines retroviral restriction (Sawyer et al., 2005, Stremlau et al., 2005, Yap et al., 2005). 
Certain New World monkey as well as some Old World monkey species have evolved on two 
independent occasions a fusion protein consisting of the TRIM5 RBCC and cyclophilin A 
(CypA) ((Song et al., 2005, Newman et al., 2008)). The TRIMCyp fusion protein of the Owl 
monkeys potently restricts HIV-1 infection, a process that can be antagonized by addition of 
cyclosporine A, which prevents interaction of the CypA domain with the viral capsid protein, 
thereby rescuing infection in cells from these monkeys (Keckesova et al., 2006). 
The IFITM protein family is encoded by five genes in humans, including the immune-related 
IFITM1, IFITM2, and IFITM3, as well as IFITM5 and IFITM10 which have no characterized 
roles in immunity (Diamond and Farzan, 2013). Besides some HIV-1 restriction, IFITMs also 
show strong inhibition activities against dengue virus, influenza A virus, West Nile virus and 
vesicular stomatitis virus (Lu et al., 2011, Brass et al., 2009, Jiang et al., 2010, Weidner et al., 
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2010). Lu et al. demonstrated that IFITMs inhibit the entry step that is mediated by the envelope 
proteins of certain viruses (Lu et al., 2011), especially IFITM 2 and IFITM3 (Yu et al., 2015). 
Viruses on the other hand have evolved countermeasures depicted in blue in figure 3. The HIV-
1 capsid (CA) protein does not very efficiently interact with human TRIM5alpha although it 
strongly restricts equine infectious anemia virus (EIAV) and N-tropic murine leukemia virus 
(N-MLV) (Stremlau et al., 2004, Yap et al., 2004, Hatziioannou et al., 2004, Keckesova et al., 
2004). However, a recent report suggested that even this weak interaction can lead to a 
substantial restrictive effect, in the presence of type I IFNs that activate the immunoproteasome 
(Jimenez-Guardeno et al., 2019). HIV-1 expresses Vif to counteract APOBEC3G/F and cause 
its degradation by the proteasome (Goila-Gaur and Strebel, 2008, Sheehy et al., 2002, Yu et al., 
2003). HIV-1 Nef binds and prevents antiviral activity of SERINC proteins (Rosa et al., 2015, 
Usami et al., 2015). HIV-2 and SIVs have evolved the Vpx protein that binds to and induces 
the degradation of SAMHD1 (Hrecka et al., 2011, Laguette et al., 2011a). The antiretroviral 
activity of Tetherin is counteracted by the accessory protein Vpu of HIV-1 and by the Env 
protein of other lentiviruses (Van Damme et al., 2008). To date no apparent antagonistic viral 
protein against the IFN-induced MX2 protein or against SAMHD1 has been discovered for 
HIV-1. Restriction factor research, especially identifying novel restriction factors, promises to 
open up new ways to combat HIV/AIDS. 
 
Figure 3: Host restrictions factors and viral countermessures. 
Viral host restriction factors are depicted in red and evolved viral countermesures are shown in blue boxes. From 
(Seissler et al., 2017) 
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 Vpx 
Viral protein x (Vpx) is a 12-16 kDa viral protein encoded by simian immunodeficiency viruses 
(SIVs) and HIV-2 (Tristem et al., 1990). Vpx is incorporated into viral particles (Henderson et 
al., 1988, Franchini et al., 1988, Yu et al., 1988, Kappes et al., 1988) via an interaction with the 
p6 domain of Gag (Wu et al., 1994, Accola et al., 1999, Selig et al., 1999). Vpx harbors a C- 
terminal non-canonical nuclear localization signal (NLS) (65-SYTKYRYL-72) (Belshan and 
Ratner, 2003, Rajendra Kumar et al., 2003) as well as a presumed second N-terminal NLS 
(Singhal et al., 2006a). It is controversial whether Vpx can shuttle between the nucleus and 
cytoplasm (Belshan and Ratner, 2003, Singhal et al., 2006b). Upon transfection of plasmids 
encoding Vpx, the majority of the protein localizes to the nucleus (Depienne et al., 2000, 
Mahalingam et al., 2001, Belshan et al., 2006, Belshan and Ratner, 2003). Mangeot et al. 
published that the presence of Vpx during the transduction of monocyte-derived dendritic cells 
(MDDCs) with SIVMAC based-lentiviral vectors is crucial for infectivity (Mangeot et al., 2002). 
Later, it was shown that, when Vpx is delivered in trans via virus-like particles (VLPs), HIV-1 
transduction of MDMs and MDDCs is increased, which correlates with the accumulation of 
viral DNA (Goujon et al., 2006). The proteomic studies of Le Rouzic yielded some fundamental 
insights on Vpx and its function. He as well as the team of Zhao discovered that HIV-1 Vpr 
recruits the damage-specific DNA binding protein 1 (DDB1)-Cullin 4A (CUL4A) E3 ubiquitin 
ligase complex through the interaction of VprBP (Zhao et al., 1994, Le Rouzic et al., 2007). In 
addition, VprBP was shown to be a substrate of DDB1-CUL4A-RBX1/ROC1 complex. VprBP 
was therefore renamed DDB1-CUL4A-associated factor 1 (DCAF1) (Angers et al., 2006). Le 
Rouzic et al. revealed with the help of the yeast-two hybrid system that Vpx from SIVMAC 
which is homologous to HIV-1 Vpr (Tristem et al., 1990) was able to interact with 
VprBP/DCAF1 (Le Rouzic et al., 2007). The fact that the interaction was confirmed in 
mammalian cells (Goujon et al., 2008, Sharova et al., 2008, Srivastava et al., 2008, Bergamaschi 
et al., 2009) and RNAi-mediated depletion of DDB1 or DCAF1 resulted in reduced infection 
of HIV-2 as well as SIVMAC in macrophages led to the following model: the Vpx protein recruits 
the DCAF1/DDB1/CUL4A E3 ubiquitin ligase complex initiating proteasomal degradation by 
poly-ubiquitination of a myeloid cell-specific restriction factor that prevents viral DNA 
accumulation (Sharova et al., 2008, Srivastava et al., 2008, Bergamaschi et al., 2009). In 2011, 
two independent studies revealed sterile alpha motif (SAM) and HD-domain containing protein 
1 (SAMHD1) as one of the major binding partners of Vpx (Hrecka et al., 2011, Laguette et al., 
2011a). Both studies showed that Vpx induces SAMHD1 degradation via proteasomal 
degradation (Figure 4 B). Lim et al. concluded that SAMHD1 antagonism is conserved in all 
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clades of Vpx proteins in a species-specific way (Lim et al., 2012). HIV-1 infection can be 
rescued from the type I IFN-induced block in myeloid cells when VLP containing Vpx from 
SIVMAC are added in trans prior to infection (Gramberg et al., 2010, Pertel et al., 2011, Goujon 
et al., 2013b). In contrast, adding VpxMAC prior to infection with SIVMAC or HIV-2 does not 
relieve the type I IFN- induced block from SIVMAC nor HIV-2 in monocyte-derived dendritic 
cells (MDDC) (Pertel et al., 2011). The involvement of SAMHD1 in the VpxMAC mediated 
rescue from the type I IFN induced block to HIV-1 infection is yet to be determined. Pertel et 
al. reported that the Vpx mutant Q76A which is unable to bind DCAF1 and to induce SAMHD1 
degradation (Srivastava et al., 2008) was still able to rescue HIV-1 infection from the type I 
IFN response in MDDC (Pertel et al., 2011). Since DCAF1 binding to Vpx is essential for 
SAMHD1 degradation, SAMHD1’s involvement in the Vpx mediated rescue from the type I 
IFN induced block to HIV-1 infection is questionable.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Schematic illustration of Vpx protein from 
SIVMAC and model of Vpx mediated degradation of 
SAMHD1.  
A) Vpx schematic structure. The three α-helices of Vpx, 
the nuclear localization signals (NLS) and the critical 
residue that determines Vpx interaction with DCAF1 
(Q76) as well as the SAMHD1 interaction region are 
indicated. B) Model of Vpx recruitment by DCAF1-
DDB1-CUL4A. Vpx binds to DCAF1 and recruits the 
DDB1-CUL4A-RBX1 E3 ubiquitin ligase complex. Vpx 
targets like SAMHD1 are ubiquitinated trough the 
interaction of RBX1 with an E2 ligase. Nededylation of 
CUL4 is important for propper its functionality. RBX1 
interacts with the ubiquitin-conjugating enzyme UBC12 
which is crucial for the transfer of NEDD8 group from 
the NEDD8 activating enzyme (NAE). From (A)Zheng et 
al. 2012, (B)Schaller et al. 2014) 
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 SAMHD1  
7.6.1 Structure of SAMHD1 
SAMHD1 is a 626 amino acid protein harboring an amino-terminal sterile alpha motif (SAM) 
domain (residues 40-109), a catalytic core domain (HD domain residue 110-599) and a C-
terminus (residues 600-626) where the Vpx binding domain resides (Li et al., 2000, Liao et al., 
2008) (Figure 5). Due to its nuclear localization signal (NLS) at residue 11-14 (Lys-Arg-Pro-
Arg), SAMHD1 is localized in the nucleus (Hofmann et al., 2012, Brandariz-Nunez et al., 2012, 
Wei et al., 2012, Schaller et al., 2014)  
The SAM domain is also found in other proteins and is commonly involved in protein-protein 
and protein-DNA/RNA interaction ((Kim and Bowie, 2003). The precise function of the 
SAMHD1 SAM domain has yet to be determined, but it was observed that it might be 
dispensable for retroviral restriction even though it might be required for maximal enzymatic 
activity (Beloglazova et al., 2013, White et al., 2013b). The HD domain of SAMHD1 contains 
the regulatory sites, the dNTPase active site and is crucial for oligomerization and may be 
involved in nucleic acid binding (Goldstone et al., 2011, Goncalves et al., 2012b, Koharudin et 
al., 2014a). The active site within the HD domain consist of a characteristic quartet of metal 
coordinating histidine and aspartic acid residues (H167, H206, D207 and D311) (Aravind and 
Koonin, 1998). Expression of the HD domain of SAMHD1 alone is sufficient to restrict HIV-
1 infection (White et al., 2013b). 
Crosslinking experiments show that SAMHD1 forms oligomers in cells and the enzymatically 
active form of SAMHD1 is a tetramer (Zhu et al., 2013, Ji et al., 2013). The SAMHD1 monomer 
consist of two distinct allosteric binding sites A1 and A2 and a substrate-binding site (S). 
Tetramerization is driven by guanine nucleoside triphosphate (GTP or dGTP) binding to A1 
where a network of five specific hydrogen bonds are formed between the base edge of guanine 
and the surrounding residues of D137, Q142, and R145 (Ji et al., 2013, Yan et al., 2013). A1 
has been identified to exclusively bind dGTP or GTP whereas A2 can bind all dNTPs (dATP, 
Figure 5: Schematic representation of SAMHD1 domains.  
SAMHD1 consists of a SAM and HD domain. The nuclear localization signal (KRPR) resides at the N-terminus 
of SAMHD1. The Vpx binding domain is located at the -C-terminus. The start and end of each domain is 
indicated. From (Zheng et al., 2012) 
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dTTP, dGTP or dCTP (Figure 6). Given the fact that the physiologically GTP concentration is 
1,000 fold higher as compared to dGTP (Kennedy et al., 2010) and that tetramer formation is 
more stable when GTP is bound due to an extra hydrogen bond formation between GTP and 
V117, it is likely that GTP is the primary allosteric activator (Amie et al., 2013, Koharudin et 
al., 2014a, Miazzi et al., 2014, Arnold et al., 2015). 
 
 
As mentioned before SAMHD1 is localized in the nucleus. Nevertheless, the antiviral activity 
of SAMHD1 is not perturbed by disruption of its NLS sequence (Rice et al., 2009a, Brandariz-
Nunez et al., 2012, Hofmann et al., 2012, Schaller et al., 2014) but disruption hinders SIVMAC 
Vpx-mediated SAMHD1 degradation (Brandariz-Nunez et al., 2012, Hofmann et al., 2012, Wei 
et al., 2012, Guo et al., 2013). Hofmann et al. showed that Vpx can bind to cytoplasmic as well 
as nuclear SAMHD1 (Hofmann et al., 2012). This raises the question why cytoplasmic 
SAMHD1 is less sensitive to Vpx-mediated degradation.  
7.6.2 SAMHD1 is an HIV-1 restriction factor 
SAMHD1 is a deoxynucleoside-triphosphate (dNTP) triphosphohydrolase (Goldstone et al., 
2011, Powell et al., 2011, Yan et al., 2013, Lahouassa et al., 2012) and a restriction factor of 
HIV-1, likely by reducing the amount of dNTPs necessary for efficient reverse transcription 
thus reducing reverse transcription and DNA synthesis of the incoming virus (Goldstone et al., 
2011, Lahouassa et al., 2012). For that reason HIV-1 infection in myeloid cells and resting 
CD4+ T cells is rather inefficient (Lahouassa et al., 2012, St Gelais et al., 2012, Baldauf et al., 
2012, Descours et al., 2012) resulting in accumulation of viral DNA reverse transcription 
intermediates (Korin and Zack, 1999). However, it has to be made clear that SAMHD1 presents 
only one block of likely several blocks, especially in resting CD4 T cells, since inactivation of 
Figure 6: Model of SAMHD1 tetramerization.  
Each SAMHD1 monomer consists of two allosteric sites A1 and A2 and a Substrate binding site. Under conditions 
of low level of dNTPs SAMHD1 is found in a monomer dimer equilibrium. Binding of GTP/dGTP to A1 stabilizes 
the SAMHD1 dimer. Upon elevation of the dNTP level above the activation threshold (1-20µM) GTP/dGTP and 
dNTP fill the allosteric sites leading to tetramerization of SAMHD1. Activated SAMHD1 can hydrolyze dNTPs to 
lower the levels of available dNTPs that would otherwise be cytotoxic for the cell and increase the mutation rate. 
Adapted from Herold et al., 2017b 
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SAMHD1 in these cells does not rescue the large majority of infecting viruses (Descours et al., 
2012, Baldauf et al., 2017). It is also still unclear whether the depletion of the intracellular dNTP 
pool alone is sufficient for HIV-1 restriction. It has been reported more recently that a putative 
RNase activity of SAMHD1 might be key for antiviral restriction (Beloglazova et al., 2013, 
Ryoo et al., 2014a). Ryoo et al and Choi et al. reported that SAMHD1 might be able to directly 
degrade viral RNA based on increased viral RNA levels when SAMHD1 was depleted in 
MDM, PMA differentiated THP-1 cells and CD4+ T compared to non-depleted control cells 
(Ryoo et al., 2014a, Choi et al., 2015). Other groups question the RNase activity and claimed 
that the observed nuclease activity of immunoprecipitated SAMHD1 is due to an unknown co-
purified protein (Seamon et al., 2015, Antonucci et al., 2016). Furthermore SAMHD1-mediated 
block is reversible in MDM thus it is questionable whether viral RNA degradation is crucial for 
SAMHD1-mediated lentiviral restriction (Hofmann et al., 2013).  
Lentiviral restriction is prohibited by the phosphorylation at the residue T592 of SAMHD1 by 
the cell cycle regulator cyclin-dependent kinase 1/2 (CDK1/2) in proliferating cells (Cribier et 
al. 2013, St Gelais et al. 2014). Schott et al. recently reported that SAMHD1 levels did not 
change with respect to the cell cycle status in HeLa cells (Schott et al., 2018). Furthermore, 
cell-cycle analysis suggests that SAMHD1 dephosphorylation at T592 is controlled by the cell 
cycle and occurs during M/G1 transition in proliferating cells. The authors identified PP2A-
B55α holoenzyme as a key regulator of SAMHD1 dephosphorylation and thus switches on 
antiviral restriction (Schott et al. 2018). The phosphorylation defective mutant of SAMHD1 
(T592A) was shown to have antiviral functions in resting as well as dividing U937 cells (Cribier 
et al. 2013). Furthermore, the SAMHD1 phosphomimetic mutant T592E was unable to restrict 
HIV-1 infection (Welbourn et al. 2013, White et al. 2013). Despite the discrepancy of 
SAMHD1`s antiviral function in cycling vs. non-cycling cells, the phosphorylation status did 
not affect SAMHD1`s ability to hydrolyze dNTPs, suggesting for an dNTPase-independent 
restriction mechanism (White et al. 2013).  
Recent publication identified that SAMHD1 is not only modified by phosphorylation but can 
also be modified by acetylation (Lee et al., 2017), SUMOylation (Lamoliatte et al., 2014, 
Hendriks et al., 2017, Lumpkin et al., 2017) and ubiquitination (Elia et al., 2015). The impact 
of the mentioned SAMHD1 modification on HIV-1 restriction is yet to be determined. 
Additionally, redox active cysteines were identified in SAMHD1 and are thought to be required 
for lentiviral restriction (Wang et al., 2018, Mauney et al., 2017). The C522S amino acid 
substitution had no detectable detrimental effect on SAMHD1 tetramerization or dNTPase 
activity in vitro. The authors reasoned that nucleotide dependent tetramerization and dNTPase 
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activity were needed but not sufficient for the block of retroviral infection, suggesting that the 
redox state of C522 is crucial for the SAMHD1 restriction mechanism of HIV-1 infection. 
(Wang et al., 2018). The involvement of an SAMHD1 binding partner might modify SAMHD1 
and thereby influence HIV-1 restriction. Majer et al. suggested that SAMHD1-mediated 
restriction involves not only its dNTPase function but rather involves a combination of several 
modifications and functions of SAMHD1 (Majer et al., 2019). SAMHD1 depletion in dendritic 
cells or macrophages drastically enhances HIV-1 infection, reflecting that HIV-1 does not 
encode an obvious SAMHD1 antagonist. Additionally, in the presence of Vpx, HIV-1 
experimentally made to infect dendritic cells causes the induction of an antiviral state and 
cytokine production (Manel et al., 2010). This led to the hypothesis that HIV-1 has evolved to 
avoid infection of myeloid cells in vivo possibly to reduce proinflammatory cytokine production 
and antigen presentation to minimize adaptive immune responses (Manel et al., 2010). 
SAMHD1 was shown to be expressed to similar levels in resting CD4+ T cells, MDMs and in 
activated CD4+ T cells (Baldauf et al., 2012, Descours et al., 2012), hence expression levels 
alone could not explain differential phenotypes with regards to Vpx-induced rescue of HIV-1 
infection.  
 
Figure 7: Model for SAMHD1 function in HIV-1 restriction. 
In myeloid cells infected with HIV activated SAMHD1 catalyzes the cleavage of dNTPs into the composite 
deoxynucleoside and inorganic triphosphate. The deoxynucleotide pool is suppressed thus reverse 
transcription is inhibited leading to a block of HIV-1 infection. In the presence of Vpx, Vpx hijacks the DDB1–
CUL4A-RBX1 E3 ubiquitin ligase complex by recruiting DCAF1 thereby initiating proteasomal for 
degradation of SAMHD1 SAMHD1 can no longer reduce the pol of dNTPs necessary for reverse transcription. 
modified from (Goldstone et al., 2011) 
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7.6.3 Deoxynucleotide metabolism overview 
Precise regulation of the intracellular dNTP level is crucial to cell survival and genomic 
integrity (Meuth, 1989, Kumar et al., 2011, Kumar et al., 2010, Buckland et al., 2014). In order 
to control synthesis and degradation organisms have evolved complex and dynamic 
mechanisms and checkpoints (Figure 8) (Lane and Fan, 2015, Rampazzo et al., 2010). Enzymes 
are frequently regulated in a concentration dependent manner with respect to their substrates 
and products, usually via allosteric activation or inhibition (Hofer et al., 2012, Wallden and 
Nordlund, 2011, Johansson et al., 2001, Hunsucker et al., 2005, Bianchi and Spychala, 2003). 
dNTP synthesis consists of two distinct pathways; the de novo synthesis and the salvage 
pathway (Reichard, 1988, Mathews, 2006). The key enzyme in the de novo synthesis is the 
ribonucleotide reductase (RNR) which converts ribonucleoside diphosphate (NDPs) to 
deoxyribonucleoside diphosphate (dNDPs) which are subsequently phosphorylated to provide 
dNTPs for DNA synthesis and repair. SAMHD1 and RNR are similar in the way that both have 
two allosteric sites and one catalytic site. Furthermore the active form of both enzymes is an 
oligomer (Aye et al., 2015). The salvage pathway is constantly active in the cytosol and in 
mitochondrial compartments (Figure 8) (Rampazzo et al., 2010).  
 
 
 
Figure 8: Overview of the dNTP 
metabolism.  
The de novo pathway of dNTP synthesis 
is depicted in a blue box and the salvage 
pathway in red. The salvage pathway 
consists of complementary pathways in 
the cytosol and mitochondria. In order to 
maintain the dNTP level cellular kinases, 
phosphorylate deoxynucleosides (dN) 
and deoxynucleotides (dNMP, dNDP), 
while 5’-deoxynucleotidases and 
phosphorylases catalyze the opposing 
reactions. The SAMHD1 
triphosphohydrolase reaction is 
highlighted in green. SAMHD1 is crucial 
to maintain the dNTP levels. From 
(Mauney and Hollis, 2018) 
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7.6.4 SAMHD1 in cancer 
SAMHD1 not only acts as a host restriction factor for viral infections, mutations in the 
SAMHD1 gene have been linked to a genetic immune disorder called Aicardi-Goutières 
Syndrome (AGS) as well as several types of cancer (Kohnken et al. 2015, Rice et al. 2009). 
These suggest the involvement of SAMHD1 in the innate immune response and cancer 
development through the control of dNTP homeostasis. 
Acute myelogenous leukemia (AML) is the most common acute leukemia in adults (Saletta et 
al., 2014). The backbone treatment against AML is the cytostatic deoxycytidine analog 
cytarabine (ara-C) (Rowe, 2013). In response to ara-C therapy, AML blasts accumulate the 
active metabolite ara-C triphosphate (ara-CTP) (Zittoun et al., 1987, Kessel et al., 1969, 
Heinemann and Jehn, 1990, Estey et al., 1987) which leads to DNA damage due to perturbation 
of DNA synthesis (Kufe et al., 1984). Antimetabolites such as 2’-deoxyribonucleosides, 
arabinose nucleoside analogs or other nucleoside derivatives- are an important class of 
chemotherapeutic agents and are used to treat cancer and viral infection (Balzarini, 2000, 
Parker, 2009, Hurwitz and Schinazi, 2013, Tsesmetzis et al., 2018). Hollenbaugh et al. studied 
the effect of stereoselective 2’ substitution of nucleoside analogues on SAMHD1 activity. 
Modeling of dCTP and ara-CTP into the catalytic pocket of SAMHD1 and biochemical analysis 
revealed that dCTP and ara-CTP fit within the catalytic site and are hydrolyzed in the presence 
of SAMHD1 (Hollenbaugh et al., 2017).  
There is increasing evidence for a tumor suppressor function of SAMHD1. Clifford et al. found 
SAMHD1 mutations in chronic lymphocytic leukemia (CLL) and they propose that mutated 
SAMHD1 could contribute to promoting leukemia development (Clifford et al., 2014). 
Furthermore Rentoft et al. analyzed 217 colon adenocarcinomas presented in The Cancer 
Genome Atlas (TCGA) and identified eight associated SAMHD1 mutations. These SAMHD1 
mutations were found in hypermutated tumors of which six had mutations in genes encoding 
mismatch repair components. Furthermore, the calculated mutation rate within the SAMHD1 
gene was higher than random (p=0.049)  (Rentoft et al., 2016). The in vitro dNTPase activity 
of four chosen amino acid variants (V133I, A338T, R366H, D497Y) were analyzed and all four 
mutations showed an overall reduced activity in comparison to wildtype with alternating 
specificity for the canonical dNTPs, which suggested an imbalanced dNTP pool in these cancer-
associated mutations. Interestingly, SAMHD1 R366H had reduced activity toward dTTP, dCTP 
and dATP, whereas dGTP hydrolysis was almost unaffected (Rentoft et al., 2016).  
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 Aims of this thesis 
 SAMHD1’s role in the type 1 interferon induced early block to HIV-1 
infection  
SAMHD1 is the target of the Vpx protein from simian lentiviruses and HIV-2 (Hrecka et al., 
2011, Laguette et al., 2011b). Vpx mediates the recruitment of the CUL 4-DDB1-DCAF1 
ubiquitin ligase machinery to SAMHD1 in order to polyubiquitinate and degrade SAMHD1 
(Le Rouzic et al., 2007). Early studies on monocyte-derived dendritic cells suggested that the 
Vpx-induced rescue of HIV-1 infectivity from early type I IFN-induced blocks was independent 
of SAMHD1, since the Vpx mutant Q76A, which is unable to recruit DCAF1 and hence unable 
to degrade SAMHD1, still rescued HIV-1 infection from the type I IFN-induced block (Pertel 
et al., 2011).To investigate the role of SAMHD1 in the Vpx-mediated rescue of HIV-1 from 
the type I IFN induced block in myeloid cells, we generated CRISPR/Cas9 THP-1 cells lacking 
a functional SAMHD1 gene. The aim of the PhD thesis was to investigate SAMHD1s role in 
the IFN induced block to HIV-1 infection and in the Vpx-mediated rescue of HIV-1 from the 
type 1 interferon induced block. We also aimed to further characterize known ISGs blocking 
HIV-1, including IFITMs and MX2 and investigate their involvement in the Vpx mediated 
increase of infectivity to HIV-1 infection. Despite the fact that HIV-1 does not encode Vpx, 
Vpx serves as a tool to further characterize the underlying mechanism of ISGs and their 
involvement in HIV-1 infection.  
 Correlation of SAMHD1 dNTPase activity with HIV-1 restriction by 
using cancer-associated naturally occurring SAMHD1 variants 
We and others demonstrated that SAMHD1 is able to detoxify ara-C treated cells by reducing 
the pool of intracellular ara-CTP (Herold et al. 2017, Schneider et al. 2017). The backbone 
treatment against AML is the cytostatic deoxycytidine analog cytarabine (ara-C) (Rowe 2013). 
Several studies reported mutation of SAMHD1 that contribute to the formation of cancer 
(Rentoft et al., 2016, Clifford et al., 2014). 
Cancer associated mutations could lead to imbalanced dNTP levels due to malfunction of the 
dNTPase, which could also result in differences in ara-CTP hydrolysis. In this way, the ara-C 
cytotox assay is an ideal tool to directly compare enzymatic activity (ara-C hydrolysis may 
correlate with dNTPase activity) with HIV-1 restriction in the same cells.  
Therefore, I expressed known SAMHD1 single nucleotide polymorphisms (SNPs) that have 
been correlated with carcinogenesis and analyzed ara-C sensitivity as well as restrictive activity 
towards HIV-1 infection. The identification of SNPs altering the sensitivity to certain anti-
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cancer chemotherapies could be a key for future personalized treatment and understanding the 
contribution of SAMHD1’s dNTPase activity towards HIV-1 restriction and to the type I IFN-
induced block in certain cell types may help to develop new strategies to combat HIV/AIDS. 
Linking both fields and activities will help to untangle the different roles of SAMHD1 in viral 
restriction, as resistance factor in chemotherapy and as a possible tumor suppressor in certain 
malignancies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
 Material and Methods 
 Material 
9.1.1 Laboratory equipment 
Name Company 
Bacteria Incubator (IN75) Memmert, Schwabach, Germany 
Bacteria Shaker Multitron Pro Infors, Bottmingen, Switzerland 
C1000 Touch Thermal Cycler  BioRad, Hercules, USA 
Cell Culture Centrifuge (MegaFuge 40R) Heraeus, Hanau, Germany 
Centrifuge J2HS with rotor JA-10 Beckman Coulter, Brea, USA 
CFX 96 Real Time PCR detector (for SG-PERT) BioRad, Hercules, USA 
Electrophoretic Transfer Cell Mini Trans-Blot® BioRad, Hercules, USA 
Flow cytometer FACS Canto II BD Biosciences, Franklin Lakes, USA 
Gel iX Imager (Agarose gel UV-imager) INTAS Science Imaging, Göttingen, 
Germany 
Ice Maker AF 103 Scotsman, Sprockhövel 
Incubator C200 Labotect Labor-Technik-Göttingen, 
Rosdorf 
L8-70M Ultracentrifuge with SW28 and SW32 rotor Beckman Coulter, Brea, USA 
Leica DMIL Led Fluorescent Microscope Leica Microsystems, Wetzlar 
Leica TCS SP8 laser scanning confocal microscope Leica Microsystems, Wetzlar 
Light Microscope ELWD 0.3 T1-SNCP Nikon Instruments Inc., Melville, USA 
Luminoscan Ascent (Luminescence plate reader) Thermo Scientific, Waltham, USA 
Microwave for Agarose gels Sharp, Cologne 
Mini-PROTEAN® Tetra Vertical Electrophoresis Cell BioRad, Hercules, USA 
NanoPhotometer  Implen, Munich 
Neubauer Counting Chamber Marienfeld, Lauda-Königshofen, 
Germany 
PCR FlexCycler2  Analytik Jena, Jena 
pH-Meter (FiveEasy) Mettler-Toledo, Columbus, OH, USA 
Plate Reader Inifinite M200 Pro  Tecan, Männedorf, Switzerland 
Roller Mixer SRT6  Stuart, Staffordshire, UK 
Thermoblock Eppendorf ThermoMixer® comfort Eppendorf, Hamburg, Germany 
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9.1.2 Laboratory materials 
Name Company 
Blotting paper 3MM Chr Whatman, Dassel, Germany 
Cell Culture Dishes (100 x 20 mm) CELLSTAR® Greiner Bio-One, Kremsmünster, Austria 
Cell Culture Flasks (25, 75 and 175 cm2) 
CELLSTAR® 
Greiner Bio-One, Kremsmünster, Austria 
Cell Culture Multiwell Plates (6, 12, 24, 48 well) 
CELLSTAR® 
Greiner Bio-One, Kremsmünster, Austria 
Counting Chamber Neubauer-improved Paul Marienfeld GmbH & Co.KG, Lauda-
Königshofen, Germany 
Cover glasses thickness No. 1 circular Paul Marienfeld GmbH & Co.KG, Lauda-
Königshofen, Germany 
Disposable Nitrile Gloves TouchNTuff® 92-600 Ansell, Richmond, Australia 
Filtered Tips AvantGuard™ (20 μl) Midwest Scientific, Valley Park, USA 
Filtered Tips OneTouch™ (10 μl, 200 μl, 1000 μl) Sorenson BioScience, Salt Lake City, 
USA 
Fluid aspiration system BVC professional VACUUBRAND, Wertheim, Germany 
Microscope slides thickness approx. 1 mm Paul Marienfeld GmbH & Co.KG, Lauda-
Königshofen, Germany 
Multichannel Pipettes 8- and 12-channel (10 μl, 100 
μl, and 300 μl) Eppendorf® Research® plus  
Eppendorf, Hamburg, Germany 
PCR Tubes (0,2 mL) Eppendorf tubes® Eppendorf, Hamburg, Germany 
PIPETBOY acu 2 INTEGRA Biosciences AG, Zizers, 
Switzerland 
Pipetting Reservoirs (25 mL) Argos Technologies, Vernon Hills, USA 
Plastic paraffin film Parafilm® Bemis Company, Neenah, USA 
Polypropylene Tubes (15 ml, 50 ml) CELLSTAR® Greiner Bio-One, Kremsmünster, Austria 
PVDF membrane, Immobilon-FL 0.45 µm Merck Millipore, Billerica, USA 
Reaction tubes (0.5-2ml) Sarstedt, Nümbrecht 
Serological pipette (5 ml, 10 ml, 25 ml, 50 ml) Sarstedt, Nürnbrecht, Germany 
Single Channel Pipettes (P2μl, P10μl, P20μl, 
P200μl, P1000μl) PIPETMAN Neo® 
Gilson Inc., Middleton, USA 
Surgical Disposable Scalpels B. Braun Melsungen, Melsungen, 
Germany 
Syringe filters units (0.22 μm, 0.45 μm) Millex® Merck Millipore, Billerica, USA 
Syringe filters units (0.45 μm) Rotilabo® KH55.1 Carl Roth, Karlsruhe, Germany 
Syringes (1ml, 3ml, 5 ml, 10 ml, 60 ml) BD Luer-
Lok™ 
Becton Dickinson, Franklin Lakes,USA 
Tubes (0,5 ml, 1.5 ml, 2 ml) SafeSeal Sarstedt, Nürnbrecht, Germany 
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9.1.3 Kits 
Name Company 
CD4+ T Cell Enrichment Cocktail RosetteSep™  
 
Stemcell Technologies, Vancouver, 
Canada 
MycoAlert Mycoplasma Detection Kit Lonza, Basel, Switzerland 
NucleoBond PC 500 Macherey-Nagel, Dueren 
NucleoBond® Xtra Midi EF Macherey-Nagel, Dueren, Germany 
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel, Dueren, Germany 
QIAamp® DNA Mini Kit Qiagen, Hilden, Germany 
Qiagen Plasmid Plus Midi kit Qiagen, Hilden 
QIAprep® Spin Miniprep Kit Qiagen, Hilden, Germany 
QuikChange Site-Directed Mutagenesis Kit Agilent Technologies, Santa Clara, USA 
9.1.4 Chemicals and reagents 
Reagent Company 
Agarose  Fisher Bio Reagents, USA 
Ammonium persulfate (APS) Sigma-Aldrich, St. Louis, USA 
Blasticidin   Thermo Scientific, Waltham, USA   
Bromophenol blue   Chroma, Fürstenfeldbruck   
BSA 100x   NEB, Ipswitch, USA   
CellTiter 96® AQueous One Solution Promega, USA 
Clarity Western ECL Substrate BIO-RAD, USA 
DMSO Merck, Darmstadt, Germany 
DNA ladder 1 kb Plus   Thermo Scientific, Waltham, USA   
dNTP Set   Thermo Scientific, Waltham, USA   
EDTA Merck, Darmstadt, Germany 
Ethanol (99 %) (EtOH)   Zentralbereich INF, Heidelberg   
Gel Loading Dye, Purple (6x) for DNA   New England Biolabs, Ipswich, USA   
Glycerol AppliChem GmbH, Darmstadt, Germany 
Glycine Carl Roth, Karlsruhe, Germany 
Isopropanol   Sigma-Aldrich, St. Louis, USA   
LB Broth (Lennox) Sigma-Aldrich, St. Louis, USA 
Methanol (MeOH) Sigma-Aldrich, St. Louis, USA 
MIDORIGreen Advance   Nippon Genetics Europe GmbH, Dueren, 
Germany 
Milk powder Carl Roth, Karlsruhe, Germany 
Paraformaldehyde (PFA) Merck, Darmstadt 
PBS Dulbecco Powder Biochrom GmbH, Berlin, Germany 
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich, St. Louis, USA 
Polyethylenimine (PEI) Sigma-Aldrich, St. Louis, USA  
Precision Plus Protein™ WesternC™ Standards  BioRad, Hercules, USA 
Protease inhibitor tablets, EDTA-free Roche, Mannheim 
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Protein marker (PageRuler Prestained) Thermo Scientific, Schwerte, Germany 
Puromycin Merck Millipore, Darmstadt 
Sodium Acetate   Sigma-Aldrich, St. Louis, USA   
Sodium Chloride Sigma-Aldrich, St. Louis, USA 
Sodium dodecyl sulfate (SDS) Applichem, Karlsruhe 
Sucrose Sigma-Aldrich, St. Louis, USA 
Tetramethylethylenediamine (TEMED) Carl Roth, Karlsruhe, Germany 
Trypsin Biochrom, Berlin, Germany 
Tween 20 Carl Roth, Karlsruhe, Germany 
β-Mercaptoethanol   Sigma-Aldrich, St. Louis, USA   
9.1.5 Buffers and solutions 
Name Component Concentration 
Buffer TfB1 
KAc 30 mM 
RbCl 100 mM 
CaCl 10 mM 
MnCl 50 mM 
glycerol  15 % 
in H2O 
Buffer TfB2 
PIPES 10 mM 
CaCl2 75 mM 
RbCl 10 mM 
glycerol  15% 
in H2O 
PBS 1x 
H2O  
NaCl 140 mM 
KCl 2.7 mM 
Na2HPO4 8 mM 
KH2PO4 1.8 mM 
PBS-T 
PBS 1x  
Tween-20 0.1 % (v/v) 
SDS blotting buffer 
 
H2O  
Tris 48 mM 
Glycine 39 mM 
SDS 0.04 % (w/v) 
Methanol 20% (v/v) 
1x SDS Running Buffer 
 
H2O  
Glycine 190 mM 
SDS 0.1% (w/v) 
Tris HCl 25 mM 
SDS sample buffer 3 x 
(for loading of lysed samples) 
ddH2O  
Tris-HCl pH 6.8 150 mM 
SDS 6 % (w/v) 
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Glycerol 30 % (w/v) 
Bromophenol Blue 0.02% (w/v) 
DTT  150 mM 
WB Stripping Buffer 
ddH2O  
  
NaOH 
0.5 M  
 
Mowiol embedding medium 
 
PBS  
Mowiol 4-88  
 8mM 
WB Blocking Buffer 
 
 1 xPBS   
milk powder 
5% (w/v)  
 
9.1.6 Cell culture media 
Name Medium Supplements 
DMEM+++ DMEM, high glucose 
(GIBCO) 
10% FCS heat inactivated 
100 U/ml penicillin 
100 µg/ml streptomycin 
RPMI+++  (GIBCO) 10% FCS heat inactivated 
100 U/ml penicillin 
100 µg/ml streptomycin 
Freezing media FCS 10 % DMSO or gycerol 
depending on cell type 
OptiMEM OptiMEM (GIBCO)  
Selection media  RPMI (GIBCO)  puromicyn or blasticidin 
9.1.7 Enzymes 
Name Company 
GoTaq Hot Start DNA Polymerase Promega, USA 
Pfu Polymerase Promega, USA 
Phusion High Fidelity DNA Polymerase New England Biolabs, USA 
T4 DNA Ligase New England Biolabs, USA 
HindIII New England Biolabs, USA 
DPN1 New England Biolabs, USA 
EcoRI New England Biolabs, USA 
Not New England Biolabs, USA 
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9.1.8 Drugs  
Name Company 
IFNα2 I (Roferon-A, IFNα-2a) Dr. Kathrin Sutter (Universitätsklinikum 
Essen) 
Cytarabine  Sigma-Aldrich 
9.1.9 Antibodies 
Name Antigen Company Species Application 
3F10 HA Roche Applied Science, 
Burgess Hill, UK 
mouse, monoclonal, 
HRP linked 
1:5000 in WB 
ECL 
Mouse IgG 
mouse 
IgG 
GE Healthcare, Little 
Chalfont, UK 
sheep, polyclonal HRP 
linked 
1: 5000 in WB 
ECL 
Rabbit IgG 
rabbit IgG GE Healthcare, Little 
Chalfont, UK 
donkey, polyclonal 
HRP linked 
1:5000 in WB 
SAMHD1 rabbit Biomol, BETHYL 
Laboratorie, INC 
Polyclonal 1:1000 WB/IF 
HSP 90α/β rabbit SANTA CRUZ 
Biotechnology 
Polyclonal IgG 1:3000 WB 
β-Actin mouse Sigam monoclonal 1:3000 
pSAMHD1 rabbit Cell Signaling 
Technology 
monoclonal 1:1000 WB 
9.1.10 Plasmids and constructs 
Plasmid name  Description  Source  
SIV3+deltaVpx SIV GagPol encoding 
plasmid lacking Env, lacking 
accessory protein Vpx 
Caroline Goujon (KCL, 
London, UK) 
pCSXW HASAMHD1 Used to create n-term HA-
tagged codon optimized 
SAMHD1 
Torsten Schaller 
pCSXW HASAMHD1nterm 
codon optimized 
N-terminal HA-tagged N-
terminal codon optimized 
(gRNA escape) human 
SAMHD1 
Template: CSXW 
HASAMHD1 
CSXWdE HAVpxMAC  Torsten Schaller (UCL 
London) 
CSXWdE HAVpxRCM  Torsten Schaller (UCL 
London) 
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pCSGW  HIV-1 vector encoding GFP (Bainbridge et al., 2001) 
pCSxW  
 
HIV-1 vector (Schaller et al., 2014) 
pCSxW-HA  
 
HIV-1 vector hemagglutinin 
(HA)- tagged 
Torsten Schaller (UCL 
London UK)  
p8.91 (pCMVdR8.91) HIV GagPol encoding 
plasmid.  
(Zufferey et al., 1997) 
plentiCRISPRv2  
 
puromycin resistance marker 
to express guide RNAs 
(gRNAs) constructs for 
CRISPR-mediated genome 
editing 
 
Addgene, Cambridge, USA 
plentiCRISPRv2SAMHD1 
gRNA2 
gRNA targeting human 
SAMHD1 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) 
plentiCRISPRv2SAMHD1 
gRNA3 
gRNA targeting human 
SAMHD1 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) 
pNL4.3  Full-length HIV-1 lab strain 
NL4.3 
Torsten Schaller (UCL 
London, UK) 
pNL4.3-GFP  
 
Full-length NL4.3 encoding 
GFP in place of Nef followed 
by an IRES-Nef cassette  
 
Torsten Schaller (UCL 
London, UK) 
pNLENG-IRES-Nef Full-length NL4.3 encoding 
GFP in place of Nef followed 
by an IRES-Nef cassette 
(Levy et al., 2004) 
pcDNA VpxMAC Q76A flag  Caroline Goujon (KCL 
London, UK) 
SIV3+  Torsten Schaller (UCL 
London) (Negre et al., 2000, 
Mangeot et al., 2000) 
pMD.G22  VSV-G expression plasmid   Didier Trono lab.  
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pcDNA WT VpxMAC flag  Caroline Goujon (KCL 
London, UK) 
 
9.1.11 Primer 
Sequencing SAMHD1 
OTS 230 
AAAGAGCTCACAACCCCTCACTCG 
OTS 733 
ATTTTGTAATCCAGAGGTTG 
OTS 20 
TCATGATCTCGGTCATGGGCC 
n-term HA tagged 
codon optimized 
SAMHD1 primer 
 
OTS1393 
GCATGCGGCCGCTCACATTGGGTCATCTTTAA
AAAGC 
OTS1394 
ATCGAATTCATGCAGCGAGCCGATTCCGAGCA
GCCGTCAAAACGACCCAGATGTGACGATTCAC
CAAGAACCCCCTCAAACAC 
The sequencing primer OTS 733/230 bind within the Vector.  
9.1.12 SAMHD1 SNP constructs 
For all SNP constructs n-term HA tagged codon optimized SAMHD1 plasmid was used for 
mutagenesis.  
SNP 
Primer 
name 
Sequence 
H233A 
OTS 293 AGGTGAAATGGACGGCTGAACAAGGCTCAGTTATG 
OTS 294 TAACTGAGCCTTGTTCAGCCGTCCATTTCACCTCC 
D311A 
OTS79 TGGCATTGATGTGGCCAAATGGGATTATTTTG 
OTS80 ATAATCCCATTTGGCCACATCAATGCCATTTC 
T592A 
OTS467 AGCCCCACTCATAGCACCTCAAAAAAAGG 
OTS468 TTTTGAGGTGCTATGAGTGGGGCTATAAC 
T592E 
OTS469 AGCCCCACTCATAGAACCTCAAAAAAAGG 
OTS470 TTTTGAGGTTCTATGAGTGGGGCTATAAC 
D137N 
OTS884 TCCGAATCATTAATACACCTCAATTTCAAC 
OTS885 ATTGAGGTGTATTAATGATTCGGACGAGGAG 
V133I 
OTS1624 ACCCTCTCCTCATCCGAATCATTGATACAC 
OTS1625 ATCAATGATTCGGATGAGGAGAGGGTGGAG 
A338T OTS1626 TTATTAAGTTTACCCGTGTCTGTGAAGTAG 
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OTS1627 TTCACAGACACGGGTAAACTTAATAAAGCG 
R366H 
OTS1628 TGTTCCACACTCACAACTCTTTACACCGTAG 
OTS1629 GGTGTAAAGAGTTGTGAGTGTGGAACATGTC 
D497Y 
OTS1630 TGAAGGCTGAATATTTTATAGTGGATGTTATC 
OTS1631 ATCCACTATAAAATATTCAGCCTTCAGTTTC 
R145Q 
OTS1705 TTTCAACGTCTTCAATACATCAAACAGCTG 
OTS1706 GTTTGATGTATTGAAGACGTTGAAATTGAG 
G90R 
OTS1715 TTGAAAATCTTAGAGTAAGTTCCTTGGGGG 
OTS1717 AGGAACTTACTCTAAGATTTTCAAAACGAG 
C522A 
OTS1854 TGTTAGCTTCTATGCTAAGACTGCCCCCAAC 
OTS1855 GGGCAGTCTTAGCATAGAAGCTAACATGATC 
C522S 
OTS1856 TGTTAGCTTCTATAGTAAGACTGCCCCCAAC 
OTS1857 GGGCAGTCTTACTATAGAAGCTAACATGATC 
A76T 
OTS1861 AAATCACAGGCACATTACTGCCTTGTCTTG 
OTS1862 AGGCAGTAATGTGCCTGTGATTTCATTTTC 
R305I 
OTS1873 TATCTAATAAAATAAATGGCATTGATGTGG 
OTS1874 ATCAATGCCATTTATTTTATTAGATACTATC 
K596fs 
OTS1879 AACACCTCAAAAAAGGAATGGAACGACAG 
OTS1880 TCGTTCCATTCCTTTTTTGAGGTGTTATG 
A525E 
OTS1914 TTGTAAGACTGAGCCCAACAGAGCAATCAG 
OTS1915 GCTCTGTTGGGCTCAGTCTTACAATAGAAG 
A525S 
OTS1916 TTGTAAGACTTCCCCCAACAGAGCAATCAG 
OTS1917 GCTCTGTTGGGGGAAGTCTTACAATAGAAG 
A525Y 
OTS1918 TTGTAAGACTTACCCCAACAGAGCAATCAG 
OTS1919 GCTCTGTTGGGGTAAGTCTTACAATAGAAG 
A525V 
OTS1920 TTGTAAGACTGTCCCCAACAGAGCAATCAG 
OTS1921 GCTCTGTTGGGGACAGTCTTACAATAGAAG 
P589T 
OTS1938 CGATGTTATAGCCACACTCATAACACCTCA 
OTS1939 AGGTGTTATGAGTGTGGCTATAACATCGCC 
T608A 
OTS1940 AGTCCAAAATCCAGCTCGCCTCCGAGAAGC 
OTS1941 CTTCTCGGAGGCGAGCTGGATTTTGGACTG 
R290H 
OTS1834 TATAAAGGGCATCCTGAAAACAAAAGCTTC 
OTS1835 TTTTGTTTTCAGGATGCCCTTTATATGGCC 
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R348C 
OTS1875 AATGAGTTGTGTATTTGTGCTAGAGATAAG 
OTS1876 TCTAGCACAAATACACAACTCATTGTCTAC 
R451P 
OTS1711 AAATTGAATACCCTAATCTATTCAAGTATG 
OTS1712 ACTTGAATAGATTAGGGTATTCAATTTGTT 
L178Q 
OTS1707 TAGCAGGATGTCAAGTTCACGCACTGGGTG 
OTS1708 AGTGCGTGAACTTGACATCCTGCTAGATAC 
A525T 
OTS1709 TTGTAAGACTACCCCCAACAGAGCAATCAG 
OTS1710 GCTCTGTTGGGGGTAGTCTTACAATAGAAG 
A338V OTS1713 TTATTAAGTTTGTCCGTGTCTGTGAAGTAG 
OTS1714 TTCACAGACACGGACAAACTTAATAAAGCG 
K05R OTS1952 TGCTGGAGGAAGAAAGTATCGCATTTCTAC 
OTS1953 AAATGCGATACTTTCTTCCTCCAGCACCTG 
R451C OTS1656 AAATTGAATACTGTAATCTATTCAAGTATG 
OTS1657 CTTGAATAGATTACAGTATTCAATTTGTTT 
9.1.13 Software 
Name Source 
DNA Dynamo BlueTractorSoftware Ltd 
Excel Microsoft, Redmond, USA 
FACSDiva BD, Franklin Lakes, USA; RRID:SCR_001456 
FlowJo V10 FlowJo LLC, Ashland, USA; RRID:SCR_008520 
Graph Pad Prism 5 GraphPad Software, Inc., La Jolla, USA; RRID:SCR_002798 
Pymol Schrödinger 
 Methods 
9.2.1 Cells  
THP-1 cells as well as their CRISPR–Cas9 derivatives were grown in RPMI-1640 Glutamax 
(Gibco) supplemented with 10% heat-inactivated fetal calf serum (FCS) and 100 U/ml 
penicillin and 100 µg/ml streptomycin at 37 °C. Passaging of the cells was performed every 2-
3 days. 293T were grown in Dulbecco’ s modified Eagle medium (DMEM Glutamax) (Gibco) 
with 10% heat-inactivated FCS and 100 U/ml penicillin and 100 µg/ml streptomycin. Passaging 
of the cells was performed every 2-3 days. For this, cells were washed with PBS and detached 
from the surface by 0.05% Trypsin/EDTA in PBS. Cells were resuspended in medium and 
diluted 1:4 (2 days) or 1:6 (3 days). Cell line stocks were maintained by cryo-conservation. For 
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this purpose, cells were pelleted (1200 rpm, 5 min), resuspended in 1 ml freezing medium (FCS 
supplemented with 10 % DMSO (adherent cells) or glycerol (suspension cells)) and transferred 
into a cryo-conservation tube. Tubes were slowly cooled to -80°C in freezing Styrofoam box. 
For long term storage cells were then transferred to liquid nitrogen. Cells were thawed rapidly 
and transferred to 75 cm2 flasks (suspension cells) or 10 cm (adherent cells) dishes containing 
10 ml pre-warmed fresh medium. The medium was changed after 24 h.  
For preparation of monocyte-derived macrophages (MDM), peripheral blood mononuclear 
cells (PBMCs) were isolated from 50 ml from buffy coats of healthy blood donors by Ficoll 
density gradient centrifugation. The buffy coats were diluted 1:2 with PBS, prior to loading 35 
ml of the diluted buffy coat on a 15 ml Ficoll cushion. Cells at the interphase of plasma and 
Ficoll were aspirated and washed twice with PBS. PBMC were seeded in RPMI 1640 medium 
which was supplemented with 10% heat inactivated FCS and antibiotics for 2 hr at 37°C. 
Afterwards PBMC were washed so that non-adherent cells were removed, and adherent 
monocytes were further cultured in RPMI 1640 containing 10% heat inactivated FCS, and 5% 
human AB serum for 10d until differentiation to macrophages was completed. 
9.2.2 Virus preparation and infection assay  
HEK293T cells were transfected with 4 μg polyethylenimine (PEI) per μg DNA in 1 ml of 
OptiMEM (Gibco) per 10 cm plate 24 h after seeding. For lentiviral vector (LV) production, 
4.5 μg of HIV-1 viral plasmid (pCSxW vector, plentiCRISPRv2 or RetroQ vectors encoding 
respectively the protein, the gRNA or the shRNA of interest) 3 μg of pCMVΔR8.91 GagPol 
encoding plasmid and 3 μg of VSV-G Env expression plasmid pMD.G2 were mixed into a 
separate reaction tube with 0,5 ml OptiMem. PEI was premixed with 0,5 ml OptiMEM. Next, 
both solutions were mixed together and were homogenized by vortexing for short time. The 
mixture was incubated for at least 15 min at room temperature and added drop-wise onto a ~75 
% confluent 10 cm dish of 293T cells prior replaced with new fresh media (8 ml). For VSV-G-
pseudotyped full length HIV-1 production, 8 μg HIV-1 GFP reporter viral plasmid pNLENG-
IRESNef (Levy et al., 2004) and 2 μg pMD.G2 were transfected per plate. To generate full-
length laboratory strains HIV-1NL4.3 4.5 μg pCSGW was cotransfected with 3 μg full-length 
viral plasmid pNL4.3 and 3 μg pMD.G2. For all virus productions, medium was replaced 24 h 
post transfection, the viral supernatant was harvested at 48 h and 72 h post transfection. Both 
collections were pooled and passed through a 0.45 μm cellulose filters to remove all cell debris. 
Depending on the experiment, viral supernatants were subjected to sucrose purification as 
described before (Goujon et al., 2013c).  
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In order to determine infectious titers, 5x104 HEK293T cells were plated in 96-well plates and 
infected the next day with 100 µl of viral supernatant diluted in a three-fold serial dilution series 
to obtain six different concentrations. Infected cells were fixed at 48 h post infection and the 
GFP expression was analyzed by FACS. 
9.2.3 Production of VLPs 
HEK293t cells were grown in 10-cm plates and transfected at a confluence of ∼75% using 4 
μg polyethylenimine (PEI) per μg DNA in 1 ml of OptiMEM (Gibco) per plate. For SIVMAC 
virus–like particle (VLP) production, plates were transfected with 8 μg GagPol encoding 
plasmid pSIV3+, encoding Vpx (Vpx-VLPs), or with a control plasmid lacking VPX (ΔVpx-
VLPs), and 2 μg VSV-G encoding plasmid pMD.G22 per plate as described previously( Herold 
et al. (2017a). The medium was changed 24 h post-transfection. The supernatant was harvested 
at 48 h and 72 h and passed through a 0.45-μm filter. 30 ml viral supernatant was sucrose-
purified and resuspended in 300 μl RPMI-1640 containing penicillin/streptomycin. For the 
transpackaging assay the following plasmid ratio was used 8 µg pcDNAwt Vpx flag or Vpx 
Q76A flag; 8 µg control plasmid lacking VPX (ΔVpx-VLPs) and 2 µg VSV-G encoding 
plasmid pMD.G22 per 10 cm plate 
9.2.4 Infections 
1x 105 THP-1 were plated in 100 µl media per well in 96-well plates and treated with 500 U 
IFNα (for Vpx experiments only) and with 25 ng/ml phorbol 12-myristate 13-acetate (Sigma 
Aldrich) for 24 h. Prior to infection 2 µl of Vpx VLP were added. Following Vpx VLP addition 
100 µl supernatant containing VSV-G pseudotyped GFP-reporter lentiviral vectors or 
NL4.3GFP-reporter virus were added. Cells were fixed in 4% paraformaldehyde (PFA) 48 h 
post infection. Infectivity was determined from the percentage of GFP positive cells by flow 
cytometry using a FACSVerse (BD Biosciences) for THP-1 cells and CELESTA for MDM 
cells.  
Experiments with MDMs were performed in 48-well plates seeding 5 x 105 monocytes per well 
prior to differentiation. For analysis by flow cytometry MDMs were trypsinized for at least 60 
min, resuspended and fixed in 4% PFA.  
9.2.5 Generation of CRISPR/Cas9 THP-1 cell clones 
THP-1 cells were transduced with VSV-G pseudotyped HIV-1 LV delivering 
plentiCRISPRv2SAMHD1g2/g3. Transduced cell populations were selected with 1 µg/ml 
puromycin for at least two weeks. Single-cell clones were generated by limiting dilution and 
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grown in 96-well plates for at least four weeks in the absence of puromycin. Afterwards cells 
were expanded and expression of SAMHD1 was analyzed by western blot. Cell clones with no 
detectable SAMHD1 level were send for sequencing.  
Oligonucleotides encoding for SAMHD1 gRNAs were caccgCTCGGGCTGTCATCGCAACG 
(fwd g2) and aaacCGTTGCGATGACAGCCCGAGc (rev g2), as well as 
caccgATCGCAACGGGGACGCTTGG (fwd g3) and aaacCCAAGCGTCCCCGTTGCGATc 
(rev g3). 
Clones were genotyped by sequencing of genomic DNA using the following primers: 
AGAGCCGCTAGGCTGCCCTG (SAMHD1 fwd 1); AAGGGCTCAACTGTCAGTGAG 
(SAMHD1 fwd 2); ACTGCCCTCAGTTCTGCTTC (SAMHD1 fwd 3); 
ATCCTACGAATCGCCTATC (SAMHD1 rev 1); and AGATCCCAATCTACGACTG 
(SAMHD1 rev 2). 
9.2.6 Generation of stable cell lines ectopically expressing proteins   
Cell lines ectopically expressing proteins of interest were generated by transduction of 
SAMHD1 knock out cells in 12-well plates with 200 µl concentrated VSV-G-pseudotyped 
HIV-1 LV encoding gRNA-resistant SAMHD1 wild type, catalytic-dead mutant H233A or 
SAMHD1 SNPs. 48 h post-transfection, cell lines were expanded in cell flask before analysis. 
9.2.7 Growth curves 
5 × 103 THP-1 SAMHD1 CRISPR–Cas9 clones g2-2 and g2-3 were seeded in six-well plates 
in 2 ml of media. The cell density was determined by counting live cells over a period of 1 
week. 
9.2.8 Proliferation assays 
1 × 105 THP-1 cells/CRISPR–Cas9 derivatives/ cells overexpressing SAMHD1 derivates were 
seeded in 96-well tissue culture plates per well and incubated for 72 h at 37 °C with ara-C in 
triplicate, before incubation with CellTiter 96 AQueous One Solution (Promega) according to 
the manufacturer's recommendations. Absorbance was measured using the Infinity M200PRO 
(TECAN), and EC50 values were calculated using Prism 6 (GraphPad Software).  
9.2.9 Preparation of chemical competent E.coli 
To generate E.coli competent for heat shock transformation the following protocol was used. 
DH5α or Stbl2 E.coli were spread on agar plates without antibiotics and grown overnight at 37 
°C. The following day 10 ml LB media were inoculated with a single Stbl2/DH5α colony and 
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bacteria were grown overnight at 350 rpm and 37 °C in a bacterial shaker. The next day 50 ml 
of LB media was inoculated with 1.25 ml of overnight bacterial culture. Bacteria were grown 
while shaking at 37 °C until an optical density of OD550nm=0.45-0.55 was reached. The 
suspension was placed on ice for 10 min. Afterwards bacteria were pelleted by centrifugation 
at 3000 rpm at 4 °C for 15 min. Pelleted bacteria were resuspended in 20 ml of cooled TfB1 
solution and left on ice for 5 min before they were centrifuged again under the same conditions 
as stated above. The bacterial pellet was resuspended in 2 ml of cooled TfB2 solution and left 
again on ice for 10 min. TfB1 and TfB1 solutions were sterile filtered and pre chilled on ice 
before use. Aliquots of 80 μl were pipetted into 0.5 ml Eppendorf tubes, which were 
immediately thrown into liquid nitrogen. Transformation competent cells were stored at -80 °C.  
9.2.10 Heat shock transformation and plasmid preparation  
Chemically competent bacteria were transformed using a heat-shock procedure. 80 µl of 
chemo-competent E. coli DH5α or Stbl2 bacteria were thawed on ice and subsequently mixed 
with 1 µg plasmid DNA or 5 µl ligation product for 40 min on ice. Heat shock was performed 
for 1,5 min at 42°C followed by incubation on ice for 2 min and afterwards 5 min at RT. Bacteria 
were directly plated on prewarmed agar plates containing ampicillin. 
To amplificate plasmid DNA, single colonies were used to inoculate overnight cultures in LB 
medium containing 100 mg/l ampicillin on a shaker at 37 °C. For small-scale preparations of 
plasmid DNA 2 ml bacterial culture was grown and purification were performed using the 
QIAprep Spin Miniprep Kit (Qiagen, Crawley, UK) following the protocols provided with the 
kits. Medium scale preparation of plasmid DNA was performed using the QIAfilter Plasmid 
Midi Kit (Qiagen, Crawley, UK) according to the manufacturer’s protocol. 100 ml overnight 
bacterial culture was grown for medium scale preparation. DNA concentration and purity were 
measured using a nanophotometer. Purity was controlled by verifying that OD260 nm/OD280 
nm ratio was between 1.8 and 2.0. DNA solutions were adjusted to 1 µg/µl using the respective 
Elution buffer. 
9.2.11 Separation of DNA by agarose gel electrophoresis  
DNA fragments were separated by electrophoresis using 1% agarose in 1x TAE buffer. 
MIDORI green was used to stain DNA (4 µl in 100 ml agarose solution prior to polymerization). 
The DNA was mixed with DNA loading buffer and loaded into the wells and run at 80 V for 
30 min. The size of DNA fragments was compared to a standard ruler (1 kb DNA ladder). Gels 
were analyzed under UV light. 
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9.2.12  DNA extraction from agarose gels 
Extraction and purification of DNA bands from agarose gels was performed using the QIAquick 
gel extraction Kit (Qiagen, Crawley, UK) according to the manufacturer’s protocol. DNA 
fragments were eluted from the column by adding 30 – 50 µl of water. 
9.2.13 Ligation of DNA-fragments 
For ligation usually 2-4 µg plasmid DNA was digested with appropriate enzymes and were gel 
purified and eluted into 50 µl of water. Usually 1 µl of digested and purified vector DNA was 
mixed with 5 µl of insert DNA or PCR product. Vector and insert DNA were mixed with 2 µl 
10 × ligase buffer, 1 μl (3 U) T4 DNA-ligase and water to a final volume of 20 µl. After 5-20 
min incubation at room temperature 5 to 10 μl of the ligation-mix were added directly to 80 μl 
competent bacteria for transformation.  
9.2.14 Analysis of DNA with restriction enzymes 
Restriction digests of DNA were performed with enzymes from the manufacturers NEB. 
Enzymes and buffers were used as stated by the manufacturer and reaction conditions were 
performed to their protocols.  
9.2.15 Polymerase Chain Reaction (PCR) 
The reaction mixture was prepared on ice. Each reaction contained 250 µM dNTPs (each 
dNTP), 1 × polymerase buffer, 10 pmol of each primer, 100 ng to 1 µg template DNA and 1 µl 
(3 U) of PFU polymerase (Promega, Southampton, UK) filled up with H2O to a final reaction 
volume of 50 µl. Annealing temperature as well as elongation time were set depending on the 
primer composition and the length of the amplified sequence, respectively. Usually 34 cycles 
were performed. All nucleotide sequences of PCR products were confirmed by sequencing 
(Eurofins, Ebersberg). 
The following thermocycling program was used (Lid 105°C): 
Step Temperature Duration 
1)      Initial denaturation  98°C 30 sec 
2)      Denaturation 98°C 10 sec 
3)      Annealing 55°C 30 sec 
4)      Elongation 72°C 15-30 s per kbp 
Repeat 2-4 30 cycles   
5)      Final extension 72°C 7 min 
6)   store 12°C   
Successful DNA amplification was monitored by running 5 µl product on a 1% agarose gel. 
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9.2.16  PCR-based mutagenesis 
To generate plasmids carrying point mutations PCR based mutagenesis was performed 
according to the Quick-change protocol (Stratagene). To engineer point mutations into a 
plasmid, PCR was performed as described above using two primers with opposite orientation 
covering the desired point mutation. Usually, 12 cycles were performed with an elongation time 
of 40 min for each step, depending on the plasmid length into which the mutation was 
introduced. Primer annealing temperatures was between 53-55 °C. To avoid errors, PFU Turbo 
DNA Polymerase was used according to the manufacturer protocol. After the amplification, the 
template plasmid was digested by adding 1 µl of DpnI and 5 µl of NEB cutsmart buffer directly 
to the PCR reaction mix and incubated at 37 °C for 1-2 h. After digestion, 10 µl of the mix was 
transformed into competent bacteria. Single cell clones were picked and DNA was send for 
sequencing. 
Step Temperature Duration 
1)      Initial denaturation  95°C 30 sec 
2)      Denaturation 95°C 10 sec 
3)      Annealing 55°C 1 min 
4)      Elongation 68°C 1 min/ kbp of plasmid 
Repeat 2-4 12 cycles 
5)      Final extension 72°C 10 min 
6)   store 12°C   
9.2.17 SDS-polyacrylamide-gel electrophoresis (SDS-PAGE) 
Gels were generated using Acrylamide Solutions TGX™ FastCast™ according to the 
manufacturer's protocol (Biorad) and an acrylamide concentration of 10 % or 12 % for the 
separating gel was used. Briefly, for each separating gel 3 ml Resolver A, 3 ml of Resolver B, 
3 μl of TEMED were mixed in a 50 ml Falcon Tube before starting gel polymerization by 
adding 30 μl of 20 % ammonium-persulfate (APS). The separating gel was quickly poured 
between two glass plates of the Bio-Rad PAGE Gel casting system. To avoid formation of air 
bubbles, isopropanol was carefully pipetted on top of the separating gel. After polymerization 
the isopropanol was disposed and washed away with water. The remaining water -was removed 
by using Whatman paper strips. To prepare the stacking gel, 1 ml of Stacker A, 1 ml of Stacker 
B, 2 μl TEMED and 10 μl APS were mixed in a 50 ml Falcon tube by briefly vortexing. The 
solution was carefully added on top of the separating. After polymerization, the glass slides 
were installed into the Biorad system, filled with SDS-PAGE running buffer and loaded with 
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20 µL sample per lane and 10 µL protein size marker. Cells were lysed by addition of denaturing 
protein sample buffer. The samples were boiled at 98 °C for at least 5 min. Aliquots of cell 
lysates were loaded onto SDS 10 % or 12 % polyacrylamide gels for electrophoresis. Gel 
electrophoresis was performed at 150 V for 60 minutes. 
9.2.18 Western blotting 
The SDS gel with the separated proteins were transferred to a 0,45 µm polyvinylidenfluorid 
transmembrane (Millipore) using Electrophoretic Transfer Cell Mini Trans-Blot® system 
(Biorad) at 100 V for 60 min in a styrofoam box with ice water. Membranes were incubated for 
1h in PBS containing 0.1 % Tween 20 (pBS-Tween 20) and 5 % (w/v) non fat milk powder to 
saturate non-specific binding sites. The membrane was washed 3 times for 5 min in PBS-Tween 
20. The primary antibody was diluted in PBS-Tween 20 and the membrane was incubated 
shaking over night at 4 o C. After being washed three times with PBS-Tween 20, the membrane 
was incubated with the secondary antibody in PBS-Tween 20 shaking at room temperature for 
45 min and afterwards washed three times for 5 min with PBS-Tween 20. Membrane- bound 
secondary antibody was detected by chemiluminescence using ECL western blotting detection 
reagent. Chemiluminescence was measured by the ECL ChemoCam Imager system (INTAS 
Science Imaging). 
9.2.19 Immunofluorescence and confocal microscopy 
Respected cells were seeded on glass cover slips in 24-well cell culture plates at a concentration 
of 2.5 × 104 cells per well. Prior to seeding the cells in the well pma (25ng/µl) was added to the 
well. The next day cells were fixed with 4 % paraformaldehyde (w/v) solution for 15 min at 
room temperature. Afterwards the cells were washed three times with 1 × PBS. For 
permeabilization the cells were incubated for 15 min with 500 µl 0.5 % Triton-x-100/ PBS (v/v) 
solution and washed 3 times with 1 × PBS. In order to block unspecific antibody binding cells 
were blocked with 5% horse serum in 1 x PBS for 30 min. The SAMHD1 antibody was diluted 
1:200 in 1 × PBS buffer containing 5 % horse serum (v/v). After 60 min incubation at room 
temperature the cells were washed 3 times with 1 × PBS for 5 min and incubated with the 
secondary antibody conjugated with fluorescent dye Alexa 488, diluted 1:1000 in a 1 × PBS 
buffer containing 5 % horse serum (v/v). After 60 min incubation at room temperature in the 
dark, the cells were washed three times with 1 × PBS. DRAG 5 (1:2000 dilution) was used for 
nuclei staining. After DRAG 5 staining the cells were washed again 3 times with 1 × PBS, 
rinsed with H2O and mounted on glass slides using Mowiol embedding medium (8 mM Mowiol 
4-88 in PBS). Immunofluorescence pictures were obtained using a Leica confocal microscope.  
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 Results  
 SAMHD1’s role in the type 1 interferon induced early block to HIV-1 
infection  
10.1.1 The VpxMAC-induced rescue of HIV-1 from the type I IFN-induced block in MDM 
depends on SAMHD1  
Vpx hijacks the Cullin4- E3 ubiquitin ligase by binding to DCAF1 (Le Rouzic et al., 2007). 
HIV-2 and SIVMAC harboring Vpx mutants unable to bind DCAF are unable to overcome the 
inhibition of infection in myeloid cells (Srivastava et al., 2008, Bergamaschi et al., 2009). The 
inhibition of HIV-1 infection in monocyte-derived macrophages (MDM) can be overcome by 
co-treatment with Vpx-containing SIVsm virus-like particles (SIV VLP) (Kaushik et al., 2009, 
Goujon et al., 2007). Pertel et al. and Reinhard et al. reported that Vpx Q76A, which is unable 
to bind DCAF1 and to degrade SAMHD1, was able to rescue HIV-1 infection from the type I 
IFN-induced block in MDDCs (Pertel et al., 2011, Reinhard et al., 2014). This suggests that the 
relief from the type I IFN induced block to HIV-1 infection may be independent of SAMHD1. 
On the other hand Hrecka et al. found out that Vpx mediated degradation of SAMHD1 is 
necessary to overcome HIV-1 restriction in macrophages (Hrecka et al., 2011). In order to 
confirm this hypothesis, we tested whether Vpx Q76A would be able to rescue HIV-1 infection 
in MDM. To do this we used a trans packaging assay, using SIVdelta Vpx and co-transfected 
SIV Vpx protein encoding plasmids during VLP production, thereby complementing the lack 
of Vpx by ectopic expression. This transpackaging assay was similarly efficient as using SIV 
encoding Vpx (Figure 9; Vpx-VLP vs wt Vpx flag trans). MDM were prepared from blood of 
healthy donors and stimulated with or without IFN overnight. Prior to infection with VSV G- 
pseudotyped HIV-1 GFP reporter virus Vpx VLP or control VLP were added to the cells. 
Infection was measured as the percentage of GFP-positive cells 2 days after challenge. Two 
independent experiments are shown in Figure 9. We found that Q76A was unable to relief HIV-
1 from the type I IFN-induced block in MDM. Wild type Vpx greatly boosted HIV-1 infection 
with or without IFN. We hypothesized that Vpx recruitment of the DCAF1-Cul4 ubiquitin 
machinery is required for the efficient increase of HIV-1 infection in type I IFN-induced MDM.  
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Figure 9: Vpx deficient for SAMHD1 degradation does not relieve HIV-1 from the type I IFN induced block in 
MDM. 
A, B) MDMs were generated using human AB serum and treated or not with 500 U/ml IFNα 2A for 72 h. Prior to 
infection cells were treated or not with SIV
MAC
 Vpx-VLPs, or control (VLPs lacking Vpx). In parallel wild type or 
mutant Vpx trans packaged into VLPs lacking Vpx were tested. The cells were then infected for 48 h with VSV-G 
pseudotyped HIV-1NL4.3GFP reporter virus. Thereafter the percentage of GFP-positive cells was determined by 
flow cytometry. B) Mean values GFP positive cells of 3 donors with standard deviations are shown. C) Western 
blot showed similar incorporation of Vpx in trans-packaging assay 
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10.1.2 The VpxMAC-induced rescue of HIV-1 from the type I IFN-induced block in MDM 
is independent of route of entry  
Furthermore, we tested in two donors whether the boost of HIV infection is VSV-G dependent 
by comparing Bal Env bearing NL4.3GFP with NL4.3GFP pseudotyped with VSV-G. We 
confirmed that the Vpx mediated increase of HIV-1 infection is not VSV G-pseudotyp 
dependent in MDM (Figure 10). Although VSV-G pseudo typing enhanced infection up to 2- 
4-fold.   
 
 
Figure 10: Vpx mediated increase of HIV-1 infection is independent of entry route.  
MDMs were generated using human AB serum and treated or not with 500 U/ml IFN alpha 2A for 24 h. Prior to 
infection cells were treated or not with SIV
MAC
 Vpx-VLPs, or cntrl. VLPs lacking Vpx. The cells were then infected 
for 72 h with VSV-G pseudotyped HIV-1 NL4.3GFP reporter virus or NL4.3 Bal Env GFP. Thereafter the 
percentage of GFP-positive cells was determined by flow cytometry  
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10.1.3 VpxMAC does not rescue HIV-1 from the type I IFN-induced block in THP-1 
SAMHD1-/- cells 
We further tested whether the presence of SAMHD1 is required for the Vpx-induced relief of 
HIV-1 from the type I IFN-induced block by generating and analyzing SAMHD1 CRISPR/Cas9 
knock-out cells. We generated single-cell clones of THP-1 cells transduced with CRISPR/Cas9 
LVs expressing individual specific guide RNAs (gRNAs). We generated six independent THP-
1 single-cell knockout clones. Gene disruption was validated by PCR sequencing across the 
gRNA target site as well as by immunoblotting (Figure 11). 
 
 
 
Figure 11: Generation of THP1 SAMHD1 CRISPR–Cas9 cells. Vpx-mediated rescue of HIV-1 from the type I 
Interferon-induced block is SAMHD1-dependent. 
A) Individual single-cell clones with disrupted SAMHD1 expression were identified by western blot using mouse 
monoclonal SAMHD1 antibody 1F9 (Abcam). B) Identified SAMHD1 knock out clones were genotyped by 
sequencing of PCR products from genomic DNA spanning the gRNA target site. 
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All generated cell lines were tested for their susceptibility to infection with VSV-G-
pseudotyped NL4.3 GFP and their potential to relive HIV from the IFN induced block when 
Vpx was supplied. SAMHD1 restricts HIV-1 infection in myeloid cells and dendritic cells but 
not in most monocytic cell lines such as cycling THP-1 cells (Laguette et al., 2011b, Hrecka et 
al., 2011).  Therefore THP-1 cells were differentiated by use of phorbol 12-myristate 13-acetate 
(PMA) for 24 h and at the same time 500 U IFN was added. Prior to infection with VSV G 
pseudotyped NL4.3 GFP reporter virus control Vpx or Vpx VLPs were added. SAMHD1 knock 
out increased the permissivity of cells to HIV-1 infection by approximately 4-fold in all tested 
SAMHD1 knockout cell lines (g2c2 and g3c2 shown in Figure 12. Additionally, Vpx was 
unable to increase HIV-1 infection in type I IFN-treated or untreated cells when SAMHD1 was 
absent (Figure 12). The Vpx-mediated boost of infection was achieved in THP-1 parental cells 
as well as in the heterozygous SAMHD1 knock-out cell line g2c1. This indicates that Vpx and 
SAMHD1 are required for the Vpx-induced boost of HIV-1 infection from the type I IFN-
induced block. The Vpx mediated increase of HIV-1 infection, however, is present with or 
without IFN. 
Figure 12: Vpx-mediated rescue of HIV-1 from the type I interferon-induced block is SAMHD1-dependent. 
THP-1 SAMHD1 knock-out clones, g2c2 and g3c2 as well as parental THP-1 and the heterozygous SAMHD1 cell 
line (g2c1) were pretreated with 25 ng/ml PMA and either with or without 500 U/ml type I interferon for 24 h. 
Prior to infection with equal amounts of VSV-G-pseudotyped wild-type HIV-1 NL4.3GFP reporter virus cells were 
treated either with SIV Vpx-VLPs, cntrl. VLPs, or no VLPs. At 48 h after infection the percentage of GFP-positive 
cells was determined by flow cytometry. Mean values with standard deviation of at least three independent 
experiments are shown. 
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In order to further confirm that SAMHD1 is crucial for the Vpx mediated increase of infection 
we re-expressed amino-terminal HA-tagged codon optimized (CRISPR/Cas9-resistant) 
SAMHD1 in the SAMHD1 knockout cells. Expression of wild type SAMHD1 reintroduced the 
block to HIV-1 infection by 6-fold compared to the SAMHD1 knockout clone when cells were 
differentiated with PMA. The SAMHD1 catalytic-dead mutant H233A showed no block to 
HIV-infection as reported by (Ryoo et al., 2014a) and Vpx was unable to boost infection (Figure 
13).  
 
 
 
 
 
 
 
Figure 13: Re-expression of SAMHD1 confirms sensitivity to Vpx. 
A,B,C,D)THP-1 SAMHD1 knockout clone g2c2 was stably transduced with LV encoding either SAMHD1 wildtype, 
SAMHD1 H233A or Luciferase, were pretreated with 25 ng/ml PMA and either with or without 500 U/ml type I 
alpha interferon for 24 h. Prior to infection with equal amounts of VSV-G-pseudotyped wild-type HIV-1 NL4.3GFP 
reporter virus cells were treated either with SIV Vpx-VLPs, cntrl. VLPs, or no VLPs. At 48 h after infection the 
percentage of GFP-positive cells was determined by flow cytometry. Mean values with standard deviation of at 
least three independent experiments are shown. E) Stable expression of SAMHD1 wt and D311A was analyzed by 
western blot. 
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10.1.4 SAMHD1 knockout has no influence on cell proliferation in THP-1 cells 
The effect of perturbed SAMHD1 expression was studied by many groups and two of them 
stated that reduced SAMHD1 activity, which increases the amount of dNTPs, results in 
uncontrolled cell proliferation (Clifford et al., 2014, Rossi, 2014). Bonifati et al. reports that 
SAMHD1 knockout by CRISPR/Cas9 in myeloid THP-1 cells increased cell proliferation and 
decreased spontaneous apoptosis (Bonifati et al., 2016). To further characterize the effect of 
SAMHD1 knockout on cell proliferation we seeded clone g2-2 (SAMHD1(-/-)) and clone g2-
3 (SAMHD1(+/+)) in a 6-well plate in 2 ml media and cell density was determined by counting 
live cells over a period of 1 week. As shown in Figure 14 A no significant increase in cell 
proliferation was seen. Additionally, our collaborators in Sweden (Nikolas Herold, Sean Rudd 
and Nikolaos Tsesmetzis) analyzed the cell cycle of g2-3 and g2-2 and observed only a small 
but significant decrease in sub-G1 cells in the SAMHD1 knockout clone (Figure 14 B).  
Figure 14: SAMHD1 knockout does not significantly alter growth kinetics or cell cycle distribution. 
A) Growth curve of SAMHD1 knockout THP-1 cells. SAMHD1 CRISPR/Cas9 THP-1 cells, clone g2-2 (SAMHD1(-
/-)) and clone g2-3(SAMHD1(+)). Shown are mean values and SEM of 2 independent experiments. Statistical 
testing was performed using an Extra-sum-of-squares F test of exponential growth curve fitted with Prism 6 
(GraphPad Software): F=1.919; DFn=2; DFd=8; ns, not significant(p=0.2086). B) Cell-cycle analysis of 
SAMHD1 KO (SAMHD1 (-) 2-2) and control cells (SAMHD1 (+)g2-3). The presented cell lines were fixed, and 
DNA stained with propidium iodide and subjected to flow cytometry analysis. Average of 3 experiments for each 
cell line performed at least in duplicates are shown alongside representative histograms, error bars indicate SD. 
Statistically significant differences between SAMHD1 knock out and control cell lines were determined using two-
tailed multiple t-tests in Prism 6 (GraphPad Software): THP-1 sub-G1; **, p=0.009, t=3.04, df=14; THP-1 G1, 
ns, not significant, p=0.79, t=0.28, df=14; **, p≤ 0.01.; THP-1 S, ns, not significant, p=0.56, t=0.59, df=14; THP-
1 G2/M, ns, not significant, p=0.72, t=0.36, df=14 (Herold et al., 2017a) 
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10.1.5 Characterization of a THP-1 cell line endogenously expressing SAMHD1 with 
truncated nuclear localization signal (Eg3c6+/-) 
To answer the question whether Vpx-induced SAMHD1 degradation is required for the rescue 
from the antiviral state, we generated cells in which SAMHD1 was endogenously truncated in 
its nuclear localization signal. We and others described that overexpressed SAMHD1 lacking 
the NLS is completely resistant to Vpx-induced degradation (Brandariz-Nunez et al., 2012, 
Hofmann et al., 2012, Wei et al., 2012, Guo et al., 2013). Hence, we reasoned that cells 
endogenously expressing NLS-deleted SAMHD1 would be ideal to test whether the Vpx-
induced relief of HIV-1 infection from the type I interferon-induced block would depend on 
SAMHD1 degradation. The generated cells were designed and selected to contain only one 
functional SAMHD1 allele, which however harbored an in frame deletion in the NLS region 
(amino acids 11KRPR14) (Figure 15 A). We found that endogenously expressed SAMHD1 
lacking the NLS was excluded from the nucleus using immunofluorescence (Figure 15 B). 
 
Figure 15: Generation of THP1 SAMHD1 CRISPR–Cas9 cells with disrupted nuclear localization signal 
(11KRPR14). 
A) Sequencing analysis of CRISPR/Cas9 THP-1 cell clone, which had one disrupted SAMHD1 allele and one 
allele, in which the entire nuclear localization signal (11KRPR14) was deleted in frame, generating an internally 
NLS-disrupted endogenously expressed SAMHD1 protein. B) Immunofluorescence-microscopy analysis of 
SAMHD1 in THP-1, NLS mutant g3c6 and the heterozygous SAMHD1 mutant clone g2c1 (+/-). DRAQ5 was used 
to visualize the nucleus. Scale bar =10 µm. 
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To our surprise, endogenously SAMHD1ΔNLS resisted Vpx-induced degradation, but was not 
completely refractory to degradation, as suggested for ectopically expressed SAMHD1ΔNLS. 
After 24h Vpx treatment SAMHD1ΔNLS levels decreased. SAMHD1 degradation by Vpx was 
seen after 2 h of Vpx treatment in g2c1 and THP-1 parental cells whereas SAMHD1 levels were 
unchanged in the NLS mutant g3c6 (Figure 16 C). To test whether the SAMHD1 NLS mutant 
was able to increase HIV-1 infection when treated with IFN upon Vpx treatment we infected 
SAMHD1∆NLS treated with IFN with VSV G-pseudotyped NL4.3 GFP in the presence or 
absence of Vpx-VLPs and found that HIV-1 infection increased 48h after infection in IFN 
untreated and IFN treated cells (Figure 16). The increase of infection was comparable to THP-
1 parental cells. Therefore, the location of SAMHD1 might not be important for the Vpx 
mediated rescue of HIV-1 from the IFN induced block.  
 
 
 
Figure 16: Vpx-mediated rescue of HIV1 from the type 1 Interferon induced block is independent of SAMHD1 
localization and despite reduced SAMHD1 degradation kinetics. 
A, B) THP-1 and NLS mutant g3c6 were pretreated with 25 ng/ml PMA and either with or without 500 U/ml type 
I interferon for 24 h. Prior to infection with equal amounts of VSV-G-pseudotyped wild-type HIV-1 NL4.3GFP 
reporter virus cells were treated either with SIV Vpx-VLPs, cntrl. VLP, or no VLPs. At 48 h after infection the 
percentage of GFP-positive cells was determined by flow cytometry. Mean values with standard deviation of at 
least three independent experiments are shown. C) g2c1, Thp-1 parental and SAMHD1 NLS mutant were seeded 
in 96 well plates and the same amount of Vpx VLP was added to each well. After 0/2/4/10/24/48 h cells were 
harvested for western blot analysis.  
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10.1.6 Interferon has no influence on -Vpx- mediated SAMHD1 degradation in cycling 
THP-1 cells 
Dragin et al. (Dragin et al., 2013) and Roesch et al. (Roesch et al., 2018) showed that interferon 
alpha (IFNα) treatment of THP-1 cells prevents degradation of SAMHD1 following incubation 
with SIVMAC virus-like particles containing Vpx. Since Vpx mediated SAMHD1 degradation 
might be the reason of the Vpx-mediated increase of HIV-1 infection in interferon alpha treated 
cells we tested SAMHD1 degradation by Vpx with and without interferon. Further-more, we 
investigated whether PMA treatment would influence SAMHD1 degradation. THP-1 cells were 
treated with or without interferon for 24 h and supplemented afterwards with Vpx-VLPs for 16 
h or 24 h. In addition, western blot samples were taken of THP-1 cells treated with or without 
PMA. As published by other groups, complete SAMHD1 degradation was achieved in the 
presence of Vpx-VLPs. In contrast to Dragin and Roesch et al. interferon alpha treatment did 
not hinder Vpx mediated SAMHD1 degradation (Figure 17).  
PMA and interferon treatment slightly hindered SAMHD1 degradation in the presence of Vpx-
VLPs but did not completely block SAMHD1 degradation, a result that is contrasting published 
data. IFN activity was tested in parallel by blocking HIV-1 infection. 
Figure 17: Vpx mediated SAMHD1 degradation was not influenced by interferon treatment in cycling. 
 A) THP-1 cells. Western blot samples were taken of THP-1 cells which were treated with or without interferon alpha 
(500 U and 1000 U) for 24 h and supplemented afterwards with Vpx-VLPs for 16 h or 24 h. This setup was used for 
THP-1 cells treated with or without PMA for 24 h. B) In parallel THP-1 cells were infected with NL4.3 GFP reporter 
virus and percentage of GFP positive cells were analyzed after 48h of infection by FACS. Cells were either treated 
with or without PMA and stimulated with or without IFN 24 h prior to infection 
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 SAMHD1 in cancer 
SAMHD1 not only acts as a host restriction factor against viral infections (Hrecka et al., 2011, 
Laguette et al., 2011a), mutations in the SAMHD1 gene have also been linked to a genetic 
immune disorder called Aicardi-Goutières Syndrome (AGS) as well as several types of cancer 
(Kohnken et al., 2015, Rice et al., 2009a). This suggests the involvement of SAMHD1 in the 
innate immune response and cancer development possibly through the control of dNTP 
homeostasis. The most active agent against acute myelogenous leukemia (AML) is the 
deoxycytidine analog cytarabine (ara-C). Outcome in patients with AML ranges from a ∼70 % 
5-year overall survival rate among children (de Rooij et al., 2015) whereas elderly adult have 
only a 20 % 2-year overall survival rate (Ossenkoppele and Lowenberg, 2015). The number 
one reason of ara-C treatment failure and relapse is the patient’s response to ara-C treatment. 
(Styczynski, 2007, Fernandez-Calotti et al., 2005). Ara-C is converted intracellularly into the 
active metabolite ara-CTP. Ara-CTP can be inserted into DNA which results in DNA damage 
and stop of DNA synthesis which eventually leads to cell death. Prior to the findings by Herold 
et al. there was no consistent explanation why patients responded differently to ara-C treatment. 
One hypothesis was that SAMHD1 might be able to bind and hydrolyze the dCTP-analog ara-
CTP and thereby detoxify the active metabolite of ara-C. Our collaborators in Sweden purified 
recombinant human SAMHD1 and analyzed its in vitro activity in an assay where the release 
of inorganic phosphate produced by the hydrolysis of dCTP or ara-CTP by SAMHD1 was 
measured. This was done in the presence of nonhydrolyzable dGTP analog or GTP, both 
functioning as activators. While dGTP can bind to both allosteric sites AS1 and AS2, GTP only 
binds to AS1. Ara-CTP hydrolysis was achieved with the nonhydrolyzable dGTP analog but 
not with GTP-activated SAMHD1 (Figure 18 A). Ara-CTP hydrolysis was not as efficient as 
compared to dCTP hydrolysis in the presence of non-hydrolysable dGTP. The results suggest 
that ara-CTP exclusively binds to the substrate-binding site and does not serve as an allosteric 
activator of AS2. To further test the relevance of ara-CTP hydrolysis in cells we used three 
approaches. Firstly, we treated the AML cell line THP-1 with SIV-Vpx-containing (X) or 
control (dX) VLPs or no VLPs in the presence or absence of ara-C and measured the efficacy 
of ara-C induced cytotoxicity. The value of the half-maximal effective concentration (EC50) of 
ara-C was up to 130-fold reduced in cells treated with Vpx VLPs compared to control VLPs, 
or untreated cells (Figure 18A). Secondly, SAMHD1 knockout in THP-1 cells resulted in 
similar decreased EC50 values for ara-C (Figure 18 B). Furthermore, we ectopically expressed 
CRISPR/Cas9-resistant wild type SAMHD1 or the catalytic dead mutants (H233A) or (D311A) 
or luciferase as negative control in the SAMHD1 knockout cells and compared the ara-C EC50 
66 
 
values. Ectopic expression of WT SAMHD1 sensitized THP-1 SAMHD1 knock-out cells to 
ara-CTP hydrolysis. In contrast, ectopic expression of the catalytic-dead mutants did not alter 
the EC50 value for ara-C as compared to SAMHD1 knock-out cells (Figure 18 D).  
Figure 18: Ara-C is a substrate of SAMHD1.  
A) Substrate-velocity curves measuring the amount of inorganic triphosphate (PPPi) produced from hydrolysis of 
dCTP or ara-CTP by SAMHD1 in the presence of GTP or a nonhydrolyzable dGTP analog (dGTPαS) in the 
enzyme-coupled malachite green assay. Error bars indicate s.e.m. of three independent experiments performed at 
least in triplicate. B) Cell viability of THP-1 which were treated with SIV-Vpx-containing (X) or control (dX) 
VLPs, or PBS (no VLPs) in the presence of ara-C. EC50 values: THP-1 dX, 3,537 nM, THP-1 X, 69 nM, THP-1 no 
VLPs, 3,159 nM. Error bars indicate s.d. of a representative of three independent experiments performed in 
triplicate. C) Cell viability of THP-1 clones SAMHD1 knock out clones using CRISPR–Cas9 (g3-2, g2-2) and 
control clones (ctrl gRNA, g2-3) in the presence of ara-C at the indicated concentrations. EC50 values: g3-2, 92 
nM; g2-2, 82 nM; ctrl gRNA, 1,305 nM, g2-3, 2,170 nM. Error bars indicate s.d. of a representative of three 
independent experiments performed in triplicates. D) THP-1 clones with genetic disruption of SAMHD1 using 
CRISPR–Cas9 (g2-2) were transduced with the indicated SAMHD1 variant. Cell viability was tested in the 
presence of ara-C at the indicated concentrations. EC50 values: HA-Luc, 132 nM; HA-H233A, 168 nM; HA-wt, 
27,922 nM; HA-D311A, 168,7 nM. Error bars indicate s.d. of a representative of three independent experiments 
performed in triplicate. A, B, C from (Herold et al., 2017a) 
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These results suggested that the increased cytotoxicity of ara-C in SAMHD1 knock-out cells or 
in THP-1 cells in which SAMHD1 was degraded by Vpx could be the result of increased ara-
CTP levels, which would lead to an increased incorporation of ara-CTP into the DNA. The 
observed data was in line with a model in which SAMHD1 hydrolyses ara-CTP and thereby 
neutralizes its toxic effects (Hollenbaugh et al., 2017). To analyse this directly, our 
collaborators measured the intracellular concentration of ara-C metabolites following a 2 h 
treatment with 3H-ara-C in THP-1 cell clones that either expressed or lacked SAMHD1. 
SAMHD1 knockout resulted in 10-fold increased ara-CTP levels, which correlated with a 10-
fold increase in DNA incorporated 3H-ara-C levels in the SAMHD1 knockout THP-1 clone. 
This indicates that the lethal incorporation of ara-CTP is prevent by SAMHD1s ability to 
hydrolyze ara-CTP (Figure 19). 
In order to test whether the amount of expressed SAMHD1 influences the block to HIV-1 and 
cell viability after ara-C treatment we transduced the SAMHD1 -/- cell line g2-2 with a serial 
dilution of lentiviral vector containing HA-tagged WT SAMHD1. After approximately 1 week 
of transduction cells were differentiated with PMA and infected with a serial dilution of HIV-
1 as before and in parallel we measured cytotoxicity to ara-C.  
High SAMHD1 expression level is crucial for an extensive block of HIV-1 and increased the 
EC50 value of ara-C by 40-fold (WT SAMHD1_HA compared to wt SAMHD1_HA 1:16) 
(Figure 20). The data suggest that a threshold of SAMHD1 protein levels may limit restriction 
of HIV-1 infection and that this threshold correlates with enhanced resistance to ara-C induced 
cytotoxicity.  
 
Figure 19: Intracellular conversion of 
cytarabine (ara-C) to ara-CTP and 
detoxification mechanism by SAMHD1.  
The schematic depicts canonical pathways 
for the intracellular conversion of ara-C to 
the active metabolite ara-CTP. Ara-CTP can 
be inserted into DNA which results in DNA 
damage and stop of DNA synthesis which 
eventually leads to cell death. Ara-CTP 
serves as a substrate of SAMHD1. Ara-CTP 
is a substrate of SAMHD1 and by the 
hydrolyzation to ara-C + PPP, ara-CTP is 
inactivated. Abbreviations: CDA, cytidine 
deaminase; DCK, deoxyctidine kinase; 
NT5C2, cytosolic nucleotidase-II; DCTD, 
deoxycytidylate deaminase 
From: (Herold et al., 2017b) 
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Figure 20: High SAMHD1 expression levels are crucial for a pronounced block of HIV-1 infection and 
enhanced cell viability after ara-C treatment.  
A) Western blot of SAMHD1 dilution series B) Cells were treated with indicated concentrations of cytarabine 
(ara-C) for 3 days to obtain maximal cytotoxicity and cell viability was determined using a colorimetric 
proliferation inhibition assay. Error bars indicate s.e.m. of three independent experiments performed at least in 
triplicate. EC50 values are the following wt SAMHD1_HA, 10616 nM; wt SAMHD1_HA 1:2, 9506 nM; wt 
SAMHD1_HA 1:4, 4282 nM; wt SAMHD1 1:8, 625,3 nM, wt SAMHD1_HA 1:16, 264,3 nM; Luc_HA, 117 nM. 
C) PMA-treated SAMHD1 -/- cells stably expressing the indicated SAMHD1 variants were challenged with serial 
dilutions of VSV-G-pseudotyped HIV-1 GFP, and the infectious units (i.u.) per ml of inoculum were calculated. 
Mean titers with standard deviations are depicted and significance to block HIV-1 in cells expressing SAMHD1 
compared to no SAMHD1(Luc_HA) are indicated). Statistical analysis was performed using an unpaired two-
tailed t test. ns, not statistically significant; *, P < 0.05; **, P < 0.01.  
Herold et al. and Schneider et al. published that malignant leukemic cells can be sensitized to 
ara-C trough degradation of SAMHD1 thereby eliminating the factor which is responsible for 
ara-CTP hydrolyzes (Herold et al., 2017a, Schneider et al., 2017). SAMHD1 has been suggested 
as tumor suppressor gene (Johansson et al., 2018, Herold et al., 2017c). Several reports suggest 
that SAMHD1 inactivation through promoter silencing or mutations within the SAMHD1 
reading frame promote tumorigenesis (Landau et al., 2013, Clifford et al., 2014, Rentoft et al., 
2016). In addition, miRNAs targeting SAMHD1 expression function as drivers of 
tumorigenesis (Kohnken et al., 2017). To date there are approximately 197 SAMHD1 mutations 
known which spread across 26 cancer projects (TCGA) (Figure 21).  
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To further investigate the influence of known SAMHD1 mutation in AML, READ, STAD and 
COAD (Table 1) on ara-CTP hydrolysis we expressed haemagglutinin (HA)-tagged 
CRISPR/Cas9-resistent SAMHD1 variants in the THP-1 g2c2 SAMHD1 -/- cell line by using 
lentiviral vectors. The main goal of this was to use naturally occurring SAMHD1 variants, to 
avoid artificially generated and possibly deleterious mutants, in order to dissect the role of the 
enzymatic SAMHD1 activity from its antiviral activity, hence to learn more about the cellular 
role of SAMHD1 in order to understand its impact on the type I interferon induced block against 
HIV-1 infection. Prior to performing experiments, we analyzed the expression levels of 
SAMHD1 variants by western blot. We investigated the sensitivity of the generated cells 
ectopically expressing SAMHD1 variants to ara-C-induced cytotoxicity. As negative control, 
we used SAMHD1 -/- cells, which were transduced with HA-tagged Luciferase (HA-Luc). We 
simultaneously analyzed HIV-1 restriction by these SAMHD1 variants in PMA differentiated 
cells by infecting them with a serial dilution of VSV-G pseudotyped HIV-1 GFP reporter and 
FACS analysis 48 h after infection. All experiments were done in triplicates and one 
representative is shown if not indicated differently.  
 
 
 
 
 
Figure 21: SAMHD1's role in tumorigenesis.  
A) There are 180 cases affected by 197 mutations in SAMHD1 across 26 projects. (according to 
portal.gdc.cancer.gov) B) Distribution of SAMHD1 mutations and occurrence of SAMHD1 mutations in Uterine 
Corpus Endometrial Carcinoma (UCEC), Rectum Adenocarcinoma (READ), Colon Adenocarcinoma (COAD), 
Acute Myeloid Leukemia (AML) and Stomach Adenocarcinoma (Manel et al.) (portal.gdc.cancer.gov.)  
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Table 1 SAMHD1 variants analyzed in this study 
 Disease  
SNP/ ID AGS CANCER AA 
change 
PMID/ Ref 
- - - WT  
Catal.site - - H233A  
Catal.site - - D311A  
  TCGA2 D137N  
TCGA-AZ-6598-01A-11D-
1771-10 
Yes TCGA2 V133I (Rentoft et al., 2016) 
 - TCGA2 A338T (Rentoft et al., 2016) 
TCGA-AD-6889-01A-11D-
1924-10 
- TCGA2 R366H (Rentoft et al., 2016) 
TCGA-AZ-4315-01A-01D-
1408-10 
- TCGA2 D497Y (Rentoft et al., 2016) 
rs515726145, TCGA-A6-3808-
01A-01W-0995-10 
Yes COSMIC, 
CLL1, 
TCGA2 
R145Q (Rentoft et al., 2016, 
Clifford et al., 2014) 
(Rice et al., 2009a) 
TCGA-CM-6674-01A-11D-
1835-10 
- TCGA2 A525T (Rentoft et al., 2016) 
TCGA-AA-A02W-01A-01W-
A00E-09 
- TCGA2 R451P (Rentoft et al., 2016) 
TCGA-G4-6588-01A-11D-
1771-10 
- TCGA2 A338V (Rentoft et al., 2016) 
TCGA-CK-4951-01A-01D-
1408-10 
- TCGA2 G90R  
rs559553527 Yes CLL1 R290H (Guieze et al., 2015, 
Goncalves et al., 2012a) 
 - TCGA2 K596fs (Rentoft et al., 2016) 
rs761561066, TCGA-AA-A01R-
01A-21W-A096-10 
- COSMIC, 
TCGA2 
R348C (Rentoft et al., 2016) 
rs141599277 - COSMIC A76T (Rentoft et al., 2016) 
TCGA-EI-6917-01A-11D-1924-
10 
- COSMIC, 
TCGA4 
R305I (Rentoft et al., 2016) 
  TCGA3 S214P  
TCGA-AB-2826-03B-01W-
0728-08 
- TCGA3 L178Q  
  TCGA5 P589T  
Acytylation   K405R (Lee et al., 2017) 
Redox   C522S (Mauney et al., 2017) 
1: UK clinical trial derived CLL samples (pretreatment and relapsed/refractory trials) 
2: TCGA-COAD 
3: TCGA-LAML 
4: TCGA-READ 
5 TCGA-STAD 
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10.2.1 SAMHD1 SNPs in Rectum Adenocarcinoma (READ) 
In Rectum Adenocarcinoma (READ) currently three missense mutation have been described: 
A76T, R305I and S302Y. According to the TCGA website the variant effect predictor (VEP) 
impact of all three mutation is moderate and the PolyPhen impact score result is benign for all 
three mutations.2 PolyPhen is a tool which predicts the possible impact of an amino acid change 
on the structure and function of a human protein using physical and comparative 
considerations.3 Another prediction tool is VEP which determines the effect of your variants on 
transcripts, genes and protein sequence, as well as regulatory regions.4 
 
Figure 22: Schematic representation of analyzed SAMHD1 mutations in Rectum Adenocarcinoma (READ). 
A76 lies within the SAM domain which was not yet crystalized (Figure 22). The R305 mutation 
residues in close proximity to the active site (Figure 23). 
 
Figure 23: SAMHD1crytal structure with dCTP bound.  
R366, R305 and R348 are in close proximity to the active site and might alter ara-CTP and nucleotide binding. 
(PDB: 4RXR) 
SAMHD1 variants A76T and R305I were expressed in the SAMHD1-/- cell line g2-2 and 
comparable expression to WT SAMHD1 was achieved (Figure 24 A). Ectopic expression of 
WT or A76T as well as R305I increased the EC50 for ara-C by 94-142-fold. R305I increased 
the EC50 for ara-C by 1,5-fold more as compared to WT SAMHD1. Both SAMHD1 variants 
sufficiently blocked HIV-1 infection and respectively to WT SAMHD1 the block to HIV-1 
                                                 
2https://portal.gdc.cancer.gov/  
3 http://genetics.bwh.harvard.edu/pph2/ 
4 https://www.ensembl.org/info/docs/tools/vep/index.html 
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infection was slightly increased hence SAMHD1 SNPs mutants A76T or R305I have no 
negative effect on ara-C sensitivity and increased HIV-1 restriction significantly.  
The reasons underlying this enhanced restriction are unclear, but the data suggest that both 
mutants A76T or R305I may impact permissivity of cells to HIV-1 infection. Whether this is 
connected to READ needs to be investigated.  
 
Figure 24: Expression of SAMHD1 SNP variants A76T or R305I in THP-1 SAMHD1 -/- cells increases HIV-
1 restriction and has no impact on ara-C sensitivity.  
A) Western blot of SAMHD1 variants B) Cells were treated with indicated concentrations of cytarabine (ara-C) 
for 3 days to obtain maximal cytotoxicity and cell viability was determined using a colorimetric proliferation 
inhibition assay. Error bars indicate s.d. of a representative of three independent experiments performed in 
triplicates. EC50 values are the following wt SAMHD1_HA, 9333 nM; Luc_HA, 98,48 nM; A76T, 9850 nM; R305I, 
14026 nM C) PMA-treated SAMHD1 -/- cells stably expressing the indicated SAMHD1 variants were challenged 
with serial dilutions of VSV-G-pseudotyped HIV-1 GFP, and the infectious units (i.u.) per ml of inoculum were 
calculated. Representative of at least 2 independent titrations is shown. Mean titers of at least 3 titration points 
with standard deviations are depicted and significance to block HIV-1 in cells expressing SAMHD1 compared to 
no SAMHD1(Luc_HA) are indicated). Statistical analysis was performed using an unpaired two-tailed t test. ns, 
not statistically significant; *, P < 0.05; **, P < 0.01. 
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10.2.2 SAMHD1 SNPs in acute myeloid leukemia (AML) 
In 144 analyzed cases of AML there were 2 cases in which SAMHD1 was mutated to either 
L178Q or S214P. For both substitutions the VEP impact is moderate, SIFT impact is deleterious 
and the PolyPhen impact predicts that the missense mutations are probably damaging 5.  
S214 is buried in the active site of SAMHD1, while L178 is close to A338, a residue that has 
functions in COAD (see below).  
 
Figure 25: Schematic representation of SAMHD1 Mutations in acute myeloid leukemia (AML). 
In the crystal structure of Zhu et al. L178 is in close proximity to A338 which might indicate 
an involvement in the dimer-dimer interface/tetramerization of SAMHD1 (Zhu et al., 2015). 
The SAMHD1 Residue S214 (Figure 27) lies close to the active site and is directly connected 
with H215 which interacts with nucleotides (Ahn, 2016). 
 
Figure 26: SAMHD1 Dimer-Dimer interface with L178 (yellow) and A338 (blue) (PDB: 4RXR). 
 
 
 
 
 
 
 
Figure 27: SAMHD1 catalytic site.  
The residue at the catalytic site H215 is connected to residue S214. (PDB: 4RXR) 
                                                 
5https://portal.gdc.cancer.gov/ 
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We ectopically expressed the two mutants in SAMHD1 knock-out cells as described above. 
The expression level of the SAMHD1 variant L178Q was significantly lower than wt SAMHD1 
expression (referred to as L178Q_HA_1 and wt SAMHD1_HA_1) (Figure 28 A1). Cell 
expressing L178Q were similarly permissive to HIV-1 infection as compared to control cells 
(Figure 28 A3). Expression of L178Q increased the EC50 value for ara-C by 5.5-fold as 
compared to control cells. To exclude effects dependent on reduced expression levels of L178Q 
as compared to WT SAMHD1 we repeated the experiments with cells expressing slightly higher 
protein levels of L178Q as compared to WT (labeled as 2 in Figure 28 A).  
Figure 28: Expression of AML SAMHD1 SNP variants L178Q or S214P in THP-1 SAMHD1 -/- cells renders 
these cells more permissive to HIV-1 infection as compared to WT and enhances ara-C sensitivity.  
A1; B1) Western blot using an HA-specific Ab to detect HA-tagged SAMHD1 variants and WT A2; B2) Cells were 
treated with indicated concentrations of cytarabine (ara-C) for 3 days to obtain maximal cytotoxicity and cell 
viability was determined using a colorimetric proliferation inhibition assay. Error bars indicate s.d. of a 
representative of three independent experiments performed in triplicates. EC50 values are the following: A1) wt 
SAMHD1_HA_1, 27922 nM; wt SAMHD1_HA_2, 13585 nM;Luc_HA, 132,3 nM; L178Q_HA_1, 731,3 nM; 
L178Q_HA_2, 5213 nM; B2) wt SAMHD1_HA, 7438 nM; S124P_HA, 61,51nM; Luc_HA 61,36 nM C1;C2) PMA-
treated SAMHD1 -/- cells stably expressing the indicated SAMHD1 variants were challenged with serial dilutions 
of VSV-G-pseudotyped HIV-1 GFP, and the infectious units (i.u.) per ml of inoculum were calculated. 
Representative of at least 2 independent titrations is shown. Mean titers of at least 3 titration points with standard 
deviations are depicted and significance to block HIV-1 in cells expressing SAMHD1 compared to no 
SAMHD1(Luc_HA) are indicated). Statistical analysis was performed using an unpaired two-tailed t test. ns, not 
statistically significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 
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The results showed that SAMHD1 L178Q blocked HIV-1 infection 2.6-fold less as compared 
to WT SAMHD1, in line with a ca. 5-fold reduced EC50 for ara-C as compared to WT 
SAMHD1(wt SAMHD1_HA_2, 13585 nM; L178Q_HA_2, 5213 nM). The second SAMHD1 
SNP mutant in AML (S214P) did not block HIV-1 infection upon expression and cells 
expressing this mutant were highly sensitive to ara-C treatment comparable to cells that lack 
SAMHD1 (Figure 28 B).  
The data suggest that the SAMHD1 variant S214P is defective in ara-CTP hydrolysis, as well 
as inactive in blocking HIV-1 infection. Hence, AML cells expressing the SNP versions L178Q 
or S214P of SAMHD1 are likely more sensitive to ara-C and detection of these SNPs in AML 
patients may be predictive for improved chances for an effective ara-C treatment during 
consolidation therapy (Herold et al., 2017a).  
10.2.3 SAMHD1 SNPs in colon adenocarcinoma (COAD) 
In 59 analyzed cases of COAD 16 mutations of SAMHD1 were identified in the TCGA 
database. We decided to analyze all 13 missense SNPs and the frameshift mutant K596Rfs*35. 
Their distribution within the SAMHD1 protein is depicted in Figure 29. Out of the 13 analyzed 
mutants 11 were predicted to be damaging by at least one of 3 computational tools 
(VEP,SIFT,PolyPhen2). Four of the mutated residues (R145, R366, R451 and D137) are 
located in vicinity of amino acid residues that have been reported to be functionally significant 
in in vitro studies (Ryoo et al., 2014b, Ji et al., 2013, White et al., 2013b, St Gelais et al., 2018). 
Among the 36 SAMHD1 mutations in the current Catalogue of Somatic Mutations in Cancer 
(COSMIC) database only 4 (5,5 %) were silent mutations. The following amino acid 
substitutions were found in hypermutated tumors (> 12 mutation per 106 bases): V133I, A338T, 
A338V, R366H, D49Y, A525T and K596Rfs*35 (Rentoft et al., 2016).  
 
Figure 29: Schematic representation of SAMHD1 Mutations in colon adenocarcinoma (COAD) and their 
appearances in analyzed cases. (adapted from TCGA) 
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Table 2 Mutation of COAD analyzed and their impact for canonical transcript.  
Abbreviation: HI: high; MO: moderate; DH: deleterious; TO: tolerated; PR: probably_damaging; PO: possibly 
damaging; BE: benign (data from portal.gdc.cancer.gov) 
Mutation Impact 
VEP SIFT PolyPhen 
K596Rfs*35 HI - - 
R451P MO DH PR 
R145Q MO DH PR 
D137N MO DH PR 
R290H MO DH PR 
R366H MO DH PO 
A525T MO DH BE 
R348C MO DH BE 
D497Y MO DH BE 
G90R MO TO PO 
A338T MO TO PO 
V133I MO TO BE 
A338V MO TO BE 
 
The G90R mutation lies closely to the end of the SAMHD1 SAM domain. Deletion construct 
studies of SAMHD1 revealed that the SAM domain is dispensable for HIV-1 restriction (White 
et al., 2013a). When SAMHD1 G90R was ectopically expressed in SAMHD1 knockout cells, 
protein expression varied in each of the three conducted experiments. Therefore, all three 
experiments are shown. SAMHD1 G90R mutant has to be expressed at higher protein levels 
than WT SAMHD1 (G90R_HA_2) in order to achieve a significant block to HIV-1 infection 
(wt SAMHD1_HA_2 vs. G90R_HA_2). Nevertheless, the block to HIV-1 infection in cells 
expressing high levels of G90R (G90R_HA_1) was 4-fold lower compared to wt SAMHD1 (wt 
SAMHD1_HA_2). Sensitivity to ara-C was 2.4-fold lower compared to wt SAMHD1 with 
higher expression (G90R_HA_1, 5647 nM vs wt SAMHD1_HA_2, 13585 nM) (Figure 30 C). 
The data suggest that COAD tumor cells with SAMHD1 SNP variant G90R may be more 
sensitive to ara-C and possibly other chemotherapeutic drugs that are converted to substrates 
for SAMHD1 in cells. 
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Figure 30: Expression of SAMHD1 SNP variant G90R in THP-1 SAMHD1 -/- cells impacts HIV-1 restriction 
and enhances ara-C sensitivity.  
A) Western blot 3 independent G90R and wt SAMHD1 transduction B) PMA-treated SAMHD1 -/- cells stably 
expressing the indicated SAMHD1 variants were challenged with serial dilutions of VSV-G-pseudotyped HIV-1 
GFP, and the infectious units (i.u.) per ml of inoculum were calculated. Mean titers of at least 3 titration points 
with standard deviations are depicted and significance to block HIV-1 in cells expressing SAMHD1 compared to 
no SAMHD1(Luc_HA) are indicated. Statistical analysis was performed using an unpaired two-tailed t test. ns, 
not statistically significant; *, P < 0.05; **, P < 0.01. C) Cells were treated with indicated concentrations of 
cytarabine (ara-C) for 3 days to obtain maximal cytotoxicity and cell viability was determined using a colorimetric 
proliferation inhibition assay. Error bars indicate s.d. of a representative of three independent experiments 
performed in triplicates. EC50 values are the following wt SAMHD1_HA_1, 27922 nM; wt SAMHD1_HA_2, 13585 
nM; wt SAMHD1_HA_1, 22287 nM; Luc_HA, 61,36 nM; G90R_HA_1, 5647 nM; G90R_HA_2, 2802 nM; 
G90R_HA_3, 713,2 nM 
Rentoft et al. analyzed A338T by recombinant protein purification and in vitro characterization. 
In vitro the dNTPase activity of A338T was significantly altered (5-6-fold reduction) for all 
four desoxynucleotide-triphosphates (Rentoft et al., 2016). This would suggest that A338T 
would not be able to restrict HIV-1 infection and ara-C sensitivity should be comparable to loss 
of SAMHD1 but only if a loss of dNTPase correlates with a loss of ara-C hydrolysis. In contrast, 
we found that A338T was still able to restrict HIV-1 infection but to a lesser extent as compared 
to WT SAMHD1. To our surprise A338T was able to neutralize the ara-C induced cytotoxicity 
to the same extend as WT SAMHD1 (Figure 31), suggesting that it has no defect in hydrolyzing 
ara-CTP. The data suggest that SAMHD1 A338T was specifically impaired in HIV-1 restriction 
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while containing full function in ara-CTP hydrolysis. It is therefore the first naturally occurring 
SAMHD1 amino acid variant that affects HIV-1 restriction.  
The SAMHD1 allosteric site mutant D137N is RNase-positive but dNTPase-negative and is 
able to restrict HIV-1 infection in PMA treated U937 cells overexpressing D137N (Ryoo et al., 
2014a). Herold et al. reported recently that ectopic expression of D137N in SAMHD1 knockout 
HuT-78 cell line did not increase the EC50 level comparable to wt SAMHD1 expression (Herold 
et al., 2017a). Residue D137 is part of the allosteric site (Figure 32)and forms hydrogen bonds 
with GTP (Arnold et al., 2015). In our case D137N expression in THP-1 SAMHD1 knockout 
cells resulted in a 38-fold decrease in ara-C sensitivity (D137N_HA, 5143 nM; Luc_HA 132,3 
nM) and HIV-1 was not blocked. 
 
Figure 31: Expression of SAMHD1 SNP variants A338T and D137N in THP-1 SAMHD1 -/- cells and their 
influence on HIV-1 restriction and sensitivity to ara-C treatment. 
A1; B1) Western blot of SAMHD1 of SAMHD1 variants and wt SAMHD1 A2; B2) Cells were treated with indicated 
concentrations of cytarabine (ara-C) for 3 days to obtain maximal cytotoxicity and cell viability was determined 
using a colorimetric proliferation inhibition assay. Error bars indicate s.d. of a representative of three independent 
experiments performed in triplicates. EC50 values are the following: A2) wt SAMHD1_HA, 13585 nM; Luc_HA, 
132,3 nM; A338T_HA, 15995 nM; B2) wt SAMHD1_HA, 27922 nM; D137N_HA, 5143 nM; Luc_HA 132,3 nM 
C1;C2) PMA-treated SAMHD1 -/- cells stably expressing the indicated SAMHD1 variants were challenged with 
serial dilutions of VSV-G-pseudotyped HIV-1 GFP, and the infectious units (i.u.) per ml of inoculum were calculated. 
Representative of at least 2 independent titrations is shown. Mean titers of at least 3 titration points with standard 
deviations are depicted and significance to block HIV-1 in cells expressing SAMHD1 compared to no 
SAMHD1(Luc_HA) are indicated). Statistical analysis was performed using an unpaired two-tailed t test. ns, not 
statistically significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 
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Rentoft et al. also analyzed V133I by recombinant protein purification and in vitro 
characterization. In vitro the dNTPase activity of V133I was significantly reduced (1.6-2-fold 
reduction) but not as strong as observed in vitro for SAMHD1 A338T for all four 
deoxynucleoside triphosphates (Rentoft et al. 2016). Therefore, we expected a slightly reduced 
block to HIV-1 infection and ara-C sensitivity should be comparable to wt SAMHD1 with a 
minor reduction. As seen in Figure 33 V133 resides close to the allosteric site. In our 
experimental setup V133I expression significantly boosted HIV-1 restriction compared to WT 
SAMHD1 and ara-C sensitivity was not affected compared to wt SAMHD1. The data suggest 
that V133I specifically affects HIV-1 restriction but not ara-CTPase activity. SAMHD1 has 
been involved in intrinsic immunity and it is possible that V133I affects this part of the function 
of this protein inducing a more potent antiviral state in the cells as compared to WT SAMHD1. 
 
 
 
 
 
 
SAMHD1 A525T was also found associated with COAD (TCGA) and structural analyzed 
revealed that A525 lies close to the border of the connecting monomers (Figure 34).  
 
 
 
 
Figure 33: SAMHD1 allosteric site.  
V133 is near the allosteric site pocket. (PDB: 4RXR) 
Figure 32: SAMHD1 allosteric site with D137 residue depicted in 
orange.  
D137N forms hydrogen bonds with the G base. (PDB: 4RXR) 
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Figure 34: Crystal SAMHD1 tetramer structure.  
Residue A525 is depicted in red. (PDB: 4TNP) 
We analyzed this mutant in a similar way to the mutants described above. We found that 
SAMHD1 A525T expression reduced ara-C induced cytotoxicity, hence it is presumably able 
to detoxify the cell of ara-CTP. In contrast, SAMHD1 A525T was unable to block HIV-1 
infection (Figure 35 B2, B3).  
Figure 35: Expression of SAMHD1 SNP variants V133I and A525T in THP-1 SAMHD1 -/- cells and their 
influence on HIV-1 restriction and sensitivity to ara-C treatment. 
A1; B1) Western blot of SAMHD1 of SAMHD1 variants and wt SAMHD1 A2; B2) Cells were treated with 
indicated concentrations of cytarabine (ara-C) for 3 days to obtain maximal cytotoxicity and cell viability was 
determined using a colorimetric proliferation inhibition assay. Error bars indicate s.d. of a representative of three 
independent experiments performed in triplicates. EC50 values are the following: A2) wt SAMHD1_HA,9333 nM; 
Luc_HA, 98,48 nM; V133I_HA, 8222 nM; B2) wt SAMHD1_HA, 27922 nM; A525T_HA, 16754 nM; Luc_HA 
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168,7 nM C1; C2) PMA-treated SAMHD1 -/- cells stably expressing the indicated SAMHD1 variants were 
challenged with serial dilutions of VSV-G-pseudotyped HIV-1 GFP, and the infectious units (i.u.) per ml of 
inoculum were calculated. Representative of at least 2 independent titrations is shown. Mean titers of at least 3 
titration points with standard deviations are depicted and significance to block HIV-1 in cells expressing SAMHD1 
compared to no SAMHD1(Luc_HA) are indicated). Statistical analysis was performed using an unpaired two-
tailed t test. ns, not statistically significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 
The phosphorylation prediction screen identified Cdk2 as possible enzyme to phosphorylate the 
T525 site. A constant phosphorylation could explain the loss of the block to HIV-1 infection, 
in a similar way as has been described for T592 (White et al., 2013a, Ryoo et al., 2014a, 
Welbourn et al., 2013, Arnold et al., 2015). We analyzed whether PMA treatment still resulted 
in T592 dephosphorylation. As seen in figure 36 there are no differences in T592 
dephosphorylation between the A525T variant and WT SAMHD1. To further determine the 
function of this amino acid residue we designed the following SAMHD1 variants: A525S, 
A525E, A525V and A525Y. All variants neutralized the cytotoxic effects of ara-C but were not 
able to block HIV-1 infection efficiently (Figure 36).  
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This indicates that constant phosphorylation might not be the reason for the lower restriction 
compared to WT SAMHD1. Only A525E showed a significant but weak block to HIV-1 
infection when compared to WT SAMHD1. Furthermore, we tested the ability to rescue HIV-
1 from the type I IFN induced block in the A525T variant of SAMHD1 by addition of Vpx. As 
seen in figure 37 A, when cells expressing the SAMHD1 variant A525T were treated with Vpx 
VLPs HIV-1 infection was not rescued from the type I IFN induced block (Figure 37 B). 
However, this could be at least partially explained by reduced degradation kinetics of A525T 
compared to WT SAMHD1 when challenged with Vpx-VLPs (Figure 37 A). Since Vpx is still 
able to degrade SAMHD1, binding to DCAF1 is likely not affected in the A525T variant. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Expression of SAMHD1 SNP variants A525T in THP-1 SAMHD1 -/- cells and its influence on 
phosphorylation and further analyzes of A525S, A525E, A525V and A525Y their influence on HIV-1 restriction 
and sensitivity to ara-C treatment. 
A) Phosphorylation analyzes by western blot. SAMHD1 variant A525T, wt SAMHD1 and the two phosphomutants 
T592A or T592E were stably expressed in THP-1 SAMHD1 -/- cells. Cells were treated 24 hours with pma +IFN, 
pma -IFN, no pma +IFN and no pma -IFN. Levels of phosphorylated SAMHD1 were analyzed by western blot. B) 
Variants of SAMHD1 A525 were stably expressed in THP-1 SAMHD1 -/- cells and expression was monitored by 
western blot. C) THP-1 SAMHD1 -/- cells transduced with SAMHD1 variants of A525 were treated with the indicated 
concentrations of cytarabine (Ara-C). Cells were treated for 3 days to obtain maximal cytotoxicity and cell viability 
was determined using a colorimetric proliferation inhibition assay. Error bars indicate s.d. of a representative of 
three independent experiments performed in triplicates. The EC50 values are the following: wt SAMHD1_HA, 27922 
nM; Luc_Ha, 132,3 nM; D311A_HA, 168,7 nM; H233A_HA, 203 nM; A525T_HA, 16754 nM; A525V_HA, 7576 
nM; A525S_HA, 3239 nM; A525E_HA, 8157 nM; A525Y_HA, 5665 nM c) PMA-treated SAMHD1 -/- cells stably 
expressing the indicated SAMHD1 variants were challenged with serial dilutions of VSV-G-pseudotyped HIV-1 GFP, 
and the infectious units (i.u.) per ml of inoculum were calculated. and the infectious units (i.u.) per ml of inoculum 
were calculated. Representative of at least 2 independent titrations is shown. Mean titers of at least 3 titration points 
with standard deviations are depicted and significance to block HIV-1 in cells expressing SAMHD1 compared to no 
SAMHD1(Luc_HA) are indicated). Statistical analysis was performed using an unpaired two-tailed t test. ns, not 
statistically significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 
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Next, we assessed mutant R348C which residues close to the active site (Figure 23) was slightly 
lower expressed as compared to wt SAMHD1. Nevertheless ara- C sensitivity did only 
marginally increase by 1.4-fold and the block to HIV-1 decreased by 2.4-fold compared to wt 
SAMHD1 and was significant when statistically analyzed. Since the aim was to identify 
mutants with different phenotypes with regards to HIV-1 block and ara-C sensitivity this mutant 
was not studied further.  
 
 
The R451 residue was previously identified as part of the cyclin binding motif (RXL residue 
451-453). Structural and functional analyses of R451A mutant revealed that the SAMHD1 
tetramer formation is disrupted and that dNTPase activity is lost in vitro and in cells (St Gelais 
et al., 2018). Structural analyzes seen in figure 39 shows that R451 residues between the two 
monomers which is close to the allosteric site. St. Gelais et al. also state that the RXL motif is 
crucial for HIV-1 restriction and efficient phosphorylation (St Gelais et al., 2018).  
Figure 37: SAMHD1 variant A525T is resistant to Vpx-induced degradation and Vpx is unable to rescue HIV-
1 from the type I interferon induced block in presence of SAMHD1 A525T. 
A) THP-1 SAMHD1 -/- cells transduced with wt SAMHD1-HA and the SAMHD1 variant A525T, were plated 
1*105 in a 96 well plate and treated with 25 ng/ml PMA for 24 h. Cells were harvested for SAMHD1 western blot 
analysis after 0h, 2h, 4h, 6h, 8h, 24h, 48h after VPX-VLP treatment. B) THP-1 and THP-1 SAMHD1 -/- cells 
expressing wt SAMHD1-HA, H233A-HA and A525T-HA were pretreated with 25 ng/ml PMA and either with or 
without 500 U/ml type I interferon for 24 h. Prior to infection with equal amounts of VSV-G-pseudotyped wild-
type HIV-1 NL4.3GFP reporter virus cells were treated either with SIV Vpx-VLPs or cntrl. VLP. At 48 h after 
infection the percentage of GFP-positive cells was determined by flow cytometry. Representative of 2 independent 
experiments are shown. Numbers indicate fold change. 
Figure 38: Effects of R348C SAMHD1 variant on the restriction to HIV-1 infection and sensitivity towards 
ara-C.  
A) Western blot of SAMHD1 variants and wt SAMHD1 B) Cells were treated with indicated concentrations of 
cytarabine (ara-C) for 3 days to obtain maximal cytotoxicity and cell viability was determined using a colorimetric 
proliferation inhibition assay. Experiment was performed in triplicates. Error bars indicate s.d. of a 
representative of three independent experiments performed in triplicates.  EC50 values are the following wt 
SAMHD1_HA, 9333 nM; Luc_HA, 98,48; R348C_HA, 6623 nM C) PMA-treated SAMHD1 -/- cells stably 
expressing the indicated SAMHD1 variants were challenged with serial dilutions of VSV-G-pseudotyped HIV-1 
GFP, and the infectious units (i.u.) per ml of inoculum were calculated. Representative of at least 2 independent 
titrations is shown. Mean titers of at least 3 titration points with standard deviations are depicted and significance 
to block HIV-1 in cells expressing SAMHD1 compared to no SAMHD1(Luc_HA) are indicated). Statistical 
analysis was performed using an unpaired two-tailed t test. ns, not statistically significant; **, P < 0.01. 
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Figure 39: Allosteric site of SAMHD1 with R451 residue shown in yellow.  
R451 lies in the interface of the two monomers and close to GTP. (PDB: 4RXR) 
Furthermore, R451C and R451L mutation were identified in a CLL patient sample study 
(Clifford et al., 2014). R451P variant was also identified in COAD. We therefore studied R451P 
and R451C. Both SAMHD1 variants did not restrict HIV-1 infection and cells expressing these 
mutants were highly sensitive to ara-C treatment (Figure 40), which is consistent with the 
observations made by St. Gelais et al.s that the RXL motive is crucial for HIV-1 restriction.  
Figure 40: Effects of R451P and R451C SAMHD1 variant on the restriction to HIV-1 infection and sensitivity 
towards ara-C.  
A) Western blot of SAMHD1 variants and wt SAMHD1 B) Cells were treated with indicated concentrations of 
cytarabine (ara-C) for 3 days to obtain maximal cytotoxicity and cell viability was determined using a colorimetric 
proliferation inhibition assay. Error bars indicate s.d. of a representative of three independent experiments 
performed in triplicates. EC50 values are the following wt SAMHD1_HA, 7438 nM; Luc_HA, 61,36; R451C_HA, 
76,88 nM; R451P_HA, 65,82 nM C) PMA-treated SAMHD1 -/- cells stably expressing the indicated SAMHD1 
variants were challenged with serial dilutions of VSV-G-pseudotyped HIV-1 GFP, and the infectious units (i.u.) per 
ml of inoculum were calculated. Representative of at least 2 independent titrations is shown. Mean titers of at least 
3 titration points with standard deviations are depicted and significance to block HIV-1 in cells expressing SAMHD1 
compared to no SAMHD1(Luc_HA) are indicated). Statistical analysis was performed using an unpaired two-tailed 
t test. ns, not statistically significant; **, P < 0.01,***, P < 0.001. 
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Rentoft et al. identified colon cancer-associated mutations of SAMHD1 and studied four 
mutations in greater detail among those are R366H and D497Y. dNTPase activity assay 
revealed that D497Y SAMHD1 variant had nearly abolished dNTPase activity whereas R366H 
still sustained dNTPase activity but significantly reduced (Rentoft et al., 2016). The R366 
resides in the catalytic site of SAMHD1 (Figure 41) and forms hydrogen bond and stacking 
interactions with the phosphate, the deoxyribose, and the base of the substrate, respectively. 
Mutation of this residue to A366 abolished the catalytic activity of SAMHD1 (Ji et al., 2013).  
 
Figure 41: Catalytic site of SAMHD1 with dCTP bound.  
Residue R366 is depicted in red. (PDB: 4RXR) 
 
Figure 42: SAMHD1 dimer with residue D497 depicted in red.  
D497 is not close to the active or allosteric site of SAMHD1. (PDB: 4RXR) 
Structural analyzes of the D497 residue within the SAMHD1 tetramer shows that D497 residues 
not close to the allosteric sites and the catalytic site (Figure 42). Taken both studies in 
consideration we assumed that both SAMHD1 variants are unable to block HIV-1 restriction 
and are sensitive to ara-C treatment. As shown in Figure 43 C both mutants did not restrict HIV-
1 and are highly sensitive to ara-C treatment.  
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The K596Rsf*35 mutation is reported by TCGA in four cancer types: COAD, Uterine Corpus 
Endometrial Carcinoma (UCEC), stomach adenocarcinoma (STAD) and Liver Hepatocellular 
Carcinoma (LIHC). When we tested this SAMHD1 variant we observed that HIV-1 restriction 
was completely lost but cells expressing this mutant were rendered more resistant to ara-C 
induced cytotoxicity, even at lower expression levels of the mutant as compared to WT 
SAMHD1 (Figure 44). This SAMHD1 variant phenocopies the A525T mutant (see above). 
Figure 44: Effects of K596Rsf*35 SAMHD1 variant on the restriction to HIV-1 infection and sensitivity towards 
ara-C.  
A) Western blot of SAMHD1 variants and wt SAMHD1 B) Cells were treated with indicated concentrations of 
cytarabine (ara-C) for 3 days to obtain maximal cytotoxicity and cell viability was determined using a colorimetric 
proliferation inhibition assay. Error bars indicate s.d. of a representative of three independent experiments 
Figure 43: Effects of R366H and D467Y SAMHD1 variant on the restriction to HIV-1 infection and sensitivity 
towards ara-C.  
A) Western blot of SAMHD1 variants and wt SAMHD1 B) Cells were treated with indicated concentrations of 
cytarabine (ara-C) for 3 days to obtain maximal cytotoxicity and cell viability was determined using a colorimetric 
proliferation inhibition assay. Error bars indicate s.d. of a representative of three independent experiments 
performed in triplicates. EC50 values are the following wt SAMHD1_HA, 7438 nM; Luc_HA, 61,36; R366H_HA, 
80,53 nM; D497Y_HA, 124,9 nM C) PMA-treated SAMHD1 -/- cells stably expressing the indicated SAMHD1 
variants were challenged with serial dilutions of VSV-G-pseudotyped HIV-1 GFP, and the infectious units (i.u.) 
per ml of inoculum were calculated. Representative of at least 2 independent titrations is shown. Mean titers of at 
least 3 titration points with standard deviations are depicted and significance to block HIV-1 in cells expressing 
SAMHD1 compared to no SAMHD1(Luc_HA) are indicated). Statistical analysis was performed using an unpaired 
two-tailed t test. ns, not statistically significant; **, P < 0.01, ***, P < 0.001. 
87 
 
performed in triplicates. EC50 values are the following wt SAMHD1_HA,6466 nM; Luc_HA, 61,36; 
K596Rsf*35_HA, 12962 nM C) PMA-treated SAMHD1 -/- cells stably expressing the indicated SAMHD1 variants 
were challenged with serial dilutions of VSV-G-pseudotyped HIV-1 GFP, and the infectious units (i.u.) per ml of 
inoculum were calculated. Representative of at least 2 independent titrations is shown. Mean titers of at least 3 
titration points with standard deviations are depicted and significance to block HIV-1 in cells expressing SAMHD1 
compared to no SAMHD1(Luc_HA) are indicated). Statistical analysis was performed using an unpaired two-
tailed t test. ns, not statistically significant; **, P < 0.01, ***, P < 0.001. 
The R145Q was found in COAD, CLL (Clifford et al., 2014)and AGS (Rice et al., 2009a). 
White et al. reported that the R145Q mutant is unable to oligomerize (White et al., 2013b). 
R145 resides in the primary allosteric site (Figure 45) and is involved in the guanine base 
recognition ((Zhu et al., 2013, Ji et al., 2014).  
 
Figure 45: Allosteric site of SAMHD1.  
Residue R145(light green) is in close proximity to GTP.  
R145A abolished HIV-1 restriction, which suggests that allosteric activation of SAMHD1 is a 
requirement for restriction (Koharudin et al., 2014b, Arnold et al., 2015). Our results confirm 
that R145 is crucial for restriction since R145Q SAMHD1 variant was unable to block HIV-1 
infection (Figure 46 C). R145Q expressing cells were sensitive to ara-C treatment comparable 
to cells lacking SAMHD1 (Figure 46 B).  
Figure 46: Effects of R145Q SAMHD1 variant on the restriction to HIV-1 infection and sensitivity towards 
ara-C.  
A) Western blot of SAMHD1 variants and wt SAMHD1 B) Cells were treated with indicated concentrations of 
cytarabine (ara-C) for 3 days to obtain maximal cytotoxicity and cell viability was determined using a colorimetric 
proliferation inhibition assay. Error bars indicate s.d. of a representative of three independent experiments 
performed in triplicates. EC50 values are the following wt SAMHD1_HA,9333 nM; Luc_HA, 98,48 R145Q_HA, 
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107,1 nM C) PMA-treated SAMHD1 -/- cells stably expressing the indicated SAMHD1 variants were challenged 
with serial dilutions of VSV-G-pseudotyped HIV-1 GFP, and the infectious units (i.u.) per ml of inoculum were 
calculated. Representative of at least 2 independent titrations is shown. Mean titers of at least 3 titration points 
with standard deviations are depicted and significance to block HIV-1 in cells expressing SAMHD1 compared to 
no SAMHD1(Luc_HA) are indicated). Statistical analysis was performed using an unpaired two-tailed t test. ns, 
not statistically significant; **, P < 0.01. 
10.2.4 Analysis of the ability of Vpx to degrade human SAMHD1 SNP variants 
Positive selection analysis of SAMHD1 by Laguette et al. revealed that the C-terminal domain 
of huSAMHD1 is required for Vpx interaction (Laguette et al., 2012). We tested the ability of 
Vpx from SIVMAC to induce degradation of the different SAMHD1 variants. As a control we 
used SIVRCM which is unable to degrade human SAMHD1 (Brandariz-Nunez et al., 2012, White 
et al., 2013a). As shown in Figure 47 we observed that all SAMHD1 variants were degraded 
by VpxMAC. The following SAMHD1 variants showed incomplete degradation: A76T, A338T, 
A525T and L178Q and at least for A338T this was likely not due to increased expression levels 
(Figure 47). 
 
Figure 47: Sensitivity of SAMHD1 variants to Vpx-induced degradation.  
293T cells were cotransfected with plasmids expressing the indicated SAMHD1 variants and HA-tagged Vpx from 
SIVRCM or SIVMAC. 24 hours after transfection the medium was changed and 36 hours after transfection cells were 
harvested and the expression level of SAMHD1 and Vpx were analyzed by Western blotting using anti-HA 
antibodies. As loading control an antibody against Hsp90 was used. Similar results were obtained in two 
independent experiments.  
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10.2.5 SNPs in stomach adenocarcinoma (STAD) 
The TCGA database reports that in 42 analyzed STAD patient tumor samples 16 mutations of 
SAMHD1 were found. A mutation conferring the P589T amino acid substitution was predicted 
to be damaging by one out of three computational analyses (VEP, SIFT, PolyPhen). P589 lies 
in close proximity to other monomers (Figure 48).  
 
Figure 48: SAMHD1 crystalized tetramer structure with P589 depicted in yellow. 
Residue P589 resides near the Dimer-Dimer interface. (PDB: 4TNP) 
When we analyzed this mutant in SAMHD1-/- cells HIV-1 restriction was not blocked. 
Sensitivity of cells expressing SAMHD1 P589T to ara-C induced cytotoxicity increased by 6-
fold as compared to WT SAMHD1 however was still 18.8-fold lower than observed in cells 
lacking SAMHD1 (Figure 49).  
 
Figure 49: Expression of SAMHD1 SNP variant P589Tin THP-1 SAMHD1 -/- cells has a negative effect on 
HIV-1 restriction and ara-C sensitivity.  
A) Western blot of SAMHD1 variant and wt SAMHD1 B) Cells were treated with indicated concentrations of 
cytarabine (ara-C) for 3 days to obtain maximal cytotoxicity and cell viability was determined using a colorimetric 
proliferation inhibition assay. Error bars indicate s.d. of a representative of three independent experiments 
performed in triplicates. EC50 values are the following wt SAMHD1_HA, 13585 nM; Luc_HA, 132,3 nM; P589T, 
2226 nM C) PMA-treated SAMHD1 -/- cells stably expressing the indicated SAMHD1 variants were challenged 
with serial dilutions of VSV-G-pseudotyped HIV-1 GFP, and the infectious units (i.u.) per ml of inoculum were 
calculated. Representative of at least 2 independent titrations is shown. Mean titers of at least 3 titration points 
with standard deviations are depicted and significance to block HIV-1 in cells expressing SAMHD1 compared to 
no SAMHD1(Luc_HA) are indicated). Statistical analysis was performed using an unpaired two-tailed t test. ns, 
not statistically significant; **, P < 0.01; ***, P < 0.001. 
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Table 3 Summary of analyzed SAMHD1 SNPs.  
Abbreviation and colors: cancer type; Rectum Adenocarcinoma (READ), Acute myeloid leukemia (AML), Colon 
Adenocarcinoma (COAD). Uterine Corpus Endometrial Carcinoma (UCEC), Stomach Adenocarcinoma (STAD) 
and Liver Hepatocellular Carcinoma (LIHC), significance of HIV-1 restriction compared to control; ns:not 
significant; +: P < 0.05; ++: P < 0.01, +++: P < 0.001, + in red over control cells, EC50 Fold change to wt 
SAMHD: in blue reduction compared to wild type and numbers in black increase compared to wt SAMHD1 EC50.  
SNP Cancer 
type 
Significance 
of HIV-1 
restriction 
compared 
to control 
EC50 Fold 
change to 
wt 
SAMHD1 
EC50 
Fold 
change 
to 
LUC 
A76T READ ++ +1,06 100,0 
R305I READ ++ +1,5 142,4 
L178Q AML + -2,6 39,4 
S214P AML ns -120,9 0 
G90R COAD ++ -2,4 92,0 
A338T COAD + +1,2 120,9 
D137N COAD ns -5,4 38,9 
V133I COAD ++ -1,1 83,5 
A525T COAD ++ -1,7 99,3 
R348C COAD ++ -1,4 67,2 
R451C COAD +++ -96,7 1,3 
R366H COAD +++ -92,4 1,3 
D497Y COAD + -59,6 2,0 
K597RSf*35 COAD 
UCEC 
STAD 
LIHC 
ns +2,0 211,2 
R145 COAD ns -87,1 1,08 
P589T STAD ++ -6,1 16,8 
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 SAMHD1 variants that influence post-translational modifications of 
SAMHD1 and their involvement in HIV-1 restriction and ara-CTP 
hydrolysis 
10.3.1 The C522 residue of SAMHD1 is crucial for the block to HIV infection but is not 
involved in conferring resistance to ara-C 
Wang et al. and Mauney et al. reported that SAMHD1 is a redox-sensitive enzyme and it poses 
three redox-active cysteines at the following location: 341, 350 and 522 (Mauney et al., 2017, 
Wang et al., 2018). Expression of the SAMHD1 variant C522S in PMA-treated U937 cell did 
not lead to HIV-1 restriction (Wang et al., 2018). They also tested dNTPase activity and 
capability of tetramerization. The C522S amino acid substitution had no detectable detrimental 
effect on SAMHD1 tetramerization or dNTPase activity in vitro. The authors reasoned that 
nucleotide dependent tetramerization and dNTPase activity were needed but not sufficient for 
the block of retroviral infection (Wang et al., 2018), suggesting that the redox state of C522 is 
crucial for the SAMHD1 restriction mechanism of HIV-1 infection. (Wang et al., 2018). HIV-
1 restriction ability of cysteine SAMHD1 mutants was evaluated in PMA-treated THP-1 
SAMHD1 -/- cells stably expressing either the C522S or C522A SAMHD1 variants using HIV-
1 virus expressing GFP, as above (Figure 50 C). Our results revealed that C522S or C522A 
mutants reduced (C522S by 8-fold; C522A by 6-fold) but not abolished HIV-1 restriction 
(Figure 50). Despite proper dNTPase function and tetramerization ability (Wang et al., 2018) 
C522S mutant was 1.4-fold more and C522A mutant was 3-fold more sensitive to ara-C 
treatment as compared to WT SAMHD1 (Figure 50). The C522S and C522A mutants 
phenocopied the A338T SAMHD1 mutant (see above). 
Figure 50: Effects of cysteine substitutions on the restriction of HIV-1 infection and sensitivity to ara-C.  
A) Western blot of SAMHD1 variants and wt SAMHD1 B) Cells were treated with indicated concentrations of 
cytarabine (ara-C) for 3 days to obtain maximal cytotoxicity and cell viability was determined using a colorimetric 
proliferation inhibition assay. Error bars indicate s.d. of a representative of three independent experiments 
performed in triplicates. EC50 values are the following wt SAMHD1_HA, 9333 nM; Luc_HA, 98,48 nM; 
C522A_HA, 3015 nM; C522S_HA, 6622 nM C) PMA-treated SAMHD1 -/- cells stably expressing the indicated 
SAMHD1 variants were challenged with serial dilutions of VSV-G-pseudotyped HIV-1 GFP, and the infectious 
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units (i.u.) per ml of inoculum were calculated. Representative of at least 2 independent titrations is shown. Mean 
titers of at least 3 titration points with standard deviations are depicted and significance to block HIV-1 in cells 
expressing SAMHD1 compared to no SAMHD1(Luc_HA) are indicated). Statistical analysis was performed using 
an unpaired two-tailed t test; *, P < 0.05; **, P < 0.01. 
10.3.2 SAMHD1 acetylation has no influence on HIV-1 restriction and only minimally 
changes the sensitivity of cells to ara-C induced cytotoxicity 
Lee et al. identified that the lysine residue 405 of SAMHD1 is acetylated by the 
acetyltransferase arrest defective protein 1 (ARD1) (Lee et al., 2017). Acetylation-defective 
mutant K405R possess lower dNTPase activity compared to wt acetylated SAMHD1 and 
acetylation promotes cancer cell proliferation (Lee et al., 2017). The authors imply that 
SAMHD1 acetylation might be of interest as a target for cancer treatment. They suggested that 
acetylation may also play a role in non-cycling cells because of its involvement in regulating 
dNTP levels and its ability to block lentiviral restriction (Lee et al., 2017). Therefore, we 
analyzed whether SAMHD1 K405R amino acid substitution would influence ara-C sensitivity 
and HIV-1 restriction in K405R expressing THP-1 SAMHD1 -/- cells. Ara-C sensitivity of cells 
expressing SAMHD K405R was similar to cells expressing WT SAMHD1 and HIV-1 
restriction was comparable to WT SAMHD1 (Figure 51). The data implicates that acetylation 
may not be critical for SAMDH1’s role in lentiviral restriction or ara-CTP hydrolysis.  
Figure 51: Effects of acetylation defective mutant K405R on the restriction to HIV-1 infection and sensitivity to 
ara-C.  
A) Western blot of SAMHD1 variant K405R and wt SAMHD1 B) Cells were treated with indicated concentrations 
of cytarabine (ara-C) for 3 days to obtain maximal cytotoxicity and cell viability was determined using a 
colorimetric proliferation inhibition assay. Error bars indicate s.d. of a representative of three independent 
experiments performed in triplicates. EC50 values are the following wt SAMHD1_HA, 7438 nM; Luc_HA, 61,36 
nM; K405R_HA, 6274 nM C) PMA-treated SAMHD1 -/- cells stably expressing the indicated SAMHD1 variants 
were challenged with serial dilutions of VSV-G-pseudotyped HIV-1 GFP, and the infectious units (i.u.) per ml of 
inoculum were calculated. Representative of at least 2 independent titrations is shown. Mean titers of at least 3 
titration points with standard deviations are depicted and significance to block HIV-1 in cells expressing SAMHD1 
compared to no SAMHD1(Luc_HA) are indicated). Statistical analysis was performed using an unpaired two-tailed 
t test. **, P < 0.01. 
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 Discussion and perspective  
 SAMHD1’s role in the type 1 interferon induced early block to HIV-1 infection  
11.1.1 The VpxMAC-induced increase of HIV-1 infection in type I IFN treated MDMs is 
SAMHD1-dependent  
I have shown that VpxMAC Q76A was unable to relief HIV-1 from the type I IFN-induced block 
in MDM. Wild type Vpx on the other hand greatly boosted HIV-1 infection with or without 
IFN pretreatment. The experiments presented here confirm that SIVMAC Vpx rescues HIV-1 
infection from the IFN-induced block in MDM (Lahouassa et al., 2012, Hrecka et al., 2011, 
Srivastava et al., 2008, Reinhard et al., 2014). The magnitude of the rescue was dependent on 
the donor and reached up to 155-fold, but the increase in type 1 IFN-treated cells was usually 
more pronounced than in untreated cells, an observation seen before in MDDCs (Pertel et al., 
2011). Despite the fact that Vpx is not a HIV-1 accessory protein, it can serve as a tool to 
identify new HIV-1 restriction factors that are involved in the type 1 IFN-induced block to early 
infection steps.  
We confirmed here that the Vpx mutant (Q76A) which is unable to bind DCAF1 failed to rescue 
HIV-1 infection in untreated MDMs or THP-1 cells (Lahouassa et al., 2012, Hrecka et al., 2011, 
Srivastava et al., 2008, Reinhard et al., 2014). Vpx binds to DCAF1 and associates with the 
DDB1/RBX1/ Cul4A E3 ubiquitin ligase complex (Sharova et al., 2008, Srivastava et al., 2008, 
Bergamaschi et al., 2009, Hrecka et al., 2007, Belzile et al., 2007, Le Rouzic et al., 2007, 
Schrofelbauer et al., 2007, Tan et al., 2007). SAMHD1s degradation is initiated by the binding 
of Vpx to SAMHD1. This induces the degradation of SAMHD1 by Vpx`s ability to hijack the 
DDB1/RBX1/ Cul4A E3 ubiquitin ligase machinery. This indicates that the 
DCAF1/DDB1/RBX1/ Cul4A E3 ubiquitin ligase complex is crucial for the phenotype reported 
here. In contrary, Pertel reported that DCAF1/DDB1/RBX1/ Cul4A E3 ubiquitin ligase 
complex is dispensable and that the Vpx-mediated relieve from the antiviral state was also seen 
in DCAF1 knockdown in MDDCs (Pertel et al., 2011). Moreover, Pertel et al. showed that 
VpxMAC Q76A rescued HIV-1 infection under proinflammatory conditions in MDDCs, which 
stands in contrast to the observations made here. This contrast might be due to cell-type specific 
effects, e.g. MDDCs may express a different set of DCAF proteins that might still be able to 
interact with VpxMAC mutant Q76A. Goujon et al. described for example that reduction of 
DCAF1 had little impact on increasing the HIV-1 infection by Vpx-VLPs (PMID: 18829761). 
Our results are consistent with a model in which SAMHD1 is an antiviral factor that is crucial 
for the Vpx mediated relief from the type I antiviral block.  
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11.1.2 The VpxMAC-induced rescue of HIV-1 from the type I IFN-induced block in MDM 
is independent of the route of entry 
It has been suggested that IFITM proteins can block VSV-G pseudotyped viral infection 
(Roesch et al., 2018, Yu et al., 2015) and hence we investigated whether the Vpx-induced rescue 
of the HIV-1 infection from the type I IFN-induced block would rely on VSV-G pseudotyping 
of HIV-1. We found that also non-pseudotyped R5-tropic BalEnv HIV-1 was efficiently 
rescued upon Vpx supplement. This suggests that Vpx mediated increase of HIV-1 infection is 
independent of HIV-1s route of entry. 
11.1.3 VpxMAC does not relieve HIV-1 from the type I IFN-induced block in THP-1 
SAMHD1-/- cells 
HIV-1 infection in PMA differentiated THP-1 cells increased by three-fold in response to Vpx 
without prior treatment of interferon. This magnitude is similar to published data (Goujon et 
al., 2013c). When THP-1 parental cells were treated prior to infection with type I interferon an 
up to 19-fold increase in infectivity was seen when infection was performed in the presence of 
Vpx. In order to test SAMHD1’s involvement in the increase of infectivity with or without prior 
type I IFN treatment we generated SAMHD1 knock-out THP-1 cell lines by using 
CRISPR/Cas9 technology. SAMHD1 knock-out increased the permissivity for HIV-1 infection 
in PMA-differentiated cells by approximately 4-fold in all tested SAMHD1 knockout cell 
clones. This is in line with published data using Vpx-VLPs to degrade SAMHD1 (Goujon et 
al., 2013c, Pertel et al., 2011). Additionally and surprisingly, Vpx was unable to further increase 
HIV-1 infection in type I IFN-treated or untreated cells when SAMHD1 was absent. This 
indicates that in the absence of SAMHD1, no additional increase in infectivity is conferred by 
Vpx – indicating that SAMHD1 is the a playing an important role in the IFN block that can be 
counteracted by Vpx. The Vpx mediated increase of HIV-1 infection is present with or without 
IFN. However, Vpx mediated increase of HIV-1 infection in IFN treated cells is usually bigger 
than in IFN untreated cells. This cannot be explained by a simple increase in SAMHD1 protein 
levels, since SAMHD1 protein levels do not change substantially upon IFN treatment. It is 
possible however, that the enzymatic activity of SAMHD1 is also regulated by IFN treatment 
without enhancing the protein levels and that the increased rescue of HIV-1 infectivity is an 
effect of reduced dNTPase activity of SAMHD1 after IFN treatment. Likewise, IFN-regulated 
co-factors of SAMHD1 could impact the Vpx-induced rescue (Buffone et al., 2019). 
In order to further confirm that SAMHD1 is crucial for the Vpx mediated increase of HIV-1 
infection from the type I IFN-induced block we re-expressed CRISPR/Cas9-resistent and 
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amino-terminal HA-tagged and amino-terminal codon-optimized (refractory to gRNA) 
SAMHD1 in SAMHD1 knockout cells. Expression of wild type SAMHD1 in SAMHD1 
knockout clones reintroduced the block to HIV-1 infection by 6-fold compared to the SAMHD1 
knockout clone in the presence or absence of type I IFN treatment. Stable ectopic expression of 
WT SAMHD1 in the SAMHD1 -/- cell line reintroduced the Vpx-mediated increase of HIV-1 
infection in those cells in the absence of pretreatment with IFN. The increase was rather small 
(3.3-fold) as compared to endogenously expressed SAMHD1. One reason underlying this weak 
Vpx-induced increase in HIV-1 infection may have been the constant high expression of 
SAMHD1 from the strong SFFV promoter of the integrated lentiviral vector that was used to 
re-express SAMHD1 in the knockout cells. Vpx, which is delivered by VLPs at a given dose, 
might not be able to overcome the constant expression of SAMHD1 even with an increase of 
Vpx. To achieve a greater increase an inducible vector with switch off or knock in mutagenesis 
could be used to achieve more physiological settings in future studies. 
11.1.4 SAMHD1 knock-out has no influence on cell proliferation in THP-1 cells 
The effect of perturbed SAMHD1 expression was studied by many groups and gave 
controversial results. As an example, reduced SAMHD1 activity results in increased dNTP 
levels, which could lead to uncontrolled cell proliferation (Clifford et al. 2014, Rossi 2014). 
Franzolin et al. and Kretschmer et al. reported that SAMHD1 RNA interference in 
immortalized fibroblast or HeLa cells, which lead to reduced SAMHD1 levels, results in 
reduced cell proliferation (Franzolin et al., 2013, Kretschmer et al., 2015). Bonifati et al. 
reported that SAMHD1 knock-out by CRISPR/Cas9 in myeloid THP-1 cells increased cell 
proliferation and decreased spontaneous apoptosis (Bonifati et al. 2016). We did not see a 
significant increase in cell proliferation only a small but significant decrease in sub-G1 cells in 
the SAMHD1 knockout clones. These results stay in contrast with studies in AGS fibroblasts 
in which abolished SAMHD1 levels slows down cell proliferation (Franzolin et al., 2013). It is 
also possible that the reported phenotypes are cell type dependent, e.g. due to off target effects 
in the different CRISPR/Cas9 clones used by Bonifati and us or that dNTP levels or RNR 
activity vary between the cells used in different laboratories (Herold et al., 2017c). Therefore, 
systematic studies have to be conducted in order to verify SAMHD1’s involvement in cell cycle 
progression and proliferation. How IFNα treatment might impact cell proliferation in absence 
or presence of SAMHD1 and how this could contribute to the Vpx-induced rescue of HIV-1 
from the type I IFN-induced block (rescue by Vpx is greater after IFN treatment as compared 
to untreated cells), is unclear at the moment and warrants further investigations. 
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11.1.5 Characterization of a THP-1 cell line endogenously expressing SAMHD1 with 
truncated nuclear localization signal (THP-1 Eg3c6+/-) 
Previous studies observed that nuclear localization of SAMHD1 is not fundamental for HIV-1 
restriction (Rice et al., 2009b, Brandariz-Nunez et al., 2012, Hofmann et al., 2012) but VpxMAC 
mediated degradation depends on nuclear localization of SAMHD1 (Schaller et al., 2014, 
Brandariz-Nunez et al., 2012, Hofmann et al., 2012, Wei et al., 2012, Guo et al., 2013).  
To answer the question whether Vpx-induced SAMHD1 degradation is required for the rescue 
from the antiviral state in type I IFN-treated cells, we generated THP-1 cells in which SAMHD1 
was endogenously truncated in its nuclear localization signal. These cells contained only one 
functional SAMHD1 allele, which harbored an in frame deletion of the NLS region. We found 
that endogenously expressed SAMHD1 lacking the NLS was excluded from the nucleus using 
immunofluorescence. Comparable to published results using overexpression assays, 
endogenously expressed SAMHD1ΔNLS resisted Vpx-induced degradation (Hofmann et al., 
2012, Schaller et al., 2014), however after 24 h Vpx treatment SAMHD1ΔNLS levels decreased 
comparable to WT SAMHD1 treated with Vpx. This indicates that cytoplasmic SAMHD1 can 
be degraded by Vpx, and that this is likely masked when using overexpression assays. Previous 
studies on cytoplasmic SAMHD1 used lentiviral vectors overexpressing SAMHD1 NLS mutant 
K11A in MDM, HeLa or THP-1 cells (Schaller et al., 2014, Brandariz-Nunez et al., 2012, 
Hofmann et al., 2012, Wei et al., 2012, Guo et al., 2013). Our system is physiologically more 
relevant since ectopic expression results in high SAMHD1 levels thus SAMHD1 regulation and 
degradation might not be identical to endogenously expressed SAMHD1. Furthermore, 
previous studies analyzed the SAMHD1 degradation by Vpx in a rather short time window of 
10 hours (Hofmann et al., 2012).  
One explanation for the delayed degradation kinetics of SAMHD1ΔNLS might be that ubiquitin 
chains that are appended to cytoplasmic SAMHD1 may differ in the linkage patterns, leading 
to delayed degradation. Schaller et al. tested this hypothesis using overexpression of the 
SAMHD1 K11A mutant. They observed differences in the polyubiquitination profiles for wild 
type and K11A SAMHD1, specifically with UbiK11R and UbiK6R, leading to increases in 
polyubiquitinated SAMHD1 K11A compared to SAMHD1 WT (Schaller et al., 2014). Future 
studies should investigate whether this holds true for endogenously expressed SAMHD1 
lacking the amino-terminal NLS and whether the different linkages may explain reduced 
degradation kinetics in presence of Vpx. Another limiting factor might be the availability of the 
DCAF1-DDB1-CUL4A E3 ubiquitin ligase complex factors in the cytoplasm. Hofmann et al 
tested whether SAMHD1ΔNLS binds to Vpx, by examining whether Vpx SAMHD1 complexes 
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could be pulled-down from cells. It was confirmed that Vpx is able to bind SAMHD1 K11A 
mutant (Hofmann et al., 2012). This indicates that Vpx binding to SAMHD1 in the cytoplasm 
is not the limiting factor. Next we tested whether this endogenously expressed SAMHD1 
lacking the NLS was able to increase HIV-1 infection in the presence of Vpx. Vpx increased 
HIV-1 infection by 4-fold, comparable to parental THP-1 cells. Vpx mediated increase in HIV-
1 infection in SAMHD1ΔNLS cells was comparable to THP-parental cells. This raises the 
question whether SAMHD1 degradation is necessary for the Vpx mediated increase of HIV-1 
infection. The window of infection when SAMHD1 is not degraded by Vpx in the ΔNLS cells 
is around 24 hours. While we have investigated effects on infection in this time window and 
stopped infection before SAMHD1ΔNLS became apparently degraded in immunoblots, we 
cannot rule out that the observed increase in infection is also due to VSV-G pseudotyped virus 
trapped in endosomes that infects at later time points when SAMHD1 is degraded. Further HIV-
1 infection experiments have to be conducted to investigate the question further, whether 
degradation of SAMHD1 is required for the Vpx-mediated effects on HIV-1 infection in the 
presence of a type I IFN-induced antiviral state. For example, proteasomal inhibitors can be 
used to allow only a brief incubation with Vpx. Comparing the SAMHD1ΔNLS mutant cells 
with parental THP-1 cells treated with Vpx for a short amount of time following infection and 
addition of proteasomal inhibitors would than allow us to further evaluate whether SAMHD1 
degradation is mandatory for the Vpx mediated boost of infection from the antiviral state. 
Furthermore, a Vpx mutant can be used which is able to bind to DCAF1 but is unable to degrade 
SAMHD1.  
Most of the AGS SAMHD1 variants reside in the nucleus and to varying degrees in the 
cytoplasm (White et al. 2017, Goncalves et al. 2012b). Studying these mutants might help to 
understand the need of SAMHD1 to localize to the nucleus. Future investigations of SAMHD1 
have to explore the nucleocytoplasmic partitioning of elements of the ubiquitin/proteasome 
system and their involvement in Vpx mediated SAMHD1 degradation. Recent studies suggest 
a role for SAMHD1 on DNA replication forks (Coquel et al., 2018), and it will be of interest to 
understand whether this is the main reason that SAMHD1 is a nuclear protein, suggesting that 
its antiviral activity may be a byproduct, rather than a specific antiviral feature gained during 
evolution. 
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11.1.6 Type I interferon has no influence on Vpx-mediated SAMHD1 degradation in 
cycling THP-1 cells 
Dragin et al. and Roesch et al. showed that interferon alpha (IFNα) treatment of THP-1 cells 
prevented degradation of SAMHD1 following incubation with SIVMAC virus-like particles 
containing Vpx (Dragin et al. 2013 Roesch et al. 2018). This would suggest that IFN stimulated 
genes interfere with SAMHD1 degradation by Vpx. Roesch et al. reported that IFITM proteins 
are involved in the IFNα mediated protection of SAMHD1 degradation by blocking VSV-G 
mediated entry of viral particles delivering Vpx (Roesch et al., 2018). Since Vpx mediated 
SAMHD1 degradation might be one explanation of the Vpx mediated increase of HIV infection 
in IFNalpha treated cells we tested SAMHD1 degradation by Vpx with and without interferon. 
Furthermore, we investigated whether PMA treatment influences SAMHD1 degradation. As 
published by other groups complete SAMHD1 degradation was achieved in the presence of 
Vpx-VLPs. In contrast to Dragin and Roesch et al. IFNalpha treatment did not hinder Vpx 
mediated SAMHD1 degradation as also seen by Goujon et al. (Goujon et al., 2013b). PMA and 
IFNα treatment together slightly hindered SAMHD1 degradation in the presence of Vpx-VLPs 
but did not completely block SAMHD1 degradation. In order to verify that IFITMs are not 
involved in the Vpx mediated degradation of SAMHD1 we created IFITIM knockout cell lines 
in which we will further test SAMHD1 degradation by Vpx and use these tools to study the 
involvement of IFITM proteins in the Vpx-mediated increase of HIV-1 infectivity.  
 
 Correlation of SAMHD1 dNTPase activity with HIV-1 restriction by 
using cancer-associated naturally occurring SAMHD1 variants 
11.2.1 SAMHD1 is a mediator of ara-C toxicity in AML cell models 
The most active agent against myelogenous leukemia (AML) is the cytostatic deoxycytidine 
analog cytarabine (ara-C) which is usually given in combination with an anthracycline 
(Ossenkoppele and Lowenberg, 2015). The American Cancer Society’s estimates for about 
61,780 new leukemia cases and 21,450 of them account for acute myeloid leukemia (AML). 
They further predict that 10,920 people mostly adults will die in 2019 of AML. The global 
annual incidence of leukemia in 2018 were 437,033 cases.6 
The active metabolite of ara-C is ara-CTP which is incorporated into the DNA and causes DNA 
damage and eventually leads to cell death. One reason for AML therapy to fail is the decrease 
                                                 
6 https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data 
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in the active metabolite ara-CTP (Zittoun et al., 1987, Early et al., 1982, Estey et al., 1987, 
Heinemann and Jehn, 1990, Hiddemann et al., 1996, Kessel et al., 1969, Rustum et al., 1987, 
Smyth et al., 1976, Yamauchi et al., 2001). Thus, there is a need to identify new strategies to 
treat AML patients.  
We and other have shown that ara-CTP is a substrate of SAMHD1 and thereby we determined 
SAMHD1 as key factor in dictating sensitivity of AML blast to ara-C (Schneider et al., 2017, 
Herold et al., 2017a, Hollenbaugh et al., 2017). Ara-C-induced cytotoxicity was substantially 
increased in THP-1 SAMHD1 knock-out cells and in THP-1 cells where SAMHD1 was 
degraded by Vpx-containing-virus-like particles (VLPs). We further assessed the importance 
of catalytic active SAMHD1 for ara-C hydrolysis by ectopic expression of CRISPR/Cas9-
resistant WT SAMHD1 or catalytic site mutants in THP-1 SAMHD1 knockout cells. Only WT 
SAMHD1 was able to decrease ara-C cytotoxicity, indicating that the enzymatic function is 
critical for the detoxification. We concluded that the dNTPase activity of SAMHD1 is crucial 
for reducing the toxic effect of ara-C treatment. This opened for us and for the first time the 
possibility to investigate directly in the same cells in parallel the antiviral activity against HIV-
1 and the enzymatic dNTPase activity of SAMHD1 with this ara-C cytotox assay. This 
investigation is important to understand the impact of the SAMHD1 enzymatic activity in the 
IFN-induced block to HIV-1. To further address SAMHD1s involvement in ara-C sensitivity 
of cells in vivo our collaborators in Schweden tested the effect of differential SAMHD1 
expression in AML tumor cells in a heterotopic and orthotropic AML mouse model. Lack of 
SAMHD1 increased the sensitivity to ara-C treatment as seen in vitro. In vivo analysis of 
catalytic dead SAMHD1 revealed that mice transplanted with cells expressing wt SAMHD1 
were more resistant to ara-C treatment than mice transplanted with cells expressing the catalytic 
dead mutants of SAMHD1. This confirmed that catalytic active SAMHD1 is required for ara-
C detoxification (Herold et al., 2017a).  
For further research SAMHD1 levels in AML blast have to be monitored during AML therapy. 
But not only protein levels are important since some cancer associated natural SAMHD1 
polymorphisms showed differential activities in neutralizing ara-C induced cytotoxicity. The 
goal would be to use SAMHD1 as biomarker to treat patients according to their SAMHD1 
levels or to their SAMHD1 sequence. Another strategy would be to include SAMHD1 inhibitors 
in AML therapy. Our collaborators tested this by delivering Vpx to AML cells by using VSV-
G pseudotyped VLPs. To date only ex vivo application of lentiviral vectors has been tested in 
clinical trials to alter hematopoietic stem cells which are administered after changes are applied 
(Booth et al., 2016, Mamcarz et al., 2019, Mansilla-Soto et al., 2016). In order to treat AML 
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SAMHD1 levels have to be changed in vivo but in vivo trials have not yet been conducted and 
are only in preparation (Alton et al., 2017). Alternative ways to deliver Vpx besides VLPs 
would be the use of small DNA viruses (Kienle et al., 2012), coupling of Vpx to antibodies 
targeting AML cells (Gamis et al., 2014), mRNA-based therapeutics (Sahin et al., 2014) or 
liposomal packaging of Vpx (Morrell et al., 2008, Chen et al., 2014). As previously reported 
SAMHD1 possesses tumor suppressor function in lung cancer (Wang et al., 2014), CLL 
(Clifford et al., 2014), COAD (Rentoft et al., 2016) and cutaneous T-cell lymphoma (Merati et 
al., 2015, Kodigepalli et al., 2017). Our collaborators at the Karolinska Institute in Stockholm 
proposed that SAMHD1 has tumor suppressor function as well in AML. Since there is a 
negative trend of low SAMHD1 expression on overall survival and event free survival it is 
possible that the missing dNTP regulation fuels tumor growth (Herold et al., 2017a). 
Furthermore, germ line mutations of SAMHD1 are one cause of AGS which leads to 
inflammatory reactions (Rice et al., 2009b). Hence it is understandable that constant down 
regulation of SAMHD1 is not favorable for the AML patient. Therefore, SAMHD1 levels 
should only be downregulated while ara-C therapy is ongoing, and the innate immune response 
should be monitored closely. Another more cost efficient, controllable and with presumed fewer 
off targets effect as lentiviral therapy approach would be small molecule inhibitors of 
SAMHD1. This warrants further investigations. SAMHD1 is a promising biomarker and further 
studies have to focus on SAMHD1s role in genome stability and cell homeostasis 
11.2.2 SAMHD1 SNPs in Cancer 
We showed that SAMHD1 is able to detoxify cells treated with ara-C by hydrolyzing the active 
metabolite ara-CTP (Herold et al., 2017a). To date there are approximately 197 SAMHD1 
mutations known, which spread across 26 cancer projects (TGGA) and some of them may be 
associated with tumorigenesis.  
We wanted to investigate the influence of known SAMHD1 mutation of AML, READ and 
COAD on ara-CTP hydrolysis and susceptibility to HIV-1 infection therefore we expressed 
these CRISPR/Cas9-resistant SAMHD1 variants in the THP-1 g2c2 SAMHD1 -/- cell line by 
using lentiviral vectors. In order to get a better impression how much SAMHD1 is needed to 
block HIV-1 infection and detoxify the cells after ara-C treatment performed a titration of 
SAMHD1 lentiviral vector. High SAMHD1 expression levels are crucial for an extensive block 
of HIV-1 infection and increased the EC50 value of ara-C by 40-fold (wt SAMHD1_HA 
compared to wt SAMHD1_HA diluted 1:16). Even weak SAMHD1 expression caused some 
HIV-1 restriction and ara-CTP hydrolysis. The data showed that there was no detectable 
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threshold that was required for HIV-1 restriction or ara-C neutralization, however, and as 
predicted, both were strongest when SAMHD1 expression levels were highest. This was also 
confirmed by dose-dependent Vpx-mediated SAMHD1 reduction which is associated with 
dose-dependent sensitization to ara-C in THP-1 cells (Herold et al., 2017a). 
11.2.2.1 SAMHD1 SNPs in Rectum Adenocarcinoma (READ) 
In Rectum Adenocarcinoma (READ) currently three missense mutation are known: A76T, 
R305I and S302Y. SAMHD1 variants A76T or R305I were expressed in the SAMHD1-/- cell 
line g2-2. Ectopic expression of wt or A76T as well as R305I increased the EC50 for ara-C by 
94 to 142-fold compared Luc-HA transduced cells. R305I increased the EC50 for ara-C by 1.5-
fold compared to wt SAMHD1. Both SAMHD1 variants efficiently blocked HIV-1 infection 
and surprisingly even significantly stronger as compared to WT SAMHD1. R305 resides 
closely to the active site and the modification might have positively influenced ara-CTP binding 
and dCTP respectively. Beloglazova et al. reported that alanine replacement of R305 had a 
negative effect on nuclease function (which is controversial) and dGTP hydrolysis 
(Beloglazova et al., 2013). Since HIV-1 restriction was not perturbed it would be surprising but 
not unlikely that R305I would show decreased dNTPase activity. Further analyses of the 
dNTPase activity and nuclease activity (although this is highly controversial) of R305I have to 
be conducted. A76 is part of the SAM domain. White et al. reported that the SAM domain is 
dispensable for HIV-1 restriction, oligomerization and RNA binding (White et al., 2013a) in 
contrary Beloglazova et al. published that the SAM domain is required for maximal activity 
and nucleic acid binding (Beloglazova et al., 2013). Here we report that change in the SAM 
domain can indeed lead to a presumably more active form of SAMHD1. READ is commonly 
treated with 5- Fluorouracil and capecitabine.7 Both antimetabolites have to be tested for their 
hydrolyzes by SAMHD1. Our collaborators have preliminary results that both antimetabolites 
can be hydrolyzed by SAMHD1. Therefore, further experiments have to investigate whether 
both READ SNPs respond differently to these drugs. 
11.2.2.2  SAMHD1 SNPs in acute myeloid leukemia (AML) 
In 144 analyzed cases of AML there were 2 cases in which SAMHD1 was mutated at positions 
L178Q as well as S214P, respectively. Comparable expression of L178Q to wt SAMHD1 
resulted in a minor but significant HIV-1 block and 2.6-fold reduction of ara-C EC50 compared 
to wt SAMHD1. Cells expressing lower amount of L178Q as compared to WT SAMHD1 did 
                                                 
7 www.cancer.org/cancer/colon-rectal-cancer/treating/by-stage-rectum.html 
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not block HIV-1 infection and showed increased EC50 value by 5.5-fold compared to control 
cells. AML patients with the L178Q mutation would presumably respond better to ara-C 
treatment depending on their SAMHD1 expression levels. L178Q mutation might influence 
dNTPase function of SAMHD1 leading to elevated dNTP levels which may increase HIV-1 
infection.  
The second SNP in AML S214P did not block HIV-1 infection and was highly sensitive to ara-
C treatment comparable to loss of SAMHD1 activity. S214 is buried in the catalytic site of 
SAMHD1 and changes at this site likely greatly influence dNTPase activity of SAMHD1 and 
hydrolysis of ara-CTP. Future studies will have to investigate this using primary AML cells 
with these SAMHD1 SNP variants. Herold et al. previous evaluation of SAMHD1 levels in 
malignant cells can be used to help determine the dose of ara-C needed to achieve sufficient 
antineoplastic activity while avoiding excessive ara-C toxicity (Herold et al., 2017a). Our 
findings suggest that protein levels as well as SAMHD1 mutations can alter the sensitivity 
towards ara-C treatment.  
11.2.2.3  SAMHD1 SNPs in colon adenocarcinoma (COAD) 
In 59 analyzed cases of COAD database there were 16 mutations of SAMHD1 found in the 
TCGA database. We decided to further analyze all 13 missense SNPs and the frameshift mutant 
K596Rfs*35. Trifluridine is one of the drugs used to treat colon cancer (Sueda et al., 2016, 
Scagliotti et al., 2016, Bando et al., 2016). In our previous study we tested whether trifluridine 
besides ara-C is a substrate of SAMHD1. SAMHD1 -/-cells displayed increased sensitivity 
toward trifluridine suggesting that triphosphate variants of trifluridine could be possible 
SAMHD1 substrates (Herold et al., 2017b). Further analysis including in vitro activity assay, 
in vivo experiments and cohort studies have to be conducted to further verify trifluridine as a 
substrate of SAMHD1. If SAMHD1 is as well able to hydrolyze triphosphate variants of 
trifluridine it would be of great interest to study COAD SAMHD1 variants which commonly 
occur and their response to trifluridine. This would be the next step to personalized medicine. 
Analyzing the expression level of SAMHD1 in tumors of COAD patients could help to 
administer the exact dose to get the greatest response of the drug. This would also presumably 
minimize side effects since COAD SAMHD1 variants can influence hydrolyzes of the drug. 
Hence a lower dose of the drug is needed to achieve aimed results.  
1. G90R variant 
The G90R mutation lies closely to the end of the SAMHD1 SAM domain. Deletion construct 
studies of SAMHD1 revealed that the SAM domain is dispensable for HIV-1 restriction (Powell 
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et al., 2011, White et al., 2013b, Goldstone et al., 2011, Yan et al., 2013, Brandariz-Nunez et 
al., 2012). Our expression studies of G90R showed that the G90R variant has to be higher 
expressed than wt SAMHD1 in order to achieve at least a 2.4-fold lower EC50 compared to wt 
SAMHD1. The block to HIV-1 was significant but 4-fold lower compared to wt SAMHD1. 
Lower expression of G90R compared to wt SAMHD1 did not block HIV-1 infection. Taken in 
consideration that according to White et al. the SAM domain is dismissible, SAMHD1 variants 
with changes located in the SAM domain should have no defect in HIV-1 restriction but yet 
G90R SAMHD1 variant showed significantly decreased HIV-1 restriction efficiency and cells 
expressing this variant were more sensitive to ara-C treatment than compared to cells expressing 
wt SAMHD1. The SAM domain might have been underestimated in the involvement of HIV-
1 restriction. The SAM domains can potentially interact in a homodimeric fashion, as well as 
with other protein domains or even with RNA (Qiao and Bowie, 2005; Rice et al., 2009). White 
et al. tested whether the SAM domain of SAMHD1 would form homodimeric complexes by an 
oligomerization assays which revealed that full-length SAMHD1 does not interact with the 
SAMHD1 variant (1–150) that contains the SAM domain, suggesting that the SAM domain of 
SAMHD1 might not be interacting with itself in the context of a dimeric SAMHD1. The 
drawback of this experiment is that the SAMHD1 variant 1–150 that contains the SAM domain 
might be a misfolded protein (White et al., 2017). Recent work by Buzovetsky et al. showed 
that the SAM domain of mouse SAMHD1 is critical for its activation and regulation. They were 
also able to achieve the crystal structure of full-length mSAMHD1 protein (Buzovetsky et al., 
2018). The structure of full-length human SAMHD1 has not yet been discovered. All published 
structures of human SAMHD1 only contain the catalytic HD domain (Goldstone et al., 2011, 
Ji et al., 2013, Zhu et al., 2013). A structural understanding of the full-length SAMHD1 is 
important as the SAM domain is required for mSAMHD1 catalysis and is likely important for 
regulating hSAMHD1 activity.The prior mentioned A76T SAMHD1 variant which also resides 
in the SAM domain showed the opposite phenotype to G90R, i.e. it enhanced the block to HIV-
1 infection. This strengthens our hypothesis that the SAM domain might be involved in the 
HIV-1 restriction mechanism of SAMHD1.  
2. A338T, V133I, R366H or D497Y SAMHD1 variants 
Rentoft et al. analyzed all four colon associated SAMHD1 amino acid changes by recombinant 
protein purification and in vitro characterization. In vitro dNTPase activity of A338T was 
significantly altered for all four nucleoside triphosphates tested (Rentoft et al. 2016). This 
would suggest that A338T would show at least a reduced block to HIV-1 infection and ara-C 
sensitivity should be altered as well. In our case A338T was still able to restrict HIV-1 infection 
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but to a minor extent as compared to wt SAMHD1 (3-fold reduction). To our surprise A338T 
was able to neutralize the ara-C induced cytotoxicity, suggesting that this mutant was able to 
hydrolyze ara-CTP to the same extent as wt SAMHD1. This might uncouple the ability of 
SAMHD1s dNTPase activity and its ara-CTP hydrolysis function and will need further 
investigation by e.g. measuring intracellular dNTP levels in cells expressing this mutant. In 
vitro dNTPase activity of V133I was significantly altered but not as strong as A338T SAMHD1 
variant mentioned above (1.6-2 fold reduction) for all four nucleoside triphosphates (Rentoft et 
al. 2016). In our experimental setup V133I expression significantly boosted the block to HIV-
1 infection compared to wt SAMHD1 and ara-C sensitivity was comparable to wt SAMHD1. 
V133 lies close to the allosteric site. Alteration of V133 might increase the affinity of dNTPs 
thereby decreasing dNTP levels. The in vitro dNTPase activity assay by Rentoft et al. revealed 
that D497Y SAMHD1 variant had nearly abolished dNTPase activity whereas R366H still 
sustained dNTPase activity but significantly reduced (Rentoft et al. 2016). The R366 resides in 
the catalytic site of SAMHD1 and forms hydrogen bond and stacking interactions with the 
phosphate, the deoxyribose, and the base of the substrate, respectively. Mutation of this residue 
to A366 abolished the catalytic activity of SAMHD1. Ji et al. suggested that this might be due 
to miss binding and orientation of the dGTP substrate for catalysis (Ji et al. 2013). Taken both 
studies in consideration we assumed that both SAMHD1 variants are unable to block HIV-1 
restriction and are sensitive to ara-C treatment. Indeed, both mutants did not restrict HIV-1 and 
are highly sensitive to ara-C treatment.  
3. A525T variant 
The SAMHD1 variant A525T did not show any defect when compared to WT SAMHD1 with 
respect to neutralize the cytotoxic effect of ara-C, hence presumably was able to detoxify the 
cell of ara-CTP but had lost its ability to block HIV-1 infection completely. The 
phosphorylation prediction screen identified Cdk 2 as possible enzyme to phosphorylate the 
T525 site. A constant phosphorylation could explain the loss of the block to HIV-1 infection. 
We therefore analyzed whether PMA treatment still resulted in T592 dephosphorylation. T592 
dephosphorylation was seen in the A525T mutant. To further determine the function of this 
amino acid residue we designed the following SAMHD1 variants: A525S, A525E 
(phosphomimetic), A525V or A525Y. All variants rescued ara-C-induced cytotoxicity hence 
presumably hydrolyzed ara-CTP but were not able to block HIV-1 infection efficiently. This 
indicates that constant phosphorylation might not be the reason for the higher infectivity 
compared to wild type expressed SAMHD1. Only A525E showed a significant but weak block 
to HIV-1 infection when compared to wt SAMHD1. This suggests that the A525 residue is 
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critical for the block to HIV-1 infection and uncouples ara-CTP hydrolysis (and dNTPase 
funtion) from HIV-1 restriction. Furthermore, we tested the ability of Vpx to rescue HIV-1 from 
the type I IFN induced block in the cells expressing the A525T variant of SAMHD1. The 
expressed SAMHD1 variant was not able to rescue HIV-1 from the type I IFN induced block 
upon Vpx addition. The reason for this was likely that A525T displayed decreased degradation 
kinetics compared to wild type expressed SAMHD1 when challenged with VPX-VLPs. Since 
Vpx was still able to degrade SAMHD1, binding to DCAF1 was likely not affected for the 
A525T variant. There might be other factors involved in the increase of HIV-1 upon Vpx 
treatment. 
4. D137N variant 
In the experiments shown here cells expressing SAMHD1 D137N showed a comparable 
sensitivity to ara-C induced cytotoxicity as compared to WT SAMHD1, however HIV-1 
restriction was completely lost. Ryoo et al. published that the D137N mutant had completely 
lost dNTPase activity in vitro using dATP, dGTP, dCTP and dTTP. In contrast, Antonucci et al 
(Nature medicine 2016) showed that D137N could hydrolyze effectively dNTPs, however with 
slightly reduced efficiency as compared to the WT protein, which is in line with our observation 
that D137N was capapble almost to WT levels to neutralize ara-C induced cytotoxicity. Choi 
et al (Retrovirology, 2015) published that D137N restricts HIV-1 as wt SAMHD1 using U937 
cells and Antonucci also saw that HIV-1 infection was reduced by SAMHD1 D137N, similar 
to WT.  While we cannot explain why we did not observe restriction by SAMHD1 D137N, one 
possible explanation could be a cell-type-dependent activity of D137N since we used THP-1 
SAMHD1 knockout cells overexpressing D137N while the previous experiments by Antonucci 
et al. or Choi et al. were conducted in PMA differentiated U937 cells. Recently Riess et al. 
showed that U937 express low levels of SAMHD1, which can be induced by IFN treatment 
(Riess et al., 2017). Further investigation of a cell-type dependent activity of D137N needs to 
clarify the underlying reasons for the observed differences.  
5. R451A variant  
The R451 residue was previously identified as part of the cyclin binding motif (RXL residue 
451-453). Structural and functional analyses of R451A revealed that tetramer formation was 
disrupted in this SAMHD1 variant and dNTPase activity was lost in in vitro and in cells. St. 
Gelais et al. also stated that the RXL motif was crucial for HIV-1 restriction and efficient 
phosphorylation (St Gelais et al. 2018). Furthermore R451C and R451L mutation were 
identified in a CLL patient sample study (Clifford et al. 2014). R451P variant was also 
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identified in COAD. We further studied R451P and R451C. Both SAMHD1 variants were 
unable to restrict HIV-1 infection and cells expressing these mutants were highly sensitive to 
ara-C treatment which confirms St. Gelais et al.s observations that the RXL motiv is crucial for 
HIV-1 restriction and it is also fundamental for ara-CTP hydrolysis.  
6. K596Rsf*35 variant 
The K596Rsf*35 mutation is reported by TCGA in four cancer types: COAD, Uterine Corpus 
Endometrial Carcinoma (UCEC), Stomach adenocarcinoma (STAD) and Liver Hepatocellular 
Carcinoma (LIHC). This SAMHD1 variant lost HIV-1 restriction but was still able to 
presumably hydrolyze ara-CTP comparable to wt SAMHD1. The C-terminus of SAMHD1 
(residues 600–626), contains a conserved di-hydrophobic amino acid motif (Leu620-Phe621) 
which can be recognized by cell cycle regulatory proteins (Yan et al., 2015).  
The antiviral activity of SAMHD1 can be post-translationally modulated by phosphorylation at 
Thr592 by cyclinA2-CDK complex in cycling cells. Cyclin A2 binds the conserved di-
hydrophobic residues (Leu620-Phe621) at the C-terminus of SAMHD1 and CDK mediates 
phosphorylation at Thr592 (Cribier et al., 2013). Overexpression of Mutation phosphomimetic 
mutants T592D or T592E did not restrict HIV-1 replication while no-phosphorylatable Mutants 
T592A and T592V were able to restrict HIV-1 infection (White et al., 2013a, Ryoo et al., 2014b, 
Welbourn et al., 2013, Arnold et al., 2015). In contrast, all four T592 mutants were efficiently 
able to deplete ara-CTP. This suggest that dNTPase activity is not alone sufficient for lentiviral 
restriction (White et al., 2013b, Welbourn et al., 2013, Welbourn and Strebel, 2016). C terminal 
deletion studies (584-626) by Arnold et al. in U937 cells abolished the block to HIV-1 
restriction. They report that the C- terminal region is indispensable for stable tetramer formation 
in vitro. However transient tetramers were crystalized. Additionally, they were able to show 
that by mutating R372 tetramerization was completely lost and the dNTPase activity was 
severely impaired which completely abolished restriction activity of SAMHD1. This would 
indicate that stable tetramer formation is required for restriction. However, even so dNTPase 
activity was 10-fold reduced in SAMHD1 C-terminal deletion mutants it was not completely 
abolished and the Km for substrates was not severely affected (Arnold et al., 2015). This is an 
indication that catalysis might not depend on stable tetramer formation. As Ji et al. reported 
SAMHD1`s affinity in the catalytic site for dNTPs is the following: dCTP > dGTP/dTTP > 
dATP (Ji et al., 2014). Structural analyzes have to verify whether ara-CTP is chosen over the 
other dNTPs. However, this would be one explanation why K596f is still able to presumably 
hydrolyze ara-CTP giving the fact that part of the C-terminal domain is missing leading to no 
phosphorylation and unstable tetramer formation.  
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7. R145Q variant 
The R145Q was found in COAD (TCGA), CLL (Clifford et al. 2014) and AGS (Rice et al. 
2009a). White et al. reported that the R145Q mutation is unable to oligomerize (White et al. 
2013b). R145 resides in the primary allosteric site and is involved in the guanine base 
recognition. A145 abolished restriction which suggest that allosteric activation of SAMHD1 is 
a further requirement for restriction (Koharudin et al. 2014b, Arnold et al. 2015a). Our results 
confirmed that R145 is crucial for restriction since R145Q SAMHD1 variant was unable to 
block HIV-1. R145Q expressing cells were sensitive to ara-C treatment comparable to cells 
lacking SAMHD1.  
 
Overall, three SAMHD1 variants (A338T; A525T and K596Rsf*35) showed EC50 comparable 
to wt SAMHD1 but HIV-1 restriction was completely lost (A525T, K596Rsf*35) or 
significantly reduced compared to wt SAMHD1 (A338T). This indicates that ara-C hydrolysis 
cannot be used as an indicator for HIV-1 restriction. All three SAMHD1 variants should still 
be able to tetramerize otherwise the ara-C detoxification ability of SAMHD1 would also be lost 
as seen in R451A SAMHD1 variant which is unable to form tetramers.  
11.2.2.4 Ability of Vpx to degrade human SAMHD1 SNP variants 
We proposed that Vpx VLPs can be used to alter SAMHD1 levels. Therefore, we wanted to 
analyze whether cancer-associated SAMHD1 amino acid variations would alter Vpx-mediated 
SAMHD1 degradation. This could also reveal which domains in SAMHD1 may affect the Vpx-
induced rescue of HIV-1 infection in type I IFN-treated cells, e.g. by revealing interfaces 
important for interaction with co-factors involved in the IFN-induced block (Buffone et al., 
2019). Laguette et al mapped the Vpx interaction with SAMHD1 to the C terminal domain of 
SAMHD1 and identified residues 595-626 to be involved in the binding to SAMHD1 (Laguette 
et al., 2012). Therefore, only K596Rsf*35 should be insensitive to Vpx-induced degradation. 
Lim et al. reported that the SAM domain and N-terminal harbor positive selection residues 
sensitive to Vpx besides the C-terminus (Lim et al., 2012). Another report proposed a model 
whereby Vpx interacts with the oligomeric interface of SAMHD1, implementing that 
oligomeric SAMHD1 is required for Vpx mediated SAMHD1 degradation (Fregoso et al., 
2013). Some of the analyzed AGS SAMHD1 by White et al. which reside not in the C-terminus 
of SAMHD1 were defective in oligomerization and their ability to be degraded by Vpx was 
also defective? (White et al., 2017). We analyzed wt SAMHD1, D137N, A76T, A338T, 
A338V, V133I, P589T, A525T, D311A, L178Q, G90R and K596Rsf*35 for their sensitivity to 
108 
 
Vpx-induced degradation. All SAMHD1 variants analyzed besides K596Rsf*35 were degraded 
efficiently by Vpx, mostly comparable to WT SAMHD1. White et al. analyzed R145Q which 
was unable to be degraded by Vpx but contrary to Fregoso et al. was not able to oligomerize 
(White et al., 2017). Further SAMHD1 variants have to be analyzed for their oligomerization 
status and their ability to be degraded by Vpx to verify Fregoso et al.`s hypothesis.  
11.2.2.5 SNP in stomach adenocarcinoma (STAD) 
The TCGA database reports that in 42 analyzed patient tumor samples of stomach 
adenocarcinoma 16 mutations of SAMHD1 were found. P589T mutation was predicted to be 
damaging by one out of three computational analyses (VEP, SIFT, PolyPhen). HIV-1 restriction 
was not blocked in SAMHD1-/- cells expressing the P589T variant and sensitivity towards ara-
C decreased by 18.8-fold compared to loss of SAMHD1. This is another example of a complete 
loss of HIV-1 restriction but SAMHD1 variant P589T is still able to presumably hydrolyze ara-
CTP.  
 SAMHD1 variants that influence post-translational modifications of 
SAMHD1 and their involvement in HIV-1 restriction and ara-CTP 
hydrolysis 
11.3.1 The C522 residue of SAMHD1 is crucial for the intensive block to HIV infection 
but presumably not for ara-CTP hydrolysis 
Retroviral restriction ability of cysteine SAMHD1 mutants was evaluated in PMA-treated THP-
1 SAMHD1 -/- cells stably expressing the C522S and C522A SAMHD1 variants were 
challenged with increasing amounts of HIV-1 virus expressing GFP as a reporter of infection. 
This study revealed that C522S and C522A mutations reduced (C522S 8-fold reduction; C522A 
6- fold reduction) but not completely abolished HIV-1 restriction. Both mutations decreased 
the ara-C detoxifying ability of SAMHD1 slightly (C522S 1.4-fold decrease of EC50; C522A 
mutant 3-fold decrease of EC50 compared to wt SAMHD1). 
Wang et al. and Mauney et al. reported that SAMHD1 is a redox-sensitive enzyme and it poses 
three redox-active cysteines at the following location: 341, 350 and 522 (Mauney et al. 2017, 
Wang et al. 2018). Expression of the SAMHD1 variant C522S in PMA-treated U937 cell did 
not lead to HIV-1 restriction. They also tested dNTPase activity and capability of 
tetramerization. C522S mutation has no detectable negative effect on SAMHD1 tetramerization 
and dNTPase activity in vitro. They reasoned that nucleotide-dependent tetramerization and 
dNTPase activity is needed but not sufficient for the block of retroviral replication. Suggesting 
that the redox activity of C522 is crucial for the block to HIV-1 infection. (Wang et al. 2018). 
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This is another example of a SAMHD1 variant which appears to be functioning properly in ara-
C hydrolysis (if dNTPas and ara-CTPase function are correlated) but fails to restrict HIV-1, like 
the phosphomemetic mutants T592E and T592D or D137N (see above). Wang et al. suggest 
that one likely possibility might be that tetramerization is only one of several ways’ dNTP 
hydrolysis can be activated and it might involve phosphorylation and redox activity of C522 
together. This however is in conflict with C522S and C522A’s ability to hydrolyze ara-CTP. 
Ara-C detoxification by SAMHD1 is therefore not as dependent on the redox state as HIV-1 
restriction.  
11.3.2 SAMHD1 acetylation has no influence on viral restriction and minimally 
changes its sensitivity to ara-C induced cytotoxicity 
Lee et al. identified that the lysine residue 405 of SAMHD1 is acetylated by the 
acetyltransferase arrest defective protein 1 (ARD1). Acetylation defective mutant K405R 
possess lower dNTPase activity compared to wt acetylated SAMHD1 and acetylation promotes 
cancer cell proliferation (Lee et al., 2017). They imply that SAMHD1 acetylation might be of 
interest as a target for cancer treatment. Therefore, we analyzed K405R influence on ara-C 
sensitivity and its restriction capability towards HIV-1 in PMA treated K405R expressing THP-
1 SAMHD1 -/- cells. A minor increase in ara-C sensitivity of 1.18-fold was seen which can be 
explained by lower expression of K405R compared to wt SAMHD1. HIV-1 restriction was 
comparable to wt. This stays in conflict with K405R decreased hydrolyzation ability (Lee et al., 
2017).Which implicates that acetylation might not be critical for SAMDH1s role in lentiviral 
restriction in pma treated THP-1 cells and ara-C hydrolysis in THP-1 cells. Lee et al. used 
HEK293T and HeLa cells for their analyzes (Lee et al., 2017). Furthermore acetylation of 
SAMHD1 peaked during the G1 phase of the cell cycle and resulted in the increased dNTPase 
activity of the enzyme in vitro (Lee et al., 2017). Our HIV-1 infection study was conducted 
with pma treated noncycling THP-1 cells. Hence the acetylation effect might not be pronounced 
in noncycling cells. THP-1 cells and other cell lines have to be evaluated in respect to their 
ARD1 levels as well as acetylation of SAMHD1 at residue K405 to rule out a cell type 
dependent acetylation. Furthermore K405R`s dNTPase function has to be evaluated further. 
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 Summary and Outlook 
 SAMHD1’s role in the type 1 interferon induced early block to HIV-1 
infection  
We could show that Vpx mutant Q76A which is unable to bind DCAF1 is unable to increase 
HIV-1 infection in macrophages treated with interferon, suggesting that SAMHD1 degradation 
is required for efficient Vpx-mediated rescue of HIV-1 from the type I IFN-induced early 
antiviral blocks in macrophages. CRISPR/Cas9 THP-1 cells lacking a functional SAMHD1 
gene did not impact the level of the type I IFN-induced early block to HIV-1 infection as well 
as cell proliferation as compared to control or parental THP-1 cells. However, while Vpx was 
able to rescue HIV-1 infectivity in parental THP-1 or CRISPR/Cas9 control cells, no rescue 
was observed when SAMHD1 protein was absent.  
To investigate whether the enzymatic activity of SAMHD1 was required for the Vpx-mediated 
rescue of HIV-1 infection from the early type I IFN-induced blocks, we reconstituted expression 
of wild type or different catalytically-inactive SAMHD1 mutants in SAMHD1-/- cells and found 
that Vpx increased HIV-1 infectivity in the presence of wild type, but not H233A mutant 
SAMHD1, suggesting that the enzymatic activity of SAMHD1 is required for a Vpx-induced 
rescue of HIV-1 infection from the type I IFN-induced block. We were able to generate a 
CRISPR/Cas9 THP-1 cell clone, which had one disrupted SAMHD1 allele and one allele, in 
which the entire nuclear localization signal (11KRPR14) was deleted in frame, generating an 
internally NLS-disrupted endogenously expressed SAMHD1 protein. In these cells, SAMHD1 
was localized to the cytoplasm. In these cells, Vpx still rescued HIV-1 from the type I IFN-
induced early blocks to infection. Of note, SAMHD1 degradation was profoundly delayed, 
suggesting that Vpx-induced polyubiquitination of SAMHD1 is sufficient to overcome early 
IFN-induced blocks to HIV-1. This hypothesis has to be further tested, however. To further 
characterize SAMHD1s role in the Vpx mediated increase of HIV-1 infectivity other cell lines 
have to be tested as well to get a better understanding of SAMHD1s broad function.  
 Correlation of SAMHD1 dNTPase activity with HIV-1 restriction by 
using cancer-associated naturally occurring SAMHD1 variants 
We used the finding by our collaborators at the Karolinksa Institute in Stockholm that 
SAMHD1 expressed in cell lines reduces their sensitivity to ara-C-induced cytotoxicity as a 
surrogate model for measuring dNTPase activity of SAMHD1 and to correlate it in the same 
cells with HIV-1 infection. This not only opened to us the possibility to investigate the 
correlation of SAMHD1s dNTPase activity with HIV-1 restriction, it also provided an assay to 
111 
 
investigate which parts of SAMHD1 are important for the Vpx-induced HIV-1 infection rescue 
in type I IFN-treated cells by using a set of naturally occurring SAMHD1 variants present in 
certain types of cancers.  
Overall, three SAMHD1 variants (A338T; A525T and K596Rsf*35) showed EC50 in ara-C 
cytotoxicity experiments comparable to wt SAMHD1 but HIV-1 restriction was completely lost 
(A525T, K596Rsf*35) or significantly reduced compared to wt SAMHD1 (A338T). Another 
mutant P589T lost HIV-1 restriction completely but was still able to presumably hydrolyze ara-
CTP. We also identified three SAMHD1 mutants, which were able to restrict HIV-1 
significantly better than wt SAMHD1 (V133I, A76T and R305I). Furthermore, we could show 
that 6 SAMHD1 SNP lost their ability to restrict HIV-1 and were highly sensitive to ara-C 
treatment. Further analyses have to focus on characterization of dNTPase activity, ara-CTP 
hydrolysis and tetramer formation. We are currently working on purifying the human SAMHD1 
variants and afterwards we will analyze the activity of these variants in vitro as previously 
shown (Herold et al., 2017a). In addition to biochemical characterization of their catalytic 
activity, we will also look at protein stability using in vitro thermal shift assays. This assay will 
inform us about the stability of the SAMHD1 variants. 
If we find a naturally occurring SAMHD1 SNP with its dNTPase activity still intact this might 
indicate that the dNTPase activity of SAMHD1 is not exclusively responsible for the block to 
HIV-1 infection. There is the possibility that cofactor binding might influence dNTPase 
activity. Identification of those SAMHD1 SNPs which are unable to block HIV-1 infection in 
newly infected HIV-1 patients could give hints to a possibly fast proceeding of HIV infection. 
An early onset of aggressive treatment might be necessary to keep the virus load under control. 
Hence it is of great interest to further study SAMHD1 SNPs and screen HIV-1 patients as well 
as cancer patients for SAMHD1 SNPs. In summary it is very likely that SAMHD1 does not 
restrict HIV-1 by one single function, but through a combination of several pathways.  
Analyzes of two SAMHD1 variants with mutated residues in the SAM domain altered HIV-1 
restriction and ara-CTP hydrolysis. Up until now it was thought that the is dismissible for HIV-
1 restriction (White et al., 2013a). The structure of full-length human SAMHD1 has not yet 
been discovered therefore scientist should aim to crystalize the full length SAMHD1 protein so 
that the function of the SAM domain can be evaluated. 
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